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Metabolic dysfunction directly links of obesity and metabolic disorders. Although poor
diet and lack of exercise are known factors for the development of metabolic disorders, there is a
clear need to identify dietary components that may be effective for preventing metabolic
dysfunction. Therefore, this dissertation aimed to define the effects of dietary sphingomyelin (SM)
on diet-induced metabolic dysfunction. In Aim 1, we explored the short-term effects of dietary
milk and egg SM on lipid homeostasis in C57BL/6J mice fed a high-fat diet. Milk SM reduced
both hepatic lipid accumulation and serum cholesterol, which correlates well with the existing
literature. Conversely, egg SM increased both hepatic and serum lipids. Having demonstrated
differences between two sources of SM, the study progressed to Aim 2, where we investigated the
effects of both egg and milk SM on preventing metabolic dysfunction in C57BL/6J mice on an
obesogenic diet. Egg SM reduced hypercholesterolemia and fasting hyperglycemia. Both SM
treatments reduced hepatic steatosis and adipose inflammation, however, egg SM was more
effective than milk SM. When designing Aim 3, we focused on defining possible antiinflammatory effects of milk SM. We observed that feeding milk SM reduced circulating cytokine
concentrations in mice fed an obesogenic diet. We also tested the effects of milk SM and its
hydrolytic products, ceramide and sphingosine, on LPS-stimulation of RAW264.7 macrophages.
We observed all three compounds to be effective inhibitors of the LPS-induced inflammatory
response. Additionally, SM hydrolysis was required for SM effectiveness. In a normal diet, the
consumption of dietary SM found in foods will be accompanied by other dietary phospholipids.
Therefore, we also tested the effects of milk phospholipids supplied by beta-serum, a dairy

Gregory H. Norris
University of Connecticut, 2018
byproduct, on diet-induced metabolic dysfunction and inflammation in hypercholesterolemic
LDL-receptor knockout mice. We found that the highest dose of milk phospholipids markedly
reduced cholesterol in both serum and liver, with more modest effects on reducing inflammation
markers in liver and adipose tissues. Overall, this work demonstrates a clear potential for dietary
SM to be useful for the prevention of obesity-associated metabolic dysfunction. More research is
warranted to translate this work into human clinical trials.
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Chapter 1. Introduction

1

1.1. Introduction
Obesity is a public health crisis. More than 1 out of every 3 Americans are obese and over twothirds are considered overweight [1]. Nutritional scientists have set forth to address this crisis
through multiple methods. Epidemiological and community-based nutrition researchers examine
populations’ eating habits, behaviors, and how those are interrelated with the public’s obesity rates.
Clinical researchers are interested in dietary interventions and how they may alter a patient’s
metabolic phenotype. Meanwhile, molecular nutrition researchers focus on preclinical trials,
finding new potential nutraceuticals to help improve obesity-related outcomes. Many molecular
researchers have focused on phytochemicals, plant-based chemicals, as potential nutraceuticals.
This is in part because the epidemiological studies indicate positive health outcomes associated
with an increase intake of plant-based foods [2]. This may have suggested animal-based foods to
be unhealthy. On the contrary, animal-based foods have many potentially beneficial components
including: high-quality protein [3], micronutrients [4], and carotenoids [5]. In fact, the field of
zoochemicals, animal-based chemicals, is continuing to produce potential nutraceuticals. One such
nutraceutical is sphingomyelin (SM), a sphingolipid commonly found in dairy, meat, and eggs [6].

1.2. Obesity and Metabolic Dysfunction
Obesity raises the risk of all-cause mortality by 21-79% [7, 8]. To combat this, the US spends $200
billion annually, in response to obesity-related health issues [9]. Cardiovascular disease (CVD),
type II diabetes (T2D), non-alcoholic fatty liver disease (NAFLD), and cancer all have strong ties
to obesity [10]. Thus, curbing obesity would be an effective measure to reduce the prevalence of
these life-threatening diseases and the economic burden. Both epidemiological and clinical trials
have reported calorie restriction combined with exercise to be an effective means to reduce obesity
for most individuals [11-13]. However, according to the Centers for Disease Control (CDC), only
2

25% of Americans meet weekly goals for both strength and aerobic exercise [14]. Meanwhile,
according to the Food and Agriculture Organization, the average American is consuming over
3,000 kilocalories per day [15]. Therefore, despite the knowledge of preventing obesity through
calorie restriction and exercise, obesity is projected to increase to 42% of the adult US population
by the year 2030 [16].
The increased risk of health complications is not due to merely obesity. It is the underlying
metabolic consequences that come from overtaxing the adipose tissues’ energy buffering capacity.
This results in metabolic dysfunction, which manifests itself as dyslipidemia, insulin resistance,
and endotoxemia or elevated lipopolysaccharide (LPS) activity [10]. These symptoms of metabolic
dysfunction are the defining difference between metabolically-healthy and unhealthy individuals.
Compared to the typically obese population, the metabolically-healthy population has a reduced
relative risk of all-cause mortality [8]. Therefore, improving metabolic health could improve the
health and economic burdens on the United States. Rodents fed calorically-dense Western-type
diets are a common preclinical model of obesity. Western-type diet is an umbrella term
encompassing several diets rich in saturated fat, simple sugars, and sometimes added cholesterol.
Rodents fed Western-type diets have increased weight gain, dyslipidemia, insulin resistance,
inflammation, and steatotic livers, which is similar to humans [17, 18].
Briefly, the pathogenesis of metabolic syndrome and insulin resistance (IR) stems from
overwhelming the lipid buffering capacity of the adipose tissue [19]. The increase in lipids
originates both from the diet and an increase in de novo lipogenesis. As adipose tissue enlarges,
the adipocytes become stressed, insulin resistant, and secrete inflammatory cytokines and nonesterified fatty acids (NEFA) into circulation [20]. These excessive lipids will accumulate
ectopically in the liver and skeletal muscle causing IR in these tissues [21]. This will impair the
3

handling of lipids and glucose, consequentially elevating the risk of the chronic metabolic-related
diseases such as CVD, T2D, NAFLD, and cancer.

1.2.1. Inhibition of Lipid Absorption Can Improve Metabolic Dysfunction

As the field of molecular nutrition has grown, the search for potential therapeutic targets to slow
down obesity has increased. The ability to prevent metabolic dysfunction is the underlying goal.
Reducing intestinal lipid absorption has been a mechanistic target that has shown some success.
First, inhibiting cholesterol absorption through use of the drug ezetimibe has shown benefits.
Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein, which is the major importer of
luminal free cholesterol into the enterocyte [22]. Luminal cholesterol is sourced from both dietary
and biliary cholesterol. When inhibiting cholesterol absorption, the net result is a lowering of
circulating cholesterol [23], and this can reduce hepatic and adipose inflammation associated with
a Western-type diet [24-26]. Additionally, ezetimibe has been shown to reduce visceral fat mass,
consequently improving metabolic dysfunction [27]. Another commonly prescribed drug is
orlistat. Orlistat inhibits intestinal lipases which slows the absorption of lipids by inhibiting their
breakdown. This is an effective treatment to reduce body weight [28]. However, pharmacological
agents can be costly. Additionally, ezetimibe and orlistat are not without their side effects [29, 30].
Therefore, the inhibition of lipid absorption is a viable target for improving metabolic dysfunction
but, there is a need for novel therapies.

1.3. Dietary Sphingolipids as a Part of the Western Diet
On average, 2-8 g/day of a typical American’s diet are phospholipids [31]. Within those 2-8 g,
sphingolipids constitute 200-400 mg/day [32]. Animal-derived sphingolipids are by far the most
abundant and the most common of them is SM [33]. Therefore, the majority of dietary
sphingolipids are SM. The average American adult consumes 200-400 mg of cholesterol per day
4

[34]. Despite the relative abundances of these lipids, dietary cholesterol has dominated the
literature (>9,000 papers available on PubMed as of January 2018) in comparison to dietary
sphingolipids (<100 papers). This discrepancy exists in spite of the potential bioactive effects of
sphingolipids [32]. Therefore, there is a clear lack of research into the effects of dietary
sphingolipids.
Once dietary SM reaches the small intestine its hydrolysis is initiated by bile salt-dependent
alkaline sphingomyelinase (alk-SMase), located on the brush border membrane in mammals and
additionally found in human bile [35]. Sphingomyelinase activity is low in the duodenum and
peaks in the mid-jejunum [36]. The delay in activity is due in part to the inhibition of alk-SMase
by common luminal lipids [37]. Hydrolysis of SM produces a phosphocholine and ceramide.
Subsequently, the ceramide will be digested by neutral ceramidase to produce sphingosine and a
fatty acid [35]. The sphingosine backbone will be readily absorbed by the enterocyte through a
passive diffusion mechanism [38]. Once absorbed, most of the sphingosine will enter the
sphingosine-1-phosphate lyase pathway to recover a fatty acid while, some can be used to
resynthesize complex sphingolipids [35].
Different food sources of SM contain structurally distinct SM profiles. Egg-derived SM
contains predominantly C16:0 N-linked acyl chains and d18:1 as the sphingoid backbone [39].
Comparatively, milk-derived SM contains N-linked acyl chains ranging from C16:0-C24:0 and
sphingoid backbones ranging from 16-19 carbons with and without a double bond [40]. The longer
saturated chains could increase hydrophobic interactions with cholesterol [41]. The SM species
with a saturated backbone in milk-derived SM are classified as dihydrosphingomyelin.
Dihydrosphingomyelin has been shown to slow cholesterol’s desorption from a model membrane
to cyclodextrin more strongly than sphingomyelin [42]. Dihydroceramides have been shown to be
5

inert in terms of apoptosis when compared to ceramide [43]. However, new insights into the
potential biological role of dihydroceramide metabolism are surfacing. While exogenous
dihydroceramides seem biologically inert [44], a build-up of dihydroceramide has been shown to
induce autophagy and coincides with both oxidative stress and hypoxia [45]. However, due to the
interconnected nature of sphingolipid metabolism, it is hard to discern whether these effects are
associated with increases in dihydroceramide or depletion of ceramide. Regardless, there is
increasing data suggesting that subtle differences between ceramide species can have distinct
biological effects [46]. Therefore, structurally-distinct dietary SM could have differing biological
effects.

1.4. Dietary Sphingomyelin for the Prevention of Metabolic Disease
Exogenous SM and its metabolites have been shown in cell culture models to modulate cholesterol
absorption [47-49], in part by decreasing the release of cholesterol from the micelles [50].
Furthermore, in animal models, reductions in both triglyceride and cholesterol absorption were
observed [41, 50-52]. In lymph duct-cannulated rats, milk-derived SM was more potent than eggderived SM when inhibiting cholesterol and triglycerides during duodenal infusion [41]. This
suggests that SM from different sources will have differential effects on lipid absorption. Since
then, studies conducted in rodents have observed reductions in serum and hepatic cholesterol
during chronic feeding of SM on a high-fat diet [52-54]. In humans, intervention studies with
purified dietary SM are scarce, but the consumption of dietary milk-derived SM for 14 days has
been shown to raise high-density lipoprotein cholesterol (HDL-C) in healthy adult men and women
[55]. There are consistently observed reductions in serum and hepatic lipids with feeding of SM.
However, comparing distinct SMs could elucidate further understanding of the mechanism.
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Dietary SM has also been investigated for its role in chemically-induced colitis and
inflammation. Two separate research groups found that dietary SM mixed into the diet reduced
inflammation induced by dextran sodium sulfate (DSS) treatment of mice [56, 57]. However, when
mice were gavaged with similar quantities of egg-derived SM, both DSS-induced and IL-10-/-induced forms of colitis were exacerbated [58]. This could be due to differences in the timing of
the dose, as the studies inhibiting inflammation gave SM over the course of the day as opposed to
a single dose. This observation is consistent with large doses of exogenous SM and ceramide
having been shown to be pro-inflammatory in cell culture [59], while lower doses of exogenous
sphingolipids are anti-inflammatory [60]. This suggests a delicate balance in sphingolipids
regulates their role in inflammation.

1.5 Objective and Central Hypothesis
The main objective of this work is to further clarify the role of dietary SM as a therapeutic food
component in preventing diet-induced metabolic dysfunction and inflammation utilizing both
animal and cell models. We hypothesize that dietary SM will be beneficial in attenuating the
progression of dyslipidemia, metabolic dysfunction, and inflammation in mice fed Western-type
diets. These effects will likely be related to the ability of dietary SM to inhibit the absorption of
other dietary, biliary, and possibly microbial lipids. Metabolic dysfunction is also associated with
systemic inflammation. Therefore, we expect to see a reduction in systemic inflammation with
dietary SM. Dietary SM has shown potential in alleviating chemically-induced colitis through a
poorly understood mechanism. Logically, there is potential for SM to reduce systemic
inflammation in a manner independent from its effects on lipid homeostasis. Thus, we will test an
in vitro model of inflammation to examine potential anti-inflammatory effects of SM. Purified SM
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is currently prohibitively expensive and therefore we will test a less expensive alternative, betaserum, a dairy byproduct that is rich in phospholipids, like SM, for reducing hypercholesterolemia.
Question 1: Are there differences in the effects of structurally-distinct dietary SM derived from
egg and milk on metabolic dysfunction when fed a short-term Western-type diet?
Hypothesis 1: We hypothesize that both SM sources will improve Western-type diet-induced
metabolic dysfunction and endotoxemia, but milk-derived SM will be more potent compared to
egg-derived SM. This difference will be due to milk-derived SM’s more potent inhibitory effect
on lipid absorption compared to egg-derived SM.
Question 2: Will either milk or egg SM slow the progression of diet-induced obesity and the onset
of metabolic dysfunction in mice fed a Western-type diet?
Hypothesis 2: Both SM treatment groups will reduce the metabolic dysfunction phenotype, due
to SM’s effects on both lipid absorption and inflammation compared to a high-fat control.
However, milk-derived SM will be more effective than egg-derived SM because of the stronger
inhibitory effect on lipid absorption.
Question 3: Will exogenous SM inhibit the LPS-stimulation of macrophages, and will this effect
be dependent on SM hydrolysis?
Hypothesis 3: We hypothesize exogenous SM treatment will inhibit LPS-stimulation of
RAW264.7 macrophages. Due to the fact that SM metabolites have been shown to have inhibitory
properties, blocking hydrolysis of SM will reduce SM’s effectiveness for inhibiting LPSstimulation. Consequently, the addition of the hydrolytic products of SM will also inhibit LPS-
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stimulation. Furthermore, dihydroceramide and ceramide with have differential effects on
inflammatory response, as they have previously shown different bioactivities.
Question 4: Does phospholipid supplementation confer hypolipidemic benefits and improve
metabolic dysfunction in genetically hypercholesterolemic LDLr-/- mice?
Hypothesis 4: Phospholipid supplementation will reduce dyslipidemia and insulin resistance in
Western-type diet-fed LDLr-/- mice. This will result in an improved hepatic phenotype and
decreased adipose inflammation.
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2.1. Introduction
In 2014, 36.5% of the US adult population was considered obese with a body mass index (BMI)
≥30 [1]. Obesity is estimated to cost the US $200 billion annually due to complications associated
with increased body weight [2]. Obesity increases the relative risk of all-cause mortality by 2179% [3, 4] due to metabolic dysfunction. Metabolic dysfunction is characterized by dyslipidemia,
insulin resistance (IR), and endotoxemia [5]. These symptoms are driving factors in the
development of type II diabetes, cardiovascular disease (CVD), and non-alcoholic fatty liver
disease (NAFLD) [5]. This is conceptually supported by metabolically healthy obese individuals,
that have a reduced relative risk of all-cause mortality compared to metabolically unhealthy
patients [4]. The metabolically healthy obese population lacks some of the critical symptoms of
metabolic dysfunction. Although proper diet and exercise can reduce BMI and lessen metabolic
dysfunction [6], the number of obese US adults is expected to increase to 42% of the total adult
population by the year 2030 [7].
One cause of increased BMI is the overconsumption of nutrients. Chronic consumption of
a high-fat diet (HFD) may provide the greatest risk of over-nutrition, due to high energy density
in concert with a lesser impact on satiety and satiation per calorie compared to other macronutrients
[8]. Several epidemiological studies show when dietary fat increases, so does the prevalence of
obesity [9-11]. High-fat diets are used in rodent models to induce characteristics similar to human
obesity, such as increased weight gain, dyslipidemia, IR, inflammation, and steatotic livers [12,
13]. Thus, HFD-fed rodents are commonly used in preclinical trials to study obesity. The strong
association of these comorbidities with metabolic disease warrants the identification of dietary
interventions to prevent or slow their progression. The overall goal of these interventions is to
reduce the incidence of obesity-related disease.
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2.2. Pathogenesis of Metabolic Dysfunction and Insulin Resistance
2.2.1. Adipose Tissue Dysfunction

Historically, obesity’s role in metabolic dysfunction was attributed to adipose tissue inflammation
and IR. More recently, the gut microbiota and intestinal inflammation are being recognized as
potential initiators of metabolic dysfunction that may compound the effects of adipose tissue
dysfunction [14]. Gut microbiota and intestinal inflammation will be discussed later in this review.
When adults gain fat mass, they enlarge existing adipocytes via hypertrophy to deal with
the increased fat load, to a much greater extent than creating more adipocytes via hyperplasia [15].
When adipocytes approach their maximum size/capacity, which depends heavily on genetic factors
and fat depot, they can begin to malfunction; setting off the cascade of events associated with
metabolic dysfunction. This malfunction originates from many related pathways. For example, as
the size of adipocytes increase, adipocyte stress may increase in part due to hypoxia. Larger
adipocytes are typically >100 μm in diameter [16]. Some larger adipocytes may not receive a full
supply of oxygen from blood vessels due to oxygen’s limited diffusion distance in tissues (100200 μm) [17]. Diet-induced obese mice have been found to have <50% of the oxygenation of
adipose tissue of lean mice [18]. Hypoxia will induce several inflammatory pathways and inhibit
insulin signaling [18, 19]. This inflammation will contribute to the IR and lipolysis seen in
dysfunctional adipose tissue.
Endoplasmic reticulum (ER) stress is another insult to hypertrophic adipocytes. High-fat
fed and genetically obese ob/ob mice both show increased adipose tissue ER stress compared to
lean controls [20, 21]. ER stress is characterized by the unfolded protein response (UPR). The
UPR occurs when the demand for protein synthesis produces more protein than cellular chaperone
folding proteins can manage or when there is damage to the ER, such as disruption of the ER
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membrane. One inducer of ER stress is high cellular concentration of long-chain free fatty acids.
Saturated fatty acids seem to be more cytotoxic and may disrupt the fluidity of the ER membrane
[22]. This has been shown by using chemical chaperones to increase protein folding to alleviate
ER stress in mice [23]. ER stress will induce apoptosis [24], and in the adipose tissue this will
release fatty acids into the interstitial space and circulation.
Systemic oxidative stress is another contributor to adipose tissue dysfunction.
Unsurprisingly, obesity and systemic oxidative stress correlate well [25]. Oxidative stress is
increased by a myriad of causes, including hyperleptinemia [26], hyperglycemia [27], and
mitochondrial dysfunction [28]. Several of these have direct links to obesity and adipose
hypertrophy. Serum leptin concentrations are positively correlated with adipose tissue mass [29].
Hyperleptinemia increases oxidative stress and adipose dysfunction in mice and differentiated
mouse pre-adipocytes (3T3-L1) [30] Hyperglycemia can drive metabolic production of reactive
oxygen species (ROS) from oxidative phosphorylation in the mitochondria [31]. Insulin resistance
reduces glucose transporter 4 (GLUT4)-dependent glucose uptake and subsequently increases
hyperglycemia [32, 33]. Hyperlipidemia is associated with ectopic lipid accumulation. Ectopic
lipid accumulation will progress to lipotoxicity contributing to IR in non-adipose tissues [34]. It
has also been shown that excessive storage of lipids leads to an increase in lipid peroxidation
within the adipose tissue itself [35]. Oxidative stress, in general, will lead to inflammation
signaling and vice versa, which will drive IR in adipose tissue.

2.2.2. The Role of the Gut in Metabolic Dysfunction

The gut microbiota may contribute to metabolic dysfunction by extracting more energy from
undigested food which contributes to weight gain, and by activating the immune system. Germfree mice are resistant to diet-induced metabolic dysfunction and obesity [36, 37]. However, it is
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still unclear if gut microbiota from obese mice promote weight gain more than from lean mice,
although they do differentially affect IR [38]. High-fat diet has been shown to induce ileal
inflammation compared to low-fat diet in conventionally raised mice in as little as 2 weeks. This
effect was absent in germ-free mice [39]. Indeed, consumption of HFD can result in inflammation
that acutely increases gut permeability [40]. This would lead to a “leaky gut” which allows for
more bacterial byproducts to translocate into the intestinal tissue. Chronic consumption of HFD
can disrupt the balance of the gut microbiota [41], potentially reducing commensal bacteria,
allowing for more pathogens to grow. Gut-derived bacterial byproducts can also contribute to
adipose tissue inflammation. The most well studied of these byproducts is lipopolysaccharide
(LPS). Lipopolysaccharide activates Toll-like receptor 4 (TLR4), and in adipocytes increases
tumor necrosis factor α (TNF-α) production [42]. Lipopolysaccharide is also taken up by the
enterocyte likely via TLR4 and localizes to the Golgi, the site of chylomicron maturation [43].
Large amounts of dietary fat have been shown to increase the concentration of LPS-rich
chylomicrons in the lymph of mice in acute experimental conditions [44]. This effect was
facilitated by chylomicron production, as pluronic L-81, which inhibits chylomicron secretion,
reduced the appearance of LPS in the lymph [44]. Additionally, Gram-negative bacteria are taken
up by enterocytes in a manner similar to phagocytosis, through a TLR4-dependent mechanism
[45]. Although the mechanisms have not been fully elucidated, HFD can increase intestinal
inflammation and LPS translocation; both of which would increase systemic inflammation and
contribute to metabolic dysfunction.

2.2.3. Systemic Consequences of Metabolic Dysfunction

Dysfunction of the adipose has major consequences for other metabolic tissues, such as the liver
and skeletal muscle. Local inflammation of the adipose tissue will contribute to the circulating
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pool of cytokines, including TNF-α, C-C motif chemokine ligand 2/4 (CCL2 and CCL4),
interleukin 6 (IL-6), IL-1β, and interferon-γ (IFN-γ) [46]. Adipose tissue inflammation and IR will
also increase the rate of lipolysis, or release of FAs [47]. These circulating fatty acids can be stored
in other tissues if they are not oxidized and their accumulation contributes to systemic IR. This
typically can occur with diacylglycerol (DAG) buildup, which is a well-known activator of protein
kinase C [48]. Protein kinase C can phosphorylate the insulin receptor, subsequently disrupting its
signaling [48]. Insulin resistance in the adipose tissue will also increase lipolysis further increasing
the amount of FA efflux.
Adiponectin is an adipokine, known for its anti-inflammatory effects. Serum adiponectin
is reduced in obese patients compared to healthy controls [49]; furthermore, adiponectin is
inversely associated with non-alcoholic steatohepatitis (NASH), the inflammatory progression of
NAFLD [50, 51]. Mice pretreated with adiponectin were resistant to chemically-induced acute
liver failure, which was dependent on the protective effects of IL-10 [52]. High molecular weight
(HMW) adiponectin is thought to be the more bioactive form and is also found to be decreased in
obesity [53]. Adiponectin can upregulate RAW 264.7 macrophage IL-10 production, by initially
increasing nuclear factor kappa-B (NFκB)-dependent TNF-α production [54]. This mechanism can
dampen LPS sensitivity in macrophages [54]. Treating primary human macrophages with
adiponectin inhibited LPS- and TNF-α-induced inflammation independent of IL-10 [55].
Adiponectin also inhibits TNF-α and IL-6 production by LPS-stimulated human macrophages
[56]. Thus, adiponectin, which is reduced in obesity, has anti-inflammatory effects which may be
useful in preventing metabolic dysfunction.
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2.2.3.1 Effects of Metabolic Dysfunction on the Liver

The liver functions as a hub for lipoprotein transport, bile production, and detoxification. Adipose
dysfunction and IR manifests itself as hepatic lipid accumulation which precedes NAFLD and
NASH. One of the oldest hypotheses surrounding NAFLD/NASH is the “two-hit hypothesis” [57].
The “first hit” is hepatic triglyceride (TG) accumulation. The “first hit” is present in 60-90% of
obese individuals [58]. During the fed and fasted states, about 60-90% of plasma NEFAs are from
the adipose tissue in patients with both NAFLD and IR [59]. Insulin signaling inhibits lipolysis in
a healthy individual [60, 61]. Additionally, when insulin sensitivity is impaired, lipoprotein lipase
(LPL) activity in insulin-sensitive tissue is reduced [32, 33]. Delayed metabolism of chylomicrons
by the systemic tissues can increase the hepatic uptake of diet-derived TGs [62]. Lastly, if
circulating free NEFAs and glucose exceed the metabolic needs of the body, they can accumulate
and drive ectopic lipid droplet formation [63]. The excess glucose will be converted to lipid
through de novo lipogenesis. Although the classical de novo lipogenesis pathways through sterol
response element binding protein (SREBP) are insulin responsive [64]. The mechanistic target of
rapamycin (mTOR) is required for insulin-SREBP-1c signaling [65]. However, SREBP-1c
expression is increased despite IR, this has been hypothesized as a result of mTOR’s
responsiveness to nutrients [66]. Namely, the glucose signaling pathways including carbohydrate
response element binding protein (ChREBP) also contributes to de novo synthesis of lipids
independent of SREBP [67]. These accumulating lipid droplets and plasma free NEFAs exacerbate
hepatic IR through diacylglycerol activating protein kinase ε/θ [68] and saturated fatty acids
activating TLR4 [69], worsening the metabolic conditions of the liver. Although simple hepatic
steatosis is thought to be relatively benign, it sensitizes the liver to the “second hit.”
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The “second hit” exploits the heightened sensitivity of the liver to oxidative damage.
Oxidative stress is typically the initial insult stemming from the production of ROS in response to
metabolic dysfunction or inflammation. Healthy hepatocytes will produce metabolic ROS and
reactive nitrogen species that will be sufficiently neutralized/quenched with cellular antioxidant
defense systems [70]. However, in mitochondrial dysfunction the normal metabolic reactions are
perturbed or overwhelmed, leading to an increase in ROS-mediated cellular damage. It has been
shown that diet-induced mitochondrial dysfunction precedes NAFLD in fatty rats [71]. Takamura
et al. suggested obesity contributes to the leakage of electrons from electron transport chain, which
increases metabolic ROS production [72]. Reactive oxygen species drive lipid peroxidation,
especially in polyunsaturated fatty acids (PUFAs). Lipid peroxidation also occurs enzymatically
by lipoxygenases and cyclooxygenases [73]. Oxidized PUFAs will fragment, producing several
oxidized products which create a more pro-oxidative environment [74]. This can contribute to the
UPR causing hepatocyte death and liver damage [75]. Lipid peroxides can induce cell death by
either disruption of the membrane or by oxidizing protein and DNA [76]. DNA damage can induce
apoptosis through activation of the caspase mechanism [77].
Although the two-hit hypothesis appears to explain the increased prevalence of NASH in
obese populations (37%) [78] compared to the general population (13%) [79], only an estimated
3-20% of steatosis cases progress to NASH [80]. Therefore, there must be other underlying factors
that drive the progression of steatosis to NASH. Some of these factors are likely associated with
metabolic dysfunction associated with obesity. Supporting this viewpoint, there is a population of
lean NASH patients, whom are seemingly opposite of the metabolically healthy obese population,
in that despite their healthy BMI, they have central obesity and metabolic dysfunction. This
population presents with hallmarks of metabolic dysfunction, such as increased visceral adiposity,

22

dyslipidemia, and IR [81]. Additionally, adipocyte size is an independent predictor of hepatic
steatosis from obesity [82], suggesting obesity may drive the “first hit” through dysregulation of
adipocyte metabolism more so than obesity itself.
Lipotoxicity is the accumulation of toxic lipid species, such as DAG and free cholesterol,
both of which are a likely contributor to NAFLD progression. Overexpression of DAG
acyltransferase 1 and 2 (DGAT1/2) in mice fed HFD, which led to a decrease hepatic DAG,
demonstrated that hepatic TG accumulation alone was insufficient to induce inflammation and IR
in this model [83]. Triglyceride production may actually be preventative in mouse models of
NASH because TGs are biologically inert compared to DAG. Deleting stearoyl-CoA desaturase 1
(Scd1) protected mice from hepatic steatosis, by inhibiting TG synthesis. However, these mice had
exacerbated apoptosis and inflammation in liver when they were fed a methionine cholinedeficient diet [84]. A high-sucrose, low-fat diet fed to Scd1-/- mice doubled hepatic free cholesterol
and increased serum hepatic enzymes compared to wild-type (WT) mice [85]. High dietary
cholesterol is a common tool to induce NASH in animal models [86]. Genetically
hypercholesteremic mice fed Western-type diets (high-fat, high-cholesterol) are also commonly
used as animal models of NASH [87]. These models may develop NASH, in part, via elevations
in hepatic free cholesterol, which is known to activate inflammasomes [88] and induce ER stress
[89]. There are several other factors that may contribute to NASH progression, including decreased
adiponectin, increased leptin, and genetic predisposition.

2.2.3.2. Effects on Skeletal Muscle

In addition to playing an essential role in mobility, skeletal muscle also functions as both an
endocrine organ and a major site for macronutrient disposal [90]. Adipose tissue dysfunction
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drastically affects skeletal muscle metabolism due to its insulin-sensitive nature, albeit typically to
a lesser extent than in the liver. The causes of skeletal muscle dysfunction are similar to liver
dysfunction in that they share the accumulation of ectopic lipid [91] and mitochondrial dysfunction
[92]. The accumulation of lipids in the muscle is associated with IR in this tissue [93, 94]. Insulin
resistance within the muscle will decrease glucose uptake, contributing to hyperglycemia.
Mitochondrial dysfunction is associated with increased ROS production [95]. This can lead to
damage of the mitochondria that, if not repaired, could lead to decreased mitochondrial density
through autophagy [96]. The most well-studied myokine is IL-6. While IL-6 is classically thought
to be proinflammatory, IL-6 can improve skeletal muscle glucose uptake and improve whole body
insulin sensitivity [97]. Obesity’s effects on IL-6 production in the skeletal muscle remain
controversial, as some studies report increases [98] and others decreases [99]; although, this could
be due to differences in the study populations used for tissue biopsies. Decreased myocyte IL-6
was found in diabetics, while increases were found in healthy individuals in response to
conditioned medium intended to mimic obese conditions. Skeletal muscle can also secrete proinflammatory cytokines such as TNF-α and CCL2 [99, 100] which, similar to adipose tissue and
liver, will contribute to IR. TNF-α and CCL2 are increased in the skeletal muscle with the
occurrence of obesity and diabetes [99, 100]. Ultimately, obesity disrupts the skeletal muscle’s
capacity to catabolize nutrients, leaving more for the non-adipose tissues to handle, and increasing
IR. The inflammatory cytokines secreted by skeletal muscle may also contribute to systemic IR.
Figure 2.1 functions as a summary of the systemic interactions that are important for metabolic
dysfunction.
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Figure 2.1. Schematic summary of metabolic dysfunction
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2.3. Molecular Mechanisms Governing Lipid Metabolism
2.3.1. Insulin

Insulin is known for its role in modulating blood glucose levels. However, it also controls several
factors crucial for lipid synthesis and storage. As reviewed above, insulin alters skeletal muscle
and adipose tissue metabolism. Several tissues are insulin sensitive, such as liver, skeletal muscle,
and adipose tissue [101]. Insulin signaling in the liver has major implications for both carbohydrate
and lipid homeostasis. In terms of carbohydrate metabolism, insulin induces GLUT4 translocation
to the plasma membranes of skeletal muscle and adipose tissue. This allows for maximal glucose
uptake in these tissues [102]. Insulin will also inhibit the production of glucose in the liver, derived
from both gluconeogenesis and glycogenolysis. This is substantial because the liver is the major
site of gluconeogenesis in the body [103]. Insulin signaling will inhibit gluconeogenesis through
forkhead transcription factor 1 (FoxO1) [104], which is a major regulator of gluconeogenic gene
expression. Hepatic insulin signaling also stimulates glycogen synthesis [105]. In terms of lipid
metabolism, insulin stimulates many of the de novo lipogenesis genes including fatty acid synthase
(Fas) and acetyl-CoA carboxylase (Acc) [106]. Fatty acid synthesis in healthy individuals usually
accounts for about 5% of FAs in the serum but can climb to 24% in the post-absorptive state [107].
In a healthy liver, insulin affects lipid metabolism in two ways: it will 1) upregulate de novo
lipogenesis and TG synthesis; and 2) inhibit very low-density lipoprotein (VLDL) secretion [108].
This will increase the temporary storage of hepatic TGs that will be released after the post-prandial
state.
Factors outside of local insulin signaling will have effects on local insulin responsive
pathways. For example, hyperglycemia and hyperinsulinemia can suppress gluconeogenesis and
glycogenolysis independent of hepatic insulin signaling [109]. Glucagon is known to upregulate
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both hepatic gluconeogenesis and glycogenolysis [110]. Insulin signaling in pancreatic α-cells will
suppress glucagon production [111]. Another consideration is insulin’s effects on gluconeogenic
substrate availability. Triglyceride hydrolysis from adipose tissue and skeletal muscle proteolysis
can supply glycerol and amino acids, respectively. Insulin will inhibit both of these actions, and
thus limits the availability of these substrates critical for gluconeogenesis [112]. It is important to
note that when examining mice with a liver-specific insulin receptor knockout, insulin was unable
to suppress gluconeogenesis during a euglycemic clamp [113]. Thus, direct liver insulin signaling
must remain intact to suppress gluconeogenesis. This highlights the importance of considering a
whole-body system when examining insulin’s effects.

2.3.2. Peroxisome Proliferator-Activated Receptors

Regulation of lipogenesis is controlled through multiple transcription factors. Peroxisome
proliferator-activated receptors (PPARs) are major factors in the regulation of lipid metabolism.
To date, three isoforms have been identified: PPARγ, PPARα, and PPARβ/δ [114]. All of these
isoforms are ligand-binding nuclear receptors that respond to various natural and synthetic
molecules. Of these isoforms, PPARγ and PPARα are the most well-studied and control opposing
mechanisms in lipid metabolism. PPARα is a controller of genes involved in lipolysis and fatty
acid oxidation. PPARα is most strongly expressed in the heart, kidney, small intestine, liver, and
skeletal muscle [115]. PPARα regulates the expression of carnitine palmitoyltransferase 1 α/β
(Cpt1α/β), acyl-coenzyme A oxidase 1 (Acox1), and acyl-coenzyme A dehydrogenase (Acad1),
all of which are key enzymes in fatty acid oxidation [116].
PPARγ controls genes encoding crucial enzymes in TG synthesis and lipid storage.
Adipose tissue expresses the highest levels of PPARγ; however, PPARγ can be upregulated in the
liver during hepatic steatosis. In the adipose tissue, PPARγ is vital for adipocyte development and
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alongside CCAAT/enhancer-binding protein α (C/EBPα) controls adipocyte differentiation [117].
Knocking down hepatic PPARγ has been shown to reduce de novo lipogenesis and TG synthesis
[118]. In obese patients, PPARγ mRNA is significantly upregulated [119]. In obese mice, the
mRNA of a splice variant, PPARγ2, is strongly upregulated in response to HFD, suggesting it is
more nutritionally-responsive than PPARγ1 [120]. Some PPARγ target genes include: Scd1,
cluster of differentiation 36 (Cd36), fatty acid binding protein 4 (Fabp4) [121], lipoprotein lipase
(Lpl) [122], and glucose transporter 4 (Scl2a4) [123]. Thus, PPARγ plays a vital role in TG
accumulation within tissues. It may be hypothesized that PPARγ is responsible for hepatic steatosis
because its positive association with steatosis and lipogenic genes [124]. However, PPARγ
agonists such as thiazolidinediones decrease the accumulation of hepatic lipids in type II diabetes
patients likely through improving adipose tissue insulin sensitivity [125-127]. This suggests that
while hepatic PPARγ is nutritionally-responsive and contributes to hepatic steatosis, other
transcription factors and adipose insulin resistance could be important contributors to hepatic
steatosis associated with obesity.

2.3.3. Liver X Receptor

Liver X receptor (LXR) is a major nuclear receptor controlling lipid metabolism [128]. The natural
ligands for LXR are the oxysterols, which are produced when cellular cholesterol levels are high
[129]. LXR is partially responsible for maintaining cellular cholesterol balance. Two isoforms of
this transcription factor exist, LXRα/β. LXRα is more prominent in major metabolic tissues such
as the intestines, liver, and adipose [130], while LXRβ is ubiquitously expressed and at its highest
in the brain [130]. LXRα target genes include inducible degrader of the low-density lipoprotein
receptor (Idol) [131], proprotein convertase subtilisin/kexin type 9 (Pcsk9), Niemann-pick C1 like1 (Npc1l1), and the ATP-binding cassette transporter sub family (Abca1, Abcg1, Abcg5, Abcg8).
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Pcsk9 [132] and Idol [133] will both impair the recycling and induce the degradation of lowdensity lipoprotein receptor (LDLr), decreasing its presence on the cellular membrane, and
ultimately reducing LDL uptake. Npc1l1 is required for cholesterol absorption in the intestine and
will be increased when intestinal cholesterol levels are lowered [134]. Abcg5 functions in a
heterodimer with Abcg8 and will efflux free cholesterol back into the intestinal lumen [135].
Overall, LXRα functions to reduce cellular cholesterol levels.

2.3.4. Sterol Response Element Binding Proteins

Three major SREBP isoforms exist, -1a, -1c, and -2. Classically, nascent SREBP is bound to
SREBP cleavage-activating protein (SCAP) and insulin-induced gene product (INSIG) [136].
When cellular cholesterol levels are high, SREBP is retained within the endoplasmic reticulum
and effectively inactive [137]. When the ER membrane is depleted of cholesterol, SCAP and
INSIG dissociate, releasing SREBP from the ER and it is shuttled to the Golgi apparatus where it
is further matured by enzymatic cleavage [137]. Insulin can stimulate SREBP-1c protein
expression through LXR activity [138, 139]. However, LXR does not seem to strongly induce
SREBP-1c maturation [140]. Insulin also downregulates the expression of INSIG
posttranslationally, which has been shown to increase SREBP-1c maturation [136]. SREBP-1c
contributes to de novo fatty acid synthesis by controlling the gene expression of several related
enzymes. Some of its target genes are Fas, Scd1, and Acc [141]. SREBP-2 stimulates cholesterol
biosynthesis upon activation. Most notably, SREBP-2 positively regulates the transcription of 3hydroxy-3-methyl-glutaryl-coenzyme A reductase (Hmgcr) [142] and Ldlr [143]. The ratelimiting enzyme in cholesterol biosynthesis is Hmgcr. Additionally, Ldlr is an apolipoprotein (apo)
B-100 and apoE-recognizing receptor that is responsible for uptake of LDL, a cholesterol-rich
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lipoprotein, into the liver. Thus, the SREBPs help increase de novo lipogenesis when cellular
cholesterol is depleted.
The network of transcriptional regulation for lipid metabolism in the liver, adipose, and
skeletal muscle is diverse and extensive. The focus of this review was to orient the reader to some
of the key transcription factors and target genes used in the following aims to evaluate the
metabolic phenotype of mice. Although many pharmaceuticals have targeted the numerous
pathways mentioned above, they are not without negative consequences. One such pathway is at
the level of intestinal lipid absorption. Two drugs commonly used to inhibit lipid absorption are
orlistat and ezetimibe. Ezetimibe inhibits intestinal cholesterol absorption leading to lower plasma
low-density lipoprotein cholesterol (LDL-C) and CVD risk [144]. In obese patients with IR,
therapies targeting cholesterol absorption (e.g., ezetimibe) are effective in treating dyslipidemia
[145, 146], reducing visceral fat mass [146], and systemic inflammation [145]. Orlistat inhibits
lipid absorption by disrupting lipase activity. This would inhibit fatty acid uptake by not allowing
TGs to be hydrolyzed. Orlistat has been found to be an effective weight loss drug and improves
the metabolic outcomes of patients [147]. However, as with most drugs, undesirable side effects
may occur, including liver damage (e.g., ezetimibe, orlistat) [148, 149], gastrointestinal distress
(e.g., orlistat) [150], and potentially cancer-promoting effects (e.g., orlistat) [151]. Therefore, a
need exists for alternative or complementary therapies targeting lipid absorption.

2.4. Dietary Sphingomyelin for the Prevention of Metabolic Dysfunction
2.4.1. Structure of Sphingomyelin

Sphingomyelin (SM) is a dietary lipid found in eggs, dairy, and meat. Sphingomyelin is considered
a sphingolipid. Despite their immense structural diversity, all sphingolipids are grouped together
by their amino alcohol backbone [152]. Although >60 sphingoid backbones exist, the most
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common in mammalian tissues is sphingosine ((2S,3R,4E)-2-aminooctadec-4-ene-1,3-diol) [153].
Some of the most common variations include sphinganine, also known as dihydrosphingosine
((2S,3R-2-aminooctadecane-1,3-diol), which lacks the 4C double bond and phytosphingosine
((2S,3S,4R)-2-aminooctadecane-1,3,4-triol), which replaces the 4C double bond of sphingosine
with an additional hydroxyl group [153, 154]. Shorthand nomenclature for sphingoid backbones
are similar to fatty acids, in that they follow the form C:D, where C is the number of carbons and
D is the number of double bonds. The distinction between fatty acids and sphingoid bases is the
inclusion of a “d” or “t” to indicate the number of hydroxyl groups. For instance, sphingosine can
be written as d18:1, sphinganine is d18:0, while phytosphingosine is t18:0 [155]. Ceramide is
generated with the addition of an N-acylated fatty amide. In general, SM is a ceramide with
phosphodiester bound choline. For a comparison of the structures of sphingoid backbones,
ceramide, and SM refer to Figure 2.2.
Figure 2.2. Structure of common bases, ceramide, and SM

2.4.2. Sphingolipids in the Typical Diet

On average, a Western diet contains 200-400 mg/day of sphingolipids [156]. Most dietary
sphingolipids are supplied by animal products, such as meat, eggs, and dairy. Sphingomyelin is
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the predominant sphingolipid in mammalian cells, and therefore, most dietary sphingolipids are
SM. Table 2.1 contains a list of some of the most common dietary sphingolipids.
It is inaccurate to think of dietary SM as a single molecular species. In fact, SM is an
umbrella term for a family of related lipid molecules containing a sphingoid backbone, fatty amide,
and phosphorylcholine group. For comparison, both milk-derived SM and egg-derived SM vary
greatly from each other. In terms of the N-acyl linked fatty amide, milk-derived SM species have
a more varied fatty amide composition (16:0-24:0) compared to egg-derived SM species, which
contain primarily palmitate. Similarly, milk-derived SM species have sphingoid backbones
ranging from d16:0-d19:0 in contrast to egg-derived SM species, which contain almost exclusively
sphingosine [157, 158]. Figure 2.3 illustrates the comparison of milk and egg SM structures from
a commercial supplier (Avanti Polar Lipids). This difference in sphingoid backbones means milk
SM contains higher levels of dihydroSM [158]. DihydroSM binds more tightly to cholesterol than
SM in an in vitro model membrane [159]. Sphingomyelin is a potential bioactive component of
the milk fat globular membrane (MFGM) and milk polar lipid (MPL) fractions, both of which have
shown beneficial effects [160]. Studies containing these provide insight into possible whole-food
sources of dietary sphingolipids, but the bioactive effects of other phospholipids cannot be ruled
out [160, 161].
Sphingomyelin hydrolysis begins in the intestinal tract by the action of alkaline SMase
(alk-SMase) [168]. Ceramide will then be hydrolyzed further to sphingosine and a FA by neutral
ceramidase [169]. Sphingosine itself is readily absorbed [170]. Sphingomyelin digestion is delayed
by other dietary lipids through the inhibition of alk-SMase activity [171]. Alk-SMase activity
peaks around the middle of the intestines after most
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most other lipids have been absorbed. Due to the delayed activation of alk-SMase, around 20% of
intact dietary SM reaches the ileum in humans [172]. Once absorbed, sphingosine has two
metabolic fates. It can be resynthesized into ceramide or, through a two-step process, be converted
to hexadecane and ethanolamine after conversion to sphingosine-1-phosphate. The majority of
intestinal sphingosine follows the latter path [169].
Table 2.1. Common dietary sphingolipids
Sphingolipid

Sphingomyelin

Ceramide

Cerebroside

Ganglioside

Total Sphingolipids

Dietary Sources
Bovine Milk, Whole
Beef
Egg
Cottage Cheese
Mackerel
Chicken Liver
Rice Bran
Soybean
Corn
Rice Bran
Soybean
Amaranth Grain
Bovine Milk, Whole
Mackerel
Chicken Egg Yolk
Chicken Liver
All Sources

Content (mg/100g)
9
44-69
82
139
224
291
5.6
11.5
11.5
11.5
20
310
39
0-11
6.48
15.9
29
200-400 mg
consumed/day

Ref

[162]

[163]
[164]
[163]
[164]
[165]
[166]
[165]

[167]

[156]

2.4.3. Dietary Sphingomyelin and Lipid Absorption

Dietary SM dose-dependently reduces intestinal absorption of cholesterol, TG, and long-chain FAs
in rodents [173-177]. In vitro experiments demonstrated that the products of SM digestion,
ceramide and sphingosine, inhibit both cholesterol and FA uptake [178-180]. The inhibitory effects
of SM are seemingly dependent on the source. When comparing egg SM to milk SM, milk SM
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inhibited the intestinal absorption of fat and cholesterol more so than egg SM in dual-cannulated
rats [176]. This is likely due to the structural differences as mentioned above (see Figure 2.3).

Figure 2.3. Compositional differences between egg- and milk-derived SM

A) Fatty Amide Composition of Egg- and Milk-derived SM B) Sphingoid Backbone of Egg- and MilkDerived SM

2.4.3.1 Animal Studies and Serum Lipids

Due to the scarcity of studies that fed purified SM and examined serum lipids, we will review the
studies feeding any purified sphingolipid or sphingolipid-rich extracts. In several rodent feeding
studies, dietary sphingolipids or sphingolipid-rich fractions have shown mixed effects on serum
lipids. Most studies reported reductions [177, 181-185], however, others observed no effect [185188], and some found increases [181, 189]. Duivenvoorden et al. fed hyperlipidemic
APOE*3Leiden mice a Western-type diet (15% cocoa butter, 0.25% cholesterol by weight)
supplemented with various sphingolipids, ranging from SM to sphingosine [177]. At 0.2% and
0.4% (w/w of the diet) all dietary sphingolipids caused more than a 20% reduction of plasma
cholesterol and TG [177].

Zucker-fatty rats fed chicken-derived SM or corn-derived
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glycoceramides showed reduced plasma cholesterol after 4 weeks compared to control [183]. In
contrast, the addition of egg SM to a milkfat-containing high-cholesterol diet fed to C57BL/6J
mice had no effect on plasma lipids [186]. Apolipoprotein E-/- mice fed a HFD with and without
egg SM (1.2% wt:wt) demonstrated no differences in plasma lipids and no effect on atherosclerosis
development [188]. However, low-fat fed apoE-/- mice demonstrated a decrease in en face aortic
plaques with 1.2% (wt:wt) egg SM supplementation [188].
Mixed fractions of polar lipids containing SM also show equivocal results. When feeding
SM as part of a milk-derived polar lipid extract to mice fed a HFD (21% w:w butter fat, 0.15%
cholesterol), serum cholesterol and hepatic lipids were significantly reduced [184]. Similarly, MPL
fractions, fed to genetically obese AAy mice, reduced plasma cholesterol after only 4 weeks [182].
Conversely, a milk phospholipid concentrate (1.2% phospholipid w/w of diet, containing ~ 0.25%
wt:wt of the diet SM) added to a HFD (20% fat by weight) had no effect on plasma lipids over 8
weeks [187]. Plasma cholesterol, plasma SM, and aortic plaques were increased by a modified
AIN-76A diet with 1% (w/w) ox brain sphingolipids (28% SM) fed to female LDLr-/- mice for 12
weeks [189]. In the context of HFD or obesity, dietary sphingolipids generally reduce plasma
cholesterol or hepatic lipids, which will be discussed below. Only in genetically
hypercholesterolemic mice on a chow diet were elevations in plasma cholesterol reported.
Therefore, there is sufficient evidence to suggest dietary SM has hypolipidemic effects when
chronically fed to rodents.

2.4.3.2 Clinical Trials and Serum Lipid Outcomes

Unlike rodents, human bile contains alk-SMase, so the relative efficiency of SM digestion is likely
increased [172]. There is currently one study that supplemented humans with purified SM [190].
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Ramprasath et al. found that 1 g/day of purified milk SM supplementation over 2 weeks of
prepared meals raised high-density lipoprotein cholesterol (HDL-C) but did not affect non-HDLC or cholesterol absorption in healthy adults [190]. There are studies examining the effects of other
sphingolipids or sphingolipid-rich extracts on clinical lipid profiles. These may provide insight
into potential effects of feeding sphingolipids to humans. A double-blind, placebo-controlled
crossover trial supplying 1 g/day of phytosphingosine for 4 weeks to adult men with metabolic
syndrome reported a significant reduction in plasma LDL-C [191]. Rosqvist et al. supplemented
overweight adults with 40 g of milkfat/day as whipping cream in a single-blind, randomized,
controlled, isocaloric parallel study for 8 weeks. Consuming 40 g of milkfat/day as whipping
cream significantly lowered plasma LDL-C, non-HDL-C, and apoB:apoA-I ratio compared to the
same amount of milkfat as butter oil [192]. Compared to butter oil, whipping cream is rich in milkfat globular membranes, the polar lipid rich fraction in milk [192]. Two clinical trials
supplementing buttermilk for 4 weeks found different results. Ohlsson et al. observed no effect of
4-week supplementation of a buttermilk drink enriched in MFGM, supplying 700 mg milk SM/day
when measuring plasma lipids, in a placebo-controlled parallel study with healthy adults. There
was a trend for a reduction in plasma LDL-C (p = 0.056) in women who drank the treatment drink
[193]. This study was relatively small with 18 participants, and the parallel design does not help
the statistical power. In contrast, 4-week ingestion of 45 g/day of buttermilk resulted in significant
reductions in both plasma cholesterol and TG compared to a calorically-matched placebo [194].
This study was a double-blind randomized cross-over study with healthy adults and indirectly
measured cholesterol absorption through measuring serum β-sitosterol concentration. Serum βsitosterol concentration was correlated with the reductions in plasma LDL-C, suggesting a
reduction in cholesterol absorption was responsible [194]. This study was much more robust with
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38 participants, and the crossover design improved statistical power. In aggregate, there is some
clinical data supporting the hypolipidemic effects found in animals. Due to the scarcity of studies
and the sample sizes used (see Table 2.2), there is a clear need for further clinical trials to confirm
the effects. It is worth noting that rodent studies typically use larger doses of sphingolipids, even
when correcting for body surface area, therefore the smaller effect sizes in clinical studies are
expected.

2.4.4. Dietary Sphingolipids and Other Markers of Metabolic Dysfunction

As reviewed above, obesity can lead to IR and hepatic lipid accumulation. Although no studies at
this point have examined dietary SM for its effects on IR, it is important to recognize that
phytosphingosine (t18:0) has shown potential to reduce IR in both rodents [195] and humans [191].
Feeding a HFD supplemented with 0.2% (w/w) phytosphingosine to mice for 24 weeks reduced
the expression of a macrophage marker (F4/80) in adipose tissue and improved the response to a
glucose tolerance test [195]. A clinical trial examining the daily intake of phytosphingosine (1
g/day) reported a significant reduction in fasting glucose (-5%) along with an improved index of
insulin sensitivity (+10%) in men with MetS and with only minor gastrointestinal distress [191].
A substantial amount of research that examines dietary sphingolipids for the prevention of
hepatic lipid accumulation, the hepatic manifestation of IR, show an inhibitory effect towards
steatosis (see Table 2.3). Supplementing Western-type (21% butter fat, 0.15% cholesterol by
weight) diet-fed mice with egg SM at 0.6% and 1.2% (w/w) for 4 weeks reduced hepatic total lipid
content by 33% and 40%, respectively [186]. These mice also demonstrated reduced in hepatic
total cholesterol content. Meanwhile, mRNA expression of genes involved in fatty acid synthesis
increased in the 0.6% egg SM-fed mice [186]. Male Zucker fatty rats fed an AIN-76A diet with
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Table 2.2. Clinical trials evaluating hypolipidemic effects of dietary sphingolipids
Author
Year
Population
Study Design
Treatment and Duration

Results

Ohlsson
[193]

2009

Healthy adults
(n = 48)

Parallel, placebo

4 weeks of 2 drinks/day totaling 975
mg SL (700 mg SM, 180 mg GC, 95
mg GS) of test drink or 119 mg total SL
in isocaloric placebo drink

Snel
[191]

2010

Men with
MetS
(n = 12)

Double-blind,
placebo, crossover

4 weeks of phytosphingosine (1 g/day)
or placebo in capsule form

↓ Serum cholesterol (-5.6%),
↓ LDL-C (-8.8%), ↔ TG, ↔ HDL-C
compared to placebo

↓ Plasma cholesterol (-3.1%),
↓ TG (-10.7%),
trended for ↓ LDL-C (p = 0.057) compared
to placebo,
↓ LDL-C (-5.6%) in participants with highest
(top 50%) baseline LDL-C

↑ HDL-C (+13%),
↔ total cholesterol,
↔ non-HDL-C, ↔ TG with milk SM

Conway
[194]

Ramprasath
[190]

2013

Healthy adults
(n = 34)

Double-blind,
placebo, crossover

4 weeks of buttermilk powder (187.5
mg total PL, 23.6 mg SM per day) or
placebo (34.6 mg total PL) matched for
calories and minerals

2013

Healthy adults
(n = 10)

Controlled diets,
crossover

2 weeks of prepared diets (30% kcal
from fat, 240 mg cholesterol/day) with
or without 1 g/day added milk SM

↔ Plasma lipids between groups
trend for ↓ plasma LDL-C (p = 0.056) in
women compared to placebo
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Rosqvist
[192]

2015

Overweight
adults
(n = 57)

Single-blind,
parallel

8 weeks of intervention meals with
either 40 g milkfat/day as whipping
cream (19.8 mg total PL) or control diet
with butter oil (1.3 mg total PL),
matched for calories, macronutrients,
and calcium

↓ Plasma cholesterol, ↓ LDL-C,
↓ non-HDL-C,
↓ apoB:apoA-I ratio with whipping cream
vs. control group

1

ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; GC, glucosylceramide; GS, gangliosides; MetS, metabolic syndrome; PL, phospholipid; SL,
sphingolipids; SM, sphingomyelin; TG, triglyceride; ↑, increase; ↓ decrease; ↔, no change.
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and without either 0.5% (w/w) SM prepared from chicken skin, or 0.5% (w/w) glucosylceramide
from corn had significantly lower hepatic lipid content on both treatment diets compared to control
[183]. Additionally, these rats had reduced fasting plasma insulin as well as lower hepatic Scd1
and Acc mRNA in the treatment groups. Conversely, hepatic Pparα mRNA expression was
increased in the SM and glucosylceramide-fed rats, suggesting greater fatty acid oxidation [183].
Chronic supplementation of mice fed a Western-type diet (21% butter fat, 0.15% cholesterol
wt:wt) with milk phospholipid extracts (0.25%-0.35% SM w/w of diet) significantly lowered both
hepatic cholesterol and TG [184, 196]. Milk-derived ceramides (0.35% w/w of diet) given to
genetically obese KK-Ay mice for 4 weeks also reduced hepatic cholesterol and TG [182].
Mechanistically, mice fed a milk SM-enriched HFD (0.35% SM w/w, 28% fat by weight) tended
(p = 0.058) to have lower fractional synthesis of hepatic TG and palmitic acid incorporation (p =
0.062). These mice had a significant reduction in the ratio of hepatic palmitoleic acid (C16:1n7)
to palmitic acid (C16:0), an index of SCD1 activity [197]. In addition, in vitro studies that applied
very-long chain ceramides (C22:0- & C24:0-ceramides) to primary mouse hepatocytes and Huh7
hepatoma cells reduced the expression of both Pparg and Cd36 [198, 199]. This reduction in
lipogenic genes may explain the effect found in vivo [181, 182, 185]. Duivenvoorden et al. found
when female APOE*3Leiden mice were fed a Western-type diet (15% cocoa butter, 0.25%
cholesterol by weight) supplemented with 1% phytosphingosine (w/w of the diet) for 5 weeks,
their hepatic TG and cholesterol content, as well as plasma alanine transaminase and serum
amyloid A were significantly reduced. This demonstrates a less steatotic liver that is potentially
less inflamed. Interestingly, hepatic mRNA expression indicated lipid biosynthesis was
upregulated compared to control, suggesting some compensatory mechanism [177].
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Structurally distinct ceramides seemingly have different biological functions [200]. Thus, the
distribution of ceramide species could be important for normal tissue function. Notably, the
ceramide profile of rodent livers is associated with hepatic function. As an example, primary
hepatocytes from mice lacking ceramide synthase 2, an enzyme required for C22- and C24ceramide synthesis, have reduced insulin sensitivity [198, 201, 202]. C16-ceramide synthesis
increases in these mice [202], C16:0-ceramide is also associated with deleterious effects on
hepatocyte function [203, 204]. Therefore, a balance may be required between different length
ceramides. Diet-induced obesity causes an increased hepatic C16:0-ceramide concentration and
ceramide synthase 5 and 6 expression, the major enzymes responsible for C16:0-ceramide
synthesis [204, 205]. Thus, a balance between the C22-/C24-ceramides and C16-ceramide may be
important for proper liver function. Consequently, the effects of dietary sphingolipids on hepatic
sphingolipid profiles could be an important endpoint. Unfortunately, this is largely unknown. One
study reported no change in total ceramide in the livers of mice supplemented with 0.6% egg SM
(wt:wt), although C16:0-ceramide was reduced and C22- and C24- ceramides were unaffected
[186]. This was reported with an overall improved hepatic phenotype.
In summary, dietary SM has shown promise to reduce the occurrence of dysfunctional lipid
metabolism in mice. Although there are few clinical trials in the field, they show either beneficial
effects of dietary sphingolipids or may have suffered from a lack of statistical power. Therefore,
more research is needed to fully determine the efficacy of dietary SM for improvements in lipid
metabolism, especially in humans. Additionally, absorption studies suggest a functional difference
between SM derived from egg and milk due to their structural differences. This coupled with a
lack of studies comparing the two, leaves an obvious gap in the literature to directly compare the
hypolipidemic effects of dietary SM from different sources.
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Table 2.3. Dietary sphingolipids and hepatic steatosis
Author
Year
Animal Model

Duivenvoorden
[177]

Wat
[184]

Kamili
[196]

Yunoki
[183]

Diet and Duration

Hepatic Lipids Results

2006

Female ApoE*3
Leiden mice (n =
6)

5 weeks of Western-type diet (15% cocoa
butter; 0.25% cholesterol) supplemented with
0.1% (w/w) phytosphingosine (PS)

PS: ↓ TG (-56%), ↓ TC (-61%), ↓ FC
(-11%)

2009

Male C57BL/6
mice
(n = 10)

8 weeks of either LFD or Western-type diet
(21% milkfat; 0.15% cholesterol) with and
without 1.2% PL (w/w) from phospholipid-rich
dairy milk extract (PLRDME) (0.26% of diet by
weight as SM)

PLRDME with LFD: ↔ total lipid,
↔ TG, ↔TC, ↔PL PLRDME with
Western-type diet: ↓ total lipid (33%), ↓ TG (-44%), ↓ TC (-48%), ↓
PL (-16%)

2010

Male C57BL/6
mice
(n = 10)

8 weeks of Western-type diet (21% milkfat;
0.15% cholesterol) with and without 1.2% PL
(w/w) from phospholipid-rich dairy milk extract
(PLRDME) (0.26% SM w/w) or 0.2% (w/w)
milk phospholipid concentrate (PC-700) (0.34%
SM w/w)

PLRDME (0.26% SM w/w): ↓ total
lipid (-41%), ↓ TG (-47%), ↓ TC (39%)PC-700 (0.34% SM w/w): ↓
total lipid (-45%), ↓ TG (-63%), ↓
TC (-57%)

2010

Male Zucker rats
(n = 6)

45 days of AIN-93 diet supplemented with 0.5%
(w/w) of chicken skin SM or 0.5% (w/w) corn
GC

SM: ↓ total lipid (-24%), ↔ TC GC:
↓ total lipid (-18%), ↔ TC
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Watanabe
[182]

Chung
[186]

2011

2013

Female KK-Ay
mice
(n = 7)

Male C57BL/6
mice
(n = 10)

4 weeks of AIN-93G diet with1.7% (w/w) of
lipid-concentrated butter serum (LC-BS) (0.13%
SM, 0.18% ceramides by weight in diet) or
0.5% (w/w) ceramide-rich fraction (Cer-fr)
(0.34% ceramide by weight in diet) or 0.5%
(w/w) SM-rich fraction (SM-fr) (0.25% SM by
weight in diet)

LC-BS: ↓ TG (-27%), ↔ TCCer-fr:
↓ TG (-38%), ↓TC (-47%) SM-fr: ↔
TG, ↔ TC

4 weeks on a Western-type diet (21% milkfat;
0.15% cholesterol) with 0.3, 0.6, 1.2% (w/w)
egg SM

0.3% SM: ↓ total lipid (-20%), ↓ TC
(- 36%), ↓ TG (-31%)0.6% SM: ↓
total lipid (-33%), ↓ TC (- 48%), ↓
TG (-46%)1.2% SM: ↓ total lipid (40%), ↓ TC (- 67%), ↓ TG (-56%)

Cer-fr, ceramide-rich fraction; FC, free cholesterol; GC, glucosylceramides; HFD, high-fat diet; LC-BS, lipid-concentrated butter serum;
LFD, low-fat diet; PL, phospholipids; PLRDME, phospholipid-rich dairy milk extract; PS, phytosphingosine; SL, sphingolipids; SM,
sphingomyelin; SM-fr, sphingomyelin-rich fraction; TC, total cholesterol; TG, triglycerides; ↑, increase; ↓, decrease; ↔, no change.
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2.5. Other potential bioactive roles of dietary SM
In addition to the reported hypolipidemic and insulin-sensitizing effects, dietary SM may have
other bioactivities. Thus, it may confer additional benefits compared to the hypolipidemic drugs
orlistat and ezetimibe. Two of these effects include modulation of the gut microbiota and
attenuation of inflammatory signalling.

2.5.1. Anti-inflammatory Effects of Dietary Sphingolipids In Vitro

Several cell studies utilizing exogenous sphingolipids have shown these lipids to be antiinflammatory. J774 immortalized cells and thioglycollate-elicited peritoneal macrophages had
lowered LPS-induced TNF-α and macrophage inflammatory protein 2 (MIP-2) secretion when
pretreated with either 10 µM C8-ceramide or sphingosine treatment [206]. Aiming to elucidate the
mechanism, this study proceeded to explore the potential for the synthesis of sphingosine-1phosphate, a sphingolipid metabolite, to be anti-inflammatory. Supporting this hypothesis,
sphingosine-1-phosphate was found to be a PPARγ ligand [207]. However, sphingosine-1phosphate synthesis was found to be dispensable, as a sphingosine kinase inhibitor had no effect
on ceramide and sphingosine’s effects on LPS-induced TNF-α production [206]. Exogenous
sphingosine given to RAW 264.7 macrophages transfected with a PPARγ luciferase plasmid acted
as a modest agonist of PPARγ [208]. PPARγ binding can repress NF-κB activity [209], giving a
putative mechanism for the inhibition of inflammatory gene expression. Bovine brain SM was
shown to inhibit LPS-stimulation of granulocytes [210]. C8-ceramide (10 µg/mL) inhibited LPSstimulated secretion of IL-10 and IL-5 from bone marrow-derived mast cells, although ceramide
did not alter TNF-α, IL-13, or IL-6 [211]. Additionally, thioglycollate-elicited peritoneal
macrophages treated with C8-ceramide had a reduced production of IL-6, IL-12p40, and TNF-α
in response to LPS. The difference between macrophage and mast cell responses were attributed
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to variations in PI3K-Akt and mitogen-activated protein kinase (MAPK) phosphorylation between
the two cell types [211]. Thus, exogenous sphingolipids may not affect all cells similarly. Treating
RAW 264.7 macrophages with 10-50 μM of C2-ceramide inhibited both the activation of NF-κB
and adapter protein-1 by LPS, while reducing the production of nitric oxide and prostaglandin
[212].
Other complex sphingolipids and sphingolipid-rich dairy fractions have shown antiinflammatory effects. Gangliosides administered ex vivo to infant bowel epithelial cells, taken
from viable infants, inhibited LPS- and hypoxia-induced inflammation, measured by nitrite
release, IL-8, IL-6, IL-1β, eicosanoid, and hydrogen peroxide production [213]. Most studies used
LPS as the inflammatory stimuli, suggesting there may be a lipid-lipid interaction with the
sphingolipids as the potential mechanism. Interestingly, sphingolipid-rich dairy fractions inhibited
monosodium urate-induced IL-8 mRNA and protein expression in THP-1 monocytes. Although,
in this study the dairy fraction had no effect on cytokine production in response to LPS [214].
Some in vivo observations support sphingolipids for inhibiting LPS activity. For example,
sphingolipid-containing lipoproteins neutralize LPS activity by forming phospholipid:LPS
complexes [210, 215]. After intraperitoneal (IP) injection of LPS, the liver increases sphingolipid
production, enriching circulating lipoproteins [216], possibly in an effort to detoxify LPS.
Sphingosine is known to potently inhibit protein kinase C [217], an enzyme that drives
inflammatory signalling in macrophages [218].
In summary, these studies illustrate mechanistic evidence for exogenous sphingolipids and
its derivatives to have inhibitory effects on inflammation. Due to the dynamic nature of
sphingolipid metabolism, at this time it is impossible to pinpoint which metabolite is responsible.
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If the catabolic metabolites are the causal factor, the effects of glycosphingolipids could be applied
to SM.
In contrast to the above studies, some experiments demonstrate pro-inflammatory effects
of exogenous sphingolipids. Treating thioglycollate-elicited peritoneal macrophages with 50-100
µM milk-derived SM, C16-SM, or C24-SM elevated iNOS mRNA [219]. Human embryonic
kidney (HEK) cells transfected with TLR4 have an increase in TNF-α production in response to
exogenous 1.5 µM C8- and C2-ceramide treatment, however, adding soluble CD14 inhibited the
effect of C2-ceramide [220]. It should be noted that HEK cells lack CD14, while both membraneanchored and soluble CD14 are expressed across many cell types to varying degrees [221]. Thus,
disparity in CD14 expression may cause cell type-specific effects, as cells that express less CD14
may respond differently to sphingolipids. Interestingly, longer-chain ceramides may actually
compete with LPS and block TLR4 signalling, as they bind CD14 in monocytes and appear to
reduce TLR4-CD14 interactions [222]. C2-ceramide (50 μM) induces c-Jun N-terminal kinase
(JNK) and MAPK in macrophages [223]. However, C2-ceramide failed to activate NF-κB.
Furthermore, C2-ceramide had no effect on LPS-stimulated translocation of NF-κB. In another
study, RAW 264.7 macrophages incubated with 100 μM C2-ceramide stimulated JNK activity,
despite no effect on MAPK and NF-κB [224]. Although some studies report pro-inflammatory
effects, the studies with long-chain sphingolipids use much higher concentrations. C2 and C8ceramides have questionable biological relevance since they are not naturally produced and are
typically only used because they are cell permeable, unlike their long chain counterparts.
In summary, results from several studies supporting an anti-inflammatory role of
exogenous long-chain sphingolipids. However, the evidence indicating pro-inflammatory effects
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of sphingolipids in the absence of LPS when given in high doses warrants more research to uncover
the precise molecular mechanisms of exogenous sphingolipids and inflammation.

2.5.2. Animal Models of Acute Inflammation

The anti-inflammatory effects of dietary sphingolipids found in cell studies have also been
demonstrated in rodents. After chronically feeding young male Sprague Dawley rats a HFD
containing dairy-derived ganglioside (0.02% wt:wt of the diet), elevations in serum IL-1β and
TNF-α were attenuated six hours after IP injection of LPS compared to the HFD control group
[225]. The intestinal mucosa of these rats expressed less platelet activating factor, leukotriene B4,
prostaglandin E2, IL-1β, and TNF-α, alongside elevated ganglioside content, suggesting that
dietary ganglioside protected against both systemic and intestinal LPS-induced inflammation
[225]. Supporting these findings, Sprague Dawley rats fed the same ganglioside-supplemented diet
had heightened plasma and intestinal IL-10 when treated with LPS, while iNOS expression as well
as nitrate and nitrite production were blunted with ganglioside treatment [226]. These gangliosiderich diets also impaired the LPS-induced loss of occludin protein from intestinal mucosa
suggesting improved gut barrier function [226]. Male BALB/c mice on a chow diet fed a MFGMsupplemented (12.5% wt:wt) for 5 weeks were resistant to the effects of an IP LPS-challenge [227].
The MFGM mice had reduced gut permeability and reductions in serum interferon γ (IFNγ), IL-6,
IL-10, IL-17, IL-12p70, monocyte chemoattractant protein 1 (MCP-1), and TNF-α after 24 hours
[227]. MFGM also improved mouse survival at 48 hours compared to control [227]. Upon IP
injection of monosodium urate, mice fed a diet supplemented with phospholipid- and sphingolipidrich dairy fractions (0.8-7.0% wt/wt of the diet) had reduced cell migration into the peritoneal
space compared to control [214]. The dietary phospholipids seemingly reduced the recruitment of
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immune cells. Overall, animal studies examining the effects of sphingolipid and polar lipid
mixtures on acute inflammation showed a reduced inflammatory response. There are no studies
examining the effects of purified SM on acute inflammation. However, again if the effects are due
to the catabolic products as suggested by the in vitro studies, these findings could be applicable to
dietary SM.

2.5.3. Dietary Sphingolipids and Inflammation: Clinical Trials

Like the hypolipidemic effects, there are limited clinical trials exploring the potential benefits of
dietary sphingolipids in inflammation. These studies examined post-prandial inflammation due to
ethical restrictions on inducing sepsis in humans. Additionally, increased post-prandial
inflammation is linked with increased risk for cardiometabolic disease [228]. Thus, treatments that
can attenuate this inflammation could be preventative in cardiometabolic diseases. A milk fat
globular membrane fraction supplementation given to overweight adults during saturated fat-rich
meals increased serum IL-10 and decreased soluble intercellular adhesion molecule (sICAM)
compared to isocaloric control meals [229]. IL-10 and sICAM are inversely related, as IL-10 is
anti-inflammatory and sICAM is associated with inflammation [230]. A pilot study comparing
isocaloric smoothies containing palm oil, made with and without MFGM, found modest reductions
in sICAM when MFGM was fed to obese adults [231]. This study did not match fatty acids
between the meals making the detection of differences in post-prandial inflammation difficult. The
limited number of human studies, along with the use of complex mixtures of phospholipids, makes
it difficult to pinpoint the effects of sphingolipids on post-prandial inflammation in humans. Thus,
more research is needed with both polar lipid extracts and purified sphingolipids to elucidate the
effects in humans.

48

2.5.4. Dietary Sphingolipids Attenuate Animal Models of Chronic Inflammation
2.5.4.1. Colitis Models

Dietary SM (0.1% wt/wt, unspecified source) reduced colonic myeloperoxidase and histological
damage induced by dextran sodium sulfate (DSS) [232]. Additionally, feeding milk SM (0.1%
wt:wt) to DSS-treated mice moderately attenuated colitis in a PPARγ-dependent manner. These
mice had immunostimulatory gene expression including Ccl11/19/20 and Cxcl9/11 [208].
However, some anti-inflammatory genes were also upregulated and therefore, may have reduced
the potential histological damage. BALB/c mice fed a maize glucosylceramide-supplemented
(0.1% wt/wt) diet were resistant to 1,2-dimethylhydrazine induced colonic expression of TNF-α,
regulated on activation, normal T cell expressed and secreted (RANTES), macrophage colony
stimulating factor, and interferon-inducible T-cell alpha chemoattractant (I-TAC) [233].
Corroborating this, DSS-treated BALB/c mice fed glucosylceramide (0.1% wt:wt) also had
reduced colonic expression IL-1α/β, sICAM1, IL-16, interferon gamma-induced protein 10,
monokine induced by gamma interferon, and tissue inhibitor metallopeptidase 1 [234]. Overall,
there are studies suggesting an inhibitory role for dietary sphingolipids in chemically-induced
colitis. Conversely, 4 mg/day of egg SM administered via gavage exacerbated colitis and apoptosis
in both DSS and IL-10-/- colitis mouse models [235]. This study found increased ceramide content
in the intestinal epithelium. Although this study found pro-inflammatory effects, the administration
method could account for the differences. The gavage method administered the 4 mg in one dose,
whereas the chronic feeding studies dispersed the dose throughout the day. In line with what has
been observed with in vitro studies, single large doses may have pro-inflammatory effects in vivo
as well.
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Other potential roles of sphingolipids in the intestine are related to the gut barrier. Rat pups
fed milk SM have shown improved markers of gut maturation [236], suggesting dietary SM found
in breast milk [237] may be important for new-born gut development and health. Furthermore, egg
SM protects intestinal epithelial cells from the cytotoxic detergent effects of bile salts [238]. This
could have implications in HFD as deoxycholic acid plays a crucial role in HFD-induced gut
barrier dysfunction [239].

2.5.4.2. Animal Models of High-Fat Diet-Induced Inflammation

As reviewed above, inflammation is crucial in the development of metabolic dysfunction. Lecomte
et al. supplemented mice fed a HFD (40% kcal from fat) with 2% (wt/wt) MPL, supplying about
0.3% milk SM. In general, MPL protected mice from the deleterious effects of HFD [240]. For
instance, MPL increased the intestinal expression of Mucin2, suggesting increased intestinal
integrity. The adipose tissue of MPL-fed mice had reduced CD68 mRNA, a marker of adipose
macrophage infiltration [240]. The effects on inflammation may be due in part to MPL ability to
reduce intestinal leakiness [227], thus limiting endotoxin translocation. The complexity of
phospholipid extracts makes it difficult to discern the causal agent in these studies. Not only have
dietary phospholipids been reported to have their own beneficial health effects [160], they can also
increase milk SM-derived ceramide appearance in the lymph [241], and thus potentially increase
SM absorption. Further studies are needed to link dietary sphingolipids to diet-induced
inflammation, however, there is potential for anti-inflammatory effects as shown by MPL feeding.

2.4.5. Dietary Sphingolipids Interactions with the Gut Microbiota

The gut microbiota spans the length of the intestines but is orders of magnitude more
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concentrated in the colon [242]. It is important to note that significant quantities of both dietary
SM and its hydrolytic products can reach the colon in humans [172] where they may affect the
bulk of the gut microbiota. Sprong et al. reported sphingosine has in vitro bactericidal properties
against a variety of enteropathogens including bacteria from different phyla, as well as both Gramnegative and -positive bacteria [243]. Examining the translatability of this is difficult, only a few
studies report gut microbiota or microbiota-related outcomes (e.g. serum LPS) after sphingolipid
feeding. Milk fat globular membrane consumption attenuated gastrointestinal complications
associated with the administration of a diarrheagenic strain of E. coli in humans [244]. Infant
formulas containing gangliosides significantly altered the fecal microbiota by decreasing E. coli
and increasing Bifidobacterium [245]. This study suggested the effects may be related to the
oligosaccharide moieties acting as prebiotics. However, the broad spectrum bactericidal effects of
sphingosine [243] and interactions of specific ceramide moieties with bacteria may also play a role
[246]. In contrast, Reis et al. did not observe any significant differences in cecal microbiota of
mice in response to various sphingolipid-rich diets for 5 weeks [197]. Another consideration for
interactions between dietary SM and gut microbiota is the production of trimethylamine by the gut
microbiota when in the presence of excess choline. Trimethylamine is a precursor to
trimethylamine N-oxide, which has been tentatively related to CVD disease [247]. However,
recently Rye and colleagues demonstrated that only at excessively large doses of dietary egg SM
did serum trimethylamine N-oxide modestly increase [188]. Furthermore, there was a reduction in
aortic lesion area when mice were fed egg SM on a low-fat diet but, there was no difference
between the control and SM group when broad-spectrum antibiotics were used to deplete the gut
microbiota. This suggests there is an important, potentially protective interaction between SM and
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gut microbiota on atherosclerosis [188]. At this moment, more research is needed to fully
understand the interaction of dietary SM and gut microbiota.

..
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3.1. Abstract
High dietary fat intake can cause elevated serum and hepatic lipids, as well as contribute to gut
dysbiosis, intestinal barrier dysfunction and increased circulating lipopolysaccharide (LPS).
Dietary milk sphingomyelin (SM) has been shown to inhibit lipid absorption in rodents. We
evaluated the effects of milk SM on lipid metabolism and LPS levels in C57BL/6J mice fed a highfat diet for 4 weeks and compared it with egg SM. Mice were fed a high-fat diet (45% kcal from
fat) (CTL, n = 10) or the same diet modified to contain 0.25% (wt/wt) milk SM (MSM, n = 10) or
0.25% (wt/wt) egg SM (ESM, n = 10). After 4 weeks, MSM had gained significantly less weight
and had reduced serum cholesterol compared to CTL. ESM had increases in serum cholesterol,
triglycerides, phospholipids and SM compared to CTL. MSM significantly decreased, while ESM
increased, hepatic triglycerides. This may have been related to induction of hepatic stearoyl-CoA
desaturase-1 mRNA observed in ESM. MSM displayed intestinal and hepatic gene expression
changes consistent with cholesterol depletion. MSM had significantly lower serum LPS compared
to CTL, which may have been due to altered distal gut microbiota. Fecal Gram-negative bacteria
were significantly lower, while fecal Bifidobacterium were higher, in MSM. These results suggest
that milk SM is more effective than egg SM at combating the detrimental effects of a high-fat diet
in mice. Additionally, distal gut microbiota is altered with milk SM and this may have contributed
to the lower serum LPS observed.

3.2. Introduction
High dietary fat is thought to contribute to obesity incidence due to its high energy density and
therefore higher risk of overconsumption [1]. Compared with low-fat diets, feeding mice high-fat
diets or “Western”-type diets (40–60% kcal as fat) ad libitum results in development of obesity
and diabetes, characterized by increased adiposity, hepatic steatosis, systemic inflammation and
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insulin resistance [2]. In addition, high-fat diets contribute to elevated serum LPS concentrations
(also known as endotoxin), which may precede the associated increases in systemic inflammation,
insulin resistance and hepatic steatosis [3,4]. Dietary fat may increase appearance of gut-derived
LPS in circulation by enhancing transcellular transport via chylomicrons [5,6] and/or paracellular
leakage across the gut barrier [7]. High-fat-diet feeding of mice has also been shown to markedly
alter the gut microbiota [8,9]. Gut dysbiosis has been linked with endotoxin-mediated hepatic
steatosis in mouse models [10]. Detrimental effects of high-fat diet in mice appear to be influenced
by gut microbes, since administration of broad-spectrum antibiotics attenuated the elevation in
plasma LPS and improved metabolic parameters [8]. Along with excessive dietary fat, higher
cholesterol absorption is linked with deleterious health effects. Cholesterol absorption is widely
recognized to influence fasting plasma lipids and risk for cardiovascular disease [11]. Besides the
well-known effects on plasma lipids, dietary cholesterol exacerbates inflammation in adipose
tissue [12] and liver [13,14] in mouse models of obesity. Therefore, an important strategy to
manage complications of obesity would be to reduce lipid absorption as a means to improve
complications such as dyslipidemia, hepatic steatosis and low-grade inflammation.
Dietary sphingomyelin (SM) and other sphingolipids have been shown to dosedependently reduce the absorption of cholesterol, triglycerides and fatty acids in rodents [15–18].
SM consists of a ceramide (a fatty acid linked to a long-chain sphingoid base through an amide
linkage) with a phosphorylcholine head group. Digestion of SM in the intestine is slow and
incomplete but yields ceramide and sphingosine that can be absorbed into intestinal mucosal
cells [19]. Products of SM digestion, such as ceramide and sphingosine, also appear to reduce lipid
absorption [18,20]. Sphingosine has been shown to exhibit antimicrobial properties against
pathogenic bacteria, such as Escherichia coli and Salmonella enteritidis [21], suggesting that
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dietary sphingolipids can alter the gut microbiota, along with lipid absorption. The estimated
dietary intakes of sphingolipids is 300–400 mg/day in Western diets, most of which comes from
SM found in dairy products, meats and eggs [22]. SM is abundant in animal cell membranes but
is not found in plants or fungi. Egg SM and milk SM differ in their fatty acid and sphingoid base
composition and, therefore, may have different biological effects on lipid metabolism in vivo. In
rats, milk SM has been shown to be a more potent inhibitor of cholesterol and fatty acid absorption
when compared to egg SM [16]. Although milk SM has been shown repeatedly to inhibit lipid
absorption in rodents [16,17,23], the effects of chronic milk SM intake on lipid metabolism in
vivo have not been studied extensively. While milk SM and digestion products can impact
intestinal luminal interactions and absorption of cholesterol, the sphingolipids themselves may
demonstrate bioactivity and affect lipid metabolism after absorption. Furthermore, whether milk
SM displays a more potent hypolipidemic effect than egg SM is not known. A comparison of
dietary milk SM and egg SM on lipid metabolism has not yet been examined in vivo.
Therefore, we investigated the effects of dietary milk SM on lipid metabolism in C57BL/6J
mice fed a high-fat diet and compared it with egg SM feeding. We hypothesized that milk SM
would improve lipid metabolism, while also being more potent than egg SM at preventing the
elevations in serum and hepatic lipids that occur in mice fed a high-fat diet. We also hypothesized
that the addition of dietary milk SM would result in lower circulating LPS compared with a highfat control diet, by protecting the gut barrier from the damaging effects of absorbed dietary lipids
and altering the gut microbiota.
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3.3. Materials and Methods
3.3.1 Animals and Diets

Male C57BL/6J mice (8 weeks old, n = 30) were obtained from the Jackson Laboratory (Bar
Harbor, ME) and allowed to acclimate to the animal facility for 2 weeks before being fed 1 of 3
anhydrous milk-fat-based, high-fat diets for 4 weeks: high-fat diet control (CTL; 45% kcal as
fat; n = 10), high-fat diet with 0.25% of milk SM added by weight (MSM; 45% kcal as fat; n = 10)
and high-fat diet with 0.25% of egg SM added by weight (ESM; 45% kcal as fat; n = 10). Detailed
composition of the diets is listed in Table 3.1. The ingredients for experimental diets were obtained
from Dyets, Inc. (Bethlehem, PA). Milk SM (bovine) and egg SM (chicken egg) were both
obtained at > 99% purity in powdered form from Avanti Polar Lipids, Inc. (Alabaster, AL) and
were substituted into test diets for an equal amount of anhydrous milk fat. The fatty acid
distribution of the SM obtained varied between milk SM (34% C23:0, 21% C24:0, 20% C22:0,
16% C16:0, 3% C24:1 and 6% unknown) and egg SM (86% C16:0, 6% C18:0, 3% C22:0, 3%
C24:1 and 2% unknown). The sphingoid base composition has also been reported to be different
between egg SM and milk SM, with egg SM containing almost entirely sphingosine (d18:1) bases,
whereas milk SM has a more varied distribution (d16:0 to d19:0) [24]. The anhydrous milk fat
used in high-fat diets generally contains phospholipid concentrations of ~ 0.2–1% (wt/wt) [25,26],
~ 20–25% is SM [25]. Therefore, the overall contribution of SM to the control high-fat diet is
minimal (0.008–0.0525%, wt/wt) compared to what is found in the diets with added SM (0.258–
0.3025%, wt/wt). The amount of dietary SM provided by the 0.25% SM diets is equivalent to
22 mg/kg of body weight in a human or roughly 1.5 g/day to a 70-kg human, based on body surface
normalization [27].
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Table 3.1. Diet composition
g/kg of diet
CTL

MSM

ESM

195

195

195

3

3

3

340

340

340

Corn Starch

56.86

56.86

56.86

Maltodextrin

60

60

60

Anhydrous Milk Fat

210

207.5

207.5

Soybean Oil

20

20

20

Cellulose

50

50

50

Mineral Mix, AIN-93G-MX

43

43

43

Vitamin Mix, AIN-93-VX

19

19

19

Choline Bitartrate

3

3

3

0.04

0.04

0.04

Milk Sphingomyelin

0

2.5

0

Egg Sphingomyelin

0

0

2.5

Casein
L-Cystine
Sucrose

TBHQ

Food intake was assessed biweekly and body weight was assessed weekly. Fresh food was
provided on a weekly basis. After 4 weeks on experimental diets, mice were fasted for 6–8 h prior
to blood collection by cardiac puncture following euthanasia. Blood was allowed to clot at room
temperature for 30 min before serum was isolated by centrifugation (10,000gfor 10 min at 4°C)
and then stored at − 80°C. Tissues were perfused with saline before being harvested, snap-frozen
in liquid nitrogen and stored at − 80°C. The liver, skeletal muscle (quadriceps femoris), epididymal
adipose and small intestines were collected from animals. The entire small intestine from the
pylorus to the cecum was collected, cleaned and divided into four segments (SI-I, SI-II, SI-III and
SI-IV) before being snap-frozen. During the last 3 days prior to sacrifice, fecal samples were
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collected directly from the mouse into sterile tubes and stored frozen at − 20°C until analysis. All
mice were housed in a temperature-controlled room and maintained in a 12-h light/12-h dark cycle
at the University of Connecticut-Storrs vivarium. The Animal Care and Use Committee of the
University of Connecticut-Storrs approved all procedures used in the current study.
3.3.2. Serum Biochemical Analysis

Total serum cholesterol, triglycerides, phospholipids, SM, glucose and nonesterified fatty acids
(NEFA) were measured using enzymatic assays according to manufacturer instructions.
Cholesterol, triglycerides, NEFA and choline-containing phospholipids (choline oxidase method)
were measured using kits obtained from Wako Diagnostics (Richmond, VA). Serum SM was
analyzed using an enzymatic kit obtained from Abcam (Cambridge, MA). Serum
phosphatidylcholine (PC) was estimated by subtracting serum SM values from the serum cholinecontaining phospholipid values. Glucose was measured using a hexokinase kit obtained from
Pointe Scientific, Inc. (Canton, MI). Serum LPS was assessed by using a chromogenic limulus
amebocyte lysate (LAL) assay (QCL-1000) obtained from Lonza (Basel, Switzerland).

3.3.3. Hepatic Lipid Extraction and Analysis

Hepatic lipids were extracted using methods previously reported [28]. Briefly, liver lipids were
extracted with chloroform:methanol (2:1), dried under nitrogen at 60°C and solubilized in Triton
X-100. The solubilized lipid isolates were analyzed for total cholesterol and triglycerides by
enzymatic methods.
3.3.4. RNA Isolation, cDNA Synthesis and qRT-PCR

Total RNA was isolated using TRIzol reagent (Life Technologies, Carlsbad, CA) from liver,
skeletal muscle, proximal small intestine (SI-I and SI-II segments) and distal small intestine (SI-
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IV segment). Total RNA was treated with DNase I and reverse transcribed using iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA). Gene expression was assessed by quantitative real-time
polymerase chain reaction (qRT-PCR) using iTaq Universal SYBR Green Supermix (Bio-Rad)
and a CFX96 real-time PCR detection system (Bio-Rad). Gene expression was normalized to the
geometric mean of the reference genes, glyceraldehyde 3-phosphate dehydrogenase, β-actin and
ribosomal protein, large, P0 using the 2− ΔΔCt method. Primer sequences used for qRT-PCR
analysis are listed in Appendix A.
3.3.5. Gut Permeability Analysis

Intestinal permeability to macromolecules was examined using a low-molecular-weight (4-kDa)
fluorescent dextran (Sigma-Aldrich, St. Louis, MO). After 4 weeks on experimental diets, mice
were fasted for 6 h and administered fluorescein isothiocyanate (FITC)-dextran by gavage
(600 mg/kg body weight, 125 μg/μl). After 1 h, ~ 100-μl blood was collected from the tail vein.
Plasma was isolated, diluted 1:2 in PBS (pH 7.4) and analyzed for FITC-dextran on a fluorescence
spectrophotometer (BioTek Instruments, Inc. Winooski, VT) at excitation 485 nm and emission
535 nm. A standard curve was generated by diluting FITC-dextran in untreated, diluted mouse
plasma.

3.3.6. Gut Microbiota Analysis

Fecal samples were collected directly from separately housed mice and submitted to the University
of Connecticut-Storrs Microbial Analysis, Resources and Services facility for microbiota
characterization utilizing 16S V4 analysis. DNA was extracted from 0.25 g of fecal sample using
the MoBio PowerMag Soil 96-well kit (MoBio Laboratories, Inc., Carlsbad, CA) according to the
manufacturer's protocol for the Eppendorf epMotion liquid handling robot. DNA extracts were
quantified using the Quant-iT PicoGreen kit (Thermo Fisher Scientific, Waltham, MA). Partial
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bacterial 16S rRNA genes (V4) were amplified using 30 ng extracted DNA as template. The V4
region was amplified using 515F and 806R with Illumina adapters and golay indices on the 3′
end [29]. Samples were amplified in triplicate using Phusion High-Fidelity PCR master mix (New
England BioLabs, Ipswich, MA) with the addition of 10 μg BSA (New England BioLabs). PCR
products were pooled for quantification and visualization using the QIAxcel DNA Fast Analysis
(Qiagen, Venlo, Netherlands). PCR products were normalized based on the concentration of DNA
from 250 to 400 bp then pooled using the QIAgility liquid handling robot. The pooled PCR
products were cleaned using the Gene Read Size Selection kit (Qiagen) according to the
manufacturer's protocol. The cleaned pool was sequenced on the MiSeq using v2 2 × 250 basepair kit.
Demultiplexing of the sequences was done with a custom script [30] requiring 0
mismatches in the index sequences and Q25 minimum. Sequences were merged using SeqPrep
then filtered for length (maximum 300 bp) before clustering into OTUs with QIIME (for exact
commands, see https://github.com/mcnelsonphd/16S-RDS/blob/master/Qiime_Process).
3.3.7. Statistical Analysis

Differences between groups were evaluated by one-way ANOVA with post hoc comparisons
(Holm-Sidak) or by independent t tests (P <.05 deemed significant). Bivariate Pearson correlations
were used to assess relationships between variables. All statistical analyses were conducted using
GraphPad Prism version 6 software. Data are reported as mean ± SEM.

3.4. Results
3.4.1. Body and Tissue Weights

Body and tissue weights are shown in Table 1. No significant changes in food intake, week 4 body
weight or liver weight were observed between the groups. However, MSM reduced the total
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amount of weight gained over the 4 weeks. ESM experienced an increase in epididymal adipose
both in absolute weight and as a percentage of body weight compared with both CTL and MSM
groups.
3.4.2. MSM Reduced Cholesterol, While ESM Increased Serum Lipids

Fasting serum lipids and glucose values are presented in Table 3.2. MSM had significantly lower
serum cholesterol (−15%) compared to CTL. In contrast, ESM had significantly higher serum
cholesterol (+15%) and serum triglycerides (+30%) compared to CTL. Serum NEFA were 23%
lower in both SM groups compared to CTL (P =.05). ESM had significantly elevated serum
choline-containing phospholipids compared to CTL (+ 19%) and MSM groups (+ 31%), which
was primarily accounted for by higher serum SM levels
Table 3.2. Body and tissue weights of C57BL/6J mice after 4 weeks of high-fat diets
Parameter

Control

Egg SM

Milk SM

29.47 ± 0.77

28.53 ± 0.68

27.26 ± 0.74

Weight change (g)

5.14 ± 0.58a

4.48 ± 0.34ab

3.35 ± 0. 25b

Food intake (g/day)

3.80 ± 0.20

4.08 ± 0.09

4.06 ± 0.10

Liver weight (g)

1.19 ± 0.05

1.25 ± 0.04

1.12 ± 0.05

% Liver weight

4.07 ± 0.20

4.14 ± 0.13

4.09 ± 0.12

Epididymal fat (g)

0.62 ± 0.11a

0.88 ± 0.07b

0.43 ± 0.04a

% Epididymal weight

2.05 ± 0.32a

3.07 ± 0.22b

1.44 ± 0.10a

Body weight (g)

Each value represents the mean ± SEM of the values for n = 10 mice. Superscripts with different letters indicate
differences at P <.05 using post hoc comparisons.
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Table 3.3. Serum markers of C57BL/6J mice after 4 weeks of high-fat diets
Parameter

Control

Egg SM

Milk SM

Total cholesterol (mmol/L)

3.47 ± 0.12a

4.03 ± 0.18b

2.96 ± 0.17c

Triglycerides (mmol/L)

0.61 ± 0.04a

0.80 ± 0.05b

0.64 ± 0.05ab

NEFA (mmol/L)

0.68 ± 0.05

0.49 ± 0.03#

0.49 ± 0.04#

Total phospholipids (mmol/L)

2.36 ± 0.10a

2.85 ± 0.10b

2.25 ± 0.13a

SM (mmol/L)

1.15 ± 0.09a

1.55 ± 0.10b

1.23 ± 0.05a

PC (mmol/L)

1.22 ± 0.09

1.29 ± 0.13

0.93 ± 0.08

SM:PC ratio

0.845 ± 0.07

1.37 ± 0.19

1.31 ± 0.17

Fasting glucose (mmol/L)

8.02 ± 0.66

8.59 ± 0.64

7.31 ± 0.46

Each value represents the mean ± SEM of the values for n = 10 mice. Superscripts with different letters indicate
differences at P <.05 using post hoc comparisons. #P =.05 vs. control using post hoc comparisons.

(+25–35%). Serum SM was positively associated with serum cholesterol across groups
(r = 0.623, p =.0002; Figure 3.1A), whereas serum PC was not correlated with serum cholesterol
(r =− 0.011, P =.956; Figure 3.1B). No significant differences were found for fasting glucose
levels between groups.

Figure 3.1. Serum cholesterol is correlated with serum SM but not serum PC. Bivariate Pearson correlations
between serum cholesterol and serum SM (A) or serum PC (B) are shown
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3.4.3. MSM Alters Intestinal mRNA Expression of Cholesterol Transporters

In the proximal small intestine, MSM significantly increased Niemann-Pick C1-like 1 (Npc1l1)
mRNA compared to ESM (+110%) (Figure 3.2). Abcg5 mRNA expression was reduced by 42%
in MSM compared to CTL. Both Npc1l1 and Abcg5 are major transporters of free cholesterol on
the apical surface of epithelial cells. No differences were detected in the expression of genes related
to chylomicron formation or triglyceride absorption (Figure 3.2). There were also no differences
between groups in gene expression of tight junction-related proteins involved in gut barrier
function in the distal intestine (Figure 3.2).

Figure 3.2. MSM significantly altered gene expression related with intestinal cholesterol flux. Small intestine
mRNA was measured by qRT-PCR. Data were normalized to endogenous reference gene expression (n = 10 per
group, mean ± SEM). ABCG5, ATP-binding cassette subfamily G member 5; APOA4, apolipoprotein A-IV; DGAT2,
diacylglycerol O-acyltransferase 2; FABP2, fatty-acid-binding protein 2, intestinal; MTTP, microsomal triglyceride
transfer protein; OCLN, occludin; TJP1, tight junction protein 1. Values with different superscripts are P <.05
using post hoc comparisons.

3.4.4. MSM Reduced, While ESM Increased Hepatic Lipids

MSM reduced hepatic triglyceride accumulation by 47% compared with CTL, while ESM
increased triglycerides by 37% (Figure 3.3A). No significant differences were observed for liver
cholesterol between groups. MSM had significant inductions in both hepatic Srebp2 mRNA
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(+50%) and HMG-CoA reductase (Hmgcr) mRNA (+190%) compared with CTL (Figure 3.3B),
which may have impacted liver cholesterol via compensatory induction in cholesterol
biosynthesis. Further within cholesterol-regulated genes, both SM groups tended to lower hepatic
IDOL expression compared with CTL, but these changes were not significant (p = 0.1). ESM
increased stearoyl-CoA desaturase-1 (Scd1) mRNA expression by 3-fold compared to CTL. Scd1
is an enzyme involved in de novo lipogenesis. No other differences between groups were detected
for mRNA expression of genes related to lipid metabolism (Srebp1c, Lxrα, Acox and Pparα),
lipoprotein uptake (Ldlr and Pcsk9) or inflammation (Mcp1). These data show that MSM induced
the hepatic expression of a majority of the cholesterol-responsive genes examined, while ESM
induced Scd1 gene expression, which may explain the elevated hepatic triglycerides in this group.
3.4.5. SM Increases Skeletal Muscle GLUT4 mRNA Expression with No Effects on Fatty Acid
Oxidation-related Gene Expression

Skeletal muscle (quadriceps femoris) was examined for mRNA expression of genes involved in
lipid metabolism, inflammation and glucose disposal (Figure 3.4). Both SM-fed groups
experienced a 3-fold increase in Glut4 mRNA. Interleukin-6 (Il-6) mRNA expression was 70%
lower in MSM compared to CTL. There were no other differences observed between groups for
other gene expression related to fatty acid oxidation (Acad, Acox, Pgc-1α and Lpl).
3.4.6. MSM Reduce Serum LPS but Does Not Change Gut Permeability to FITC-dextran

High-fat-diet feeding of mice has been shown to increase plasma LPS after only 4 weeks [3]. Since
milk SM feeding lowered serum and liver lipids, we examined its effects on serum LPS. MSM
reduced serum LPS by 35% compared with CTL, while no difference was observed with ESM
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Figure 3.3. MSM reduces hepatic triglycerides and alters cholesterol-responsive gene expression. Hepatic lipids were extracted
with chloroform:methanol (2:1), dried under nitrogen at 60°C and solubilized in Triton X-100 as described in Materials and Methods.
Cholesterol and triglyceride were measured by enzymatic methods (A) (n = 10 per group, mean ± SEM). Hepatic mRNA expression
was measured by qRT-PCR (B). Data were normalized to endogenous reference gene expression (n = 10 per group, mean ± SEM).
ACOX, acyl-CoA oxidase 1; IDOL, inducible degrader of the LDL receptor; LDLr, LDL receptor; LXRα, liver X receptor α; MCP1,
monocyte chemotactic protein 1; PCSK9, proprotein convertase subtilisin/kexin type 9; PPARa, peroxisome proliferator-activated
receptor α; SREBP1c, sterol regulatory element-binding protein 1c; SREBP2, sterol regulatory element-binding protein 2. Values with
different superscripts are P <.05 using post hoc comparison
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(Figure 3.5A). Serum LPS was significantly associated with the amount of weight gain over the
4 weeks (Figure 3.5B). We examined effects of milk SM on gut permeability in fasting mice by
the appearance of FITC-dextran (4 kDa) in plasma after gavage. Gut permeability to FITC-dextran
was 5% lower on average in MSM (Figure 3.5C); however, this was not significantly different
compared to
average in MSM (Figure 3.5C); however, this was not significantly different compared to CTL.
Therefore, coinciding with the lack of differences in small intestine tight junction- related gene
expression (Fig. 1), it appeared that differences in serum LPS were not due to damage to the gut
barrier. Since sphingosine has been shown to display bactericidal activity against several Gramnegative strains [21], we next examined if there were differences in distal gut microbiota between
MSM and CTL.
3.4.7. MSM Alters Distal Gut Microbiota Phylogenetic Abundance and Gram-negative Bacteria

Fecal microbiota composition from separately caged mice was examined by 16S rRNA sequence
analysis and results are presented in Figure 3.6. Comparing the major bacterial phyla (Figure
3.6B), MSM had significantly higher phylogenetic relative abundance of the predominately Grampositive Firmicutes phylum (p<0.05) and significantly lower of the Gram-negative Bacteroidetes
phylum (p <0.05). Comparing the minor bacterial phyla (Figure 3.6C), MSM had significantly
higher relative abundance of the Gram-positive Actinobacteria phylum (p <0.001) and less of the
Gram-negative Tenericutes phylum (p <0.001). The relative abundance of the Gram-negative
Proteobacteria phylum did not differ between MSM and CTL groups. LPS is a component of the
outer membrane of the cell wall of Gram-negative bacteria. When classified based on Gram
staining (Figure 3.6D), MSM had significantly lower relative abundance of Gram-negative
bacteria and a reciprocal increase in the predominately Gram-positive bacteria (p <0.05). These
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Figure 3.4. MSM increases skeletal muscle GLUT4 and decreases IL-6 mRNA. Skeletal muscle mRNA
(quadriceps femoris) was measured by qRT-PCR. Data were normalized to endogenous reference gene expression
(n = 10 per group, mean ± SEM). ACAD, acyl-CoA dehydrogenase; ACOX, acyl-CoA oxidase 1; CD68, cluster of
differentiation 68; GLUT4, glucose transporter type 4; LPL, lipoprotein lipase; PGC-1α, peroxisome proliferatoractivated receptor gamma coactivator 1α. Values with different superscripts are P <.05 using post hoc comparisons.

data suggest that the lower serum LPS levels may be due to a reduction in LPS-containing Gramnegative bacteria in the gut microbiota. At the genus level (Figure 3.6E), MSM had significantly
higher relative abundance of the beneficial bacteria, Bifidobacterium (p <0.001), although no
difference in relative abundance of Lactobacillus was observed between groups. Interestingly,
MSM tended to have higher relative abundance of Bacteroides (p = 0.06), one of the few microbes
that synthesize and utilize sphingolipids [31], which was absent in CTL.
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Figure 3.5. MSM reduces serum LPS but does not influence gut permeability. Serum LPS was measured as described in Materials
and Methods using an endpoint chromogenic LAL assay (A) (n = 10 per group, mean ± SEM). Values with different superscripts
are P <.05 using post hoccomparisons. A bivariate Pearson correlation between serum LPS and 4-week weight change is shown (B).
Mice (n = 6 per group, mean ± SEM) were fasted for 6 h prior to a gavage of 4 kDa FITC-dextran (600 mg/kg body weight, 125 μg/μl)
as described in Materials and Methods. Gut permeability to FITC-dextran in fasted mice was measured in plasma by fluorometric
methods (C)
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3.5. Discussion
High-fat diet has been shown to induce dyslipidemia [32] and gut dysbiosis [33], which are both
associated with the development of diet-induced obesity. Sphingolipids are bioactives found in
food, which have been shown to reduce lipid absorption in rodents [15–18] and have potential to
alter gut microbiota [21]. In this study, C57BL/6J mice were fed SM derived from milk or egg for
4 weeks and then studied for effects on lipid metabolism. Surprisingly, egg SM increased several
serum lipids and hepatic triglycerides. In contrast, milk SM was shown to reduce serum
cholesterol, serum LPS and hepatic triglycerides. Serum LPS can be influenced by differences in
gut microbiota [8], chylomicron production [6] and differences in gut permeability [7]. In this
study, milk SM was shown to alter the gut microbiota, although no differences were found for in
vivo gut permeability in the fasted state. This study suggests that milk SM can ameliorate the
negative metabolic effects of a high-fat diet in mice.
SM and its hydrolytic byproducts have been shown to reduce the intestinal absorption of
cholesterol, triglycerides and fatty acids in rodents [15–18,20]. SM interacts with high affinity to
cholesterol and is thought to influence its micellar solubilization. Eckhardt et al. [17] observed that
feeding mice diets with milk SM at 0.1%, 0.5% or 5% (wt/wt) reduced intestinal cholesterol
absorption measured by dual-isotope method by approximately 20%, 54% and 86%, respectively.
Intestinal hydrolysis of SM is initiated by alkaline sphingomyelinase that hydrolyzes the
phosphorylcholine head, resulting in ceramide [34]. Alkaline sphingomyelinase is inhibited by
acylglycerides (monoglycerides, diglycerides and triglycerides), free fatty acids, cholesterol and
ceramide [35], all of which are highly present in the duodenum and proximal jejunum where the
majority of lipid absorption occurs. Feng et al. [36] showed that ceramide and sphingosine can
also inhibit the absorption of cholesterol by Caco-2 cells. Ceramide is a major signal for apoptosis
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and is shown to be beneficial in reducing chemically induced colorectal cancer [37]. Neutral
ceramidase functions through hydrolysis of the fatty acid ester linkage of ceramide, releasing the
sphingoid backbone, which is predominantly sphingosine [38]. Sphingosine may act as an
antimicrobial [21] and is absorbed in higher quantities than ceramide and SM [39]. As SM moves
down the intestinal tract, the activity of sphingomyelinase and ceramidase will increase due the
depletion of luminal lipids. This would likely result in the cecal and colonic bacteria being exposed
to appreciable levels of sphingosine and ceramide.
In the current study, MSM decreased (−15%) total serum cholesterol compared to the high-fat control. In
contrast, ESM increased cholesterol (+15%), triglycerides (+30%), SM (+ 35%) and total phospholipids
(+20%). Serum lipids in mice fed dietary sphingolipids has been shown to decrease [18], not change [40],
and even increase in some studies [41]. Li et al. [41] reported that feeding LDLr−/− mice for 12 weeks a
modified AIN-76A diet supplemented with 1% (wt/wt) ox brain sphingolipids (28% SM) increased plasma
cholesterol (+ 62%), plasma SM (+50%) and aortic atherosclerosis. Recently, Chung et al. [40] reported
that egg SM feeding (0.6%, wt/wt) for 18 days reduced hepatic lipid levels and increased fecal cholesterol
output in mice fed a high-fat diet (21% by weight butter fat; 0.15% by weight added cholesterol). Chung et
al. [40] also reported that egg SM feeding led to an ~ 30% reduction in cholesterol absorption, although it
did not affect plasma cholesterol or triglyceride levels. Duivenvoorden et al. [18] observed significant
reductions in plasma cholesterol and triglycerides when 0.2–0.4% egg SM (wt/wt) was added to a
Western-type diet (15% by weight cocoa butter; 0.25% by weight cholesterol added)and fed to
APOE3*Leiden female mice for 3 weeks. Overall, studies in mice where large amounts of cholesterol were
added to diets in addition to sphingolipids displayed reductions in serum cholesterol and hepatic lipids,
whereas those that did not observed elevations in serum and hepatic lipids (including the current study).
Therefore, it is possible that the weaker effect of egg SM on lipid absorption compared with milk SM [16]
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Figure 3.6. MSM group distal gut microbiota has significantly reduced Gram-negative bacteria. Fecal samples were collected
directly from separately housed mice and microbiota composition was assessed by 16S rRNA sequencing as described in Materials and
Methods. Phyla phylogenetic abundance (% of total sequences) of individual mice (A). Phylogenetic relative abundance of major phyla
Firmicutes and Bacteroidetes (B), and minor phyla Actinobacteria, Tenericutes and Proteobacteria (C). Relative abundance of Gramnegative and Gram-positive phyla (D). Relative abundance of Bifidobacterium, Lactobacillus and Bacteroides genera (n = 3 per group,
mean ± SEM, *P <.05 using t test).
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may require excess dietary cholesterol to influence serum cholesterol and hepatic lipids. Another
explanation for discrepancies in serum and hepatic cholesterol responses in the studies discussed
may be due to the different strains of mice used (i.e., wild type or transgenic). Recently,
Ramprasath et al. [42] reported that 4-week supplementation of milk SM (1 g/day) in healthy
humans significantly increased plasma HDL-C in a small crossover study (n = 10), although no
effects on non-HDL-cholesterol and cholesterol absorption were found. Lack of effects of milk
SM on cholesterol absorption in this human study may be related to greater SM digestion
efficiency in humans compared with rodents [19] or potentially related to the healthy population
examined.
The differences in serum cholesterol between groups were supported by changes in
cholesterol-regulated gene expression in the proximal intestine. Intestinal NPC1L1 mRNA, which
was increased in MSM (+110% vs. ESM), is responsible for cholesterol uptake at the apical
membrane of intestinal epithelial cells. Intestinal NPC1L1 mRNA has been shown to be reduced
by excessive cellular cholesterol and induced by cholesterol depletion [43]. ABCG5, which was
reduced in MSM (-42% vs. CTL), constitutes half of the ABCG5/8 heterodimer that enables free
cholesterol and phytosterol efflux from the intestinal cell back into the lumen [44]. The observed
changes in the gene expression of these transporters in MSM-fed mice suggest that the intestines
were compensating for cellular cholesterol depletion, likely due to lower cholesterol absorption.
Noh and Koo [15,16] reported that dietary egg SM and milk SM could both acutely reduce
intestinal lipid absorption in rodents, with milk SM being a more potent inhibitor [16].
Inhibition of intestinal cholesterol absorption through ezetimibe, a pharmacological
inhibitor of NPC1L1, can lower serum cholesterol levels and reduce hepatic lipids in mice [45].
The current study demonstrated significantly lower triglycerides in MSM livers (−47%) and higher
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in ESM (+37%), compared to CTL. Hepatic cholesterol biosynthesis may have increased with SM
treatment, suggested by the 190% increase in HMGCR mRNA in MSM and the increasing trend
(p=0.07) in ESM. Additionally, hepatic mRNA expression of SREBP2, a transcription factor that
induces genes for cholesterol biosynthesis, was increased in MSM (+54% vs. ESM, 51% vs. CTL).
In this study, compensatory increases in cholesterol biosynthesis potentially masked differences
in hepatic cholesterol levels between groups. Interestingly, egg SM increased hepatic SCD1
mRNA (+189% vs. CTL), which was not seen with milk SM feeding. SCD1 is involved in de
novo lipogenesis, enhancing hepatic triglyceride formation [32].
Skeletal muscle GLUT4 expression increased in ESM (+172%) and MSM (+ 162%)
compared to CTL. Skeletal muscle GLUT4 expression is regulated by the transcription factor
myocyte enhancer factor 2 (MEF2) [46]. PGC-1α serves as a coactivator of MEF2 transcriptional
activity and has been shown to participate in an autoregulatory loop where it induces PGC-1α
expression in skeletal muscle [47]. Milk SM (0.2% by weight) fed for 12 weeks to BALB/c mice
was reported to increase endurance capacity, associated with induction of skeletal muscle PGC-1α
mRNA [48]. We did not observe a change in PGC-1α at the mRNA level, which may be due to
differences in background diet, duration or strain of mice. There is also a possibility that PGC-1α
coactivator activity was altered, which we did not measure. Further studies examining the effects
of dietary SM on skeletal muscle lipid and glucose metabolism are warranted.
In the current study, milk SM reduced serum cholesterol and NEFA (p =0.05), suggesting
a reduction in dietary lipid absorption. Dietary lipid absorption may increase the translocation of
gut-derived LPS by enhancing transcellular transport via chylomicrons secretion [6] and/or
paracellular leakage across the gut barrier [7]. Based on these relationships, it is not surprising that
we observed 35% lower serum LPS in MSM compared to CTL. This difference did not appear to
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be due to differences in fasting gut permeability. LPS is a major constituent of the outer membrane
of cell walls of Gram-negative bacteria. Sphingosine has been shown to have strong bactericidal
effects on Gram-negative and Gram-positive bacterial pathogens in vitro [21]. As dietary SM is
slowly digested and absorbed, it is likely that much of it reaches the colon where bacteria are most
abundant. Remarkably, dietary milk SM strongly altered fecal phyla composition, with
significantly reduced relative abundance of Gram-negative phyla, such as Bacteroidetes and
Tenericutes, and reciprocal increases in predominately Gram-positive phyla, such as Firmicutes
and Actinobacteria. Interestingly, one study reported that nonobese mice fed a high-fat diet, which
are diabetes-resistant, have lower plasma LPS and gut permeability and increased cecal Firmicutes
and Actinobacteria than diabetes-prone mice [49]. Notably, milk-SM-fed mice had significantly
greater relative abundance of fecal Bifidobacterium, a genus of mutualistic “beneficial” bacteria.
Fecal Bifidobacterium are known to be dramatically reduced in mice fed high-fat diets, and
selective increases are associated with reduced plasma LPS and improvements in metabolic
parameters in mice [50]. Bifidobacteria can protect against enteropathogens [51] and are well
known to ferment prebiotic oligosaccharides and increase the production of short-chain fatty acids
(SCFA) in the colon [52]. In addition to bifidobacteria, milk-SM-fed mice tended to have higher
relative abundance of fecal Bacteroides (p =0.06), one of the few microbes that synthesize and
utilize sphingolipids [31]. Species of the Bacteroides genus are also known to ferment prebiotics
to SCFA [52], with some species shown to prevent metabolic complications of obese mice induced
with a high-fat diet when used as a probiotic [53].
The current study has several strengths. We used purified, natural sources of milk and egg
SM (> 99% pure), as opposed to a mixed phospholipid concentrate or milk globule membrane
extract, which have been studied previously [54,55]. Thus, using purified SM allows us to attribute
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the effects observed on lipid metabolism and gut microbiota directly to the additional dietary SM
ingestion. We also examined effects of dietary SM on markers of metabolic endotoxemia and gut
microbiota, which to our knowledge have never been reported. Although egg SM did not reduce
serum LPS, we did not examine effects of egg SM on gut permeability and gut microbiota, which
could be a limitation of the current study. The dose chosen for this study roughly equates to an
amount of SM (1.5 g/day) which is above the estimated sphingolipid intake (300–400 mg/day) of
Western diets. This high dosage may also be a limitation. However, it is possible that this dose
could be achievable through supplementation or through careful selection of SM-rich foods.
Overall, we observed significant differences in the effects of milk SM and egg SM on lipid
metabolism in mice fed a high-fat diet. Milk SM reduced serum cholesterol and altered gene
expression consistent with intestinal and hepatic cholesterol depletion. Milk SM also reduced
hepatic triglycerides and induced gene expression associated with cholesterol biosynthesis.
Unexpectedly, egg SM increased several serum lipids and hepatic triglycerides. A possible
explanation for the increase in lipids in egg-SM-fed mice was increased hepatic de
novo lipogenesis; however, the mechanism is not yet clear. Both SM groups demonstrated a strong
induction of GLUT4 mRNA in skeletal muscle, suggesting an increase in glucose utilization. Milk
SM also significantly lowered serum LPS and was associated with bifidogenic effects and
alterations in distal gut microbiota. In conclusion, milk SM appears to have beneficial effects in
protecting against the deleterious effects of a high-fat diet in mice. Further research is warranted
to examine the mechanisms of action of milk SM on serum LPS and alterations in gut microbiota.
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Chapter 4. Dietary Sphingomyelin
Attenuates Hepatic Steatosis and Adipose
Tissue Inflammation in High-fat-dietinduced Obese C57BL/6J Mice
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4.1. Abstract
Western-type diets can induce obesity and related conditions such as dyslipidemia, insulin
resistance, and hepatic steatosis. We evaluated the effects of milk sphingomyelin (SM) and egg
SM on diet-induced obesity, the development of hepatic steatosis, and adipose inflammation in
C57BL/6J mice fed a high fat, cholesterol-enriched diet for 10 weeks. Mice were fed either a lowfat diet (10% kcal from fat) (LFD, n = 10), a high fat diet (60% kcal from fat) (HFD, n = 14), or a
high fat diet modified to contain either 0.1% (w/w) milk SM (HFMSM, n = 14) or 0.1% (w/w) egg
SM (HFESM, n = 14). After 10 weeks, egg SM ameliorated weight gain, hypercholesterolemia,
and hyperglycemia induced by HFD. Both egg SM and milk SM attenuated hepatic steatosis
development, with significantly lower hepatic triglycerides (TG) and cholesterol relative to HFD.
This reduction in hepatic steatosis was stronger with egg SM supplementation relative to milk SM.
Reductions in hepatic TG observed with dietary SM were associated with lower hepatic mRNA
expression of PPARγ-related genes; Scd1 and Pparg2 in both SM groups, and Cd36 and Fabp4
with egg SM. Egg SM, and to a lesser extent milk SM, reduced inflammation and markers of
macrophage infiltration in adipose tissue. Egg SM also reduced skeletal muscle TG content
compared to HFD. Overall, the current study provides evidence of dietary SM improving
metabolic complications associated with diet-induced obesity in mice. Further research is
warranted to understand the differences in bioactivity observed between egg and milk SM.

4.2. Introduction
The National Center for Health Statistics reported that 36.5% of American adults were considered
obese from 2011-2014 [1]. Obesity can contribute to the development of several noncommunicable diseases, including non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes
mellitus (T2DM). Concurrent with rises in obesity and an aging population, the prevalence of
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T2DM and NAFLD have increased dramatically in recent decades [2, 3]. Obesity, particularly
abdominal obesity, is often accompanied by chronic low-grade inflammation in both adipose tissue
and systemic circulation, which may result in metabolic abnormalities such as insulin resistance
[4, 5]. Localized adipose tissue inflammation is thought to arise from a dysfunction in the normal
metabolic handling of nutrients by adipocytes, as a consequence of excessive adipocyte
enlargement, insulin resistance, and infiltration of adipose tissue with macrophages [4, 5]. Insulin
resistance and metabolic defects in lipid metabolism are associated with NAFLD, related to an
increased flux of non-esterified fatty acids (NEFA) from inflamed adipose tissue to the liver [6].
NAFLD consists of a broad spectrum of conditions occurring in the absence of alcohol use,
including steatosis, non-alcoholic steatohepatitis (NASH), and liver cirrhosis. Hepatic steatosis
has been estimated to be present in over two-thirds of the obese population [7-9]. Simple steatosis
is relatively benign; however, once steatosis has developed, the liver is “sensitized” to various
inflammatory stimuli, which can precipitate NASH [10]. Consequently, NASH can progress to
cirrhosis and may result in hepatocellular carcinoma or liver failure [11]. Currently, there is a lack
of effective management options for NAFLD besides weight reduction, which can be difficult to
maintain long-term.
Dietary lipids, such as cholesterol and triglycerides (TG), have been shown to exacerbate
adipose tissue inflammation and NAFLD in animal models [12-16]. Dietary phospholipids,
however, are a potential source of bioactive lipids which may improve cardiometabolic health [17].
Dietary sphingomyelin (SM), a sphingolipid found exclusively in animals, has been shown to dosedependently reduce the absorption of cholesterol, TG, and fatty acids both in vitro [18, 19] and in
rat models [20, 21]. Although dietary SM is often overlooked, it demonstrates potential to
influence chronic diseases, such as obesity and NAFLD. Only a few studies have evaluated the
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effects of chronic dietary SM intake on lipid metabolism in rodents [22-25]. Little is known about
an optimal intake of SM and whether an increased dietary intake of SM is beneficial to health.
Consumption of dietary sphingolipids in Western diets is relatively common (0.3-0.4 g/day) and
comes mainly from animal-based foods, including eggs and dairy [26, 27].
Previously, Chung et al. [22] reported that supplementation with egg-derived SM at 0.3%,
0.6%, and 1.2% (w/w) reduced hepatic TG in a dose-dependent manner in mice on a 4-week
Western-type diet. We have recently reported that dietary milk-derived SM (0.25% w/w) reduced
both serum lipids and hepatic TG in mice on a 4-week high fat diet (HFD) [23]. However, since
both studies were relatively short term, the efficacy of dietary SM in preventing diet-induced
obesity, adipose tissue inflammation, and hepatic steatosis were not fully examined. Furthermore,
egg SM and milk SM differ in their amide-linked fatty acid and sphingoid base compositions [2830], and therefore, may have different biological effects on lipid metabolism in vivo [21, 23]. Thus,
the current study evaluated the effects of dietary SM from both egg and milk on hepatic steatosis
and obesity in C57BL/6J mice fed a cholesterol-enriched HFD for 10 weeks. We hypothesized
that both sources of dietary SM would attenuate hepatic steatosis and obesity development, due to
their abilities to inhibit lipid absorption. Furthermore, we expected milk SM to be more effective
than egg SM, based on its greater potency to inhibit lipid absorption in rodent models [21].

4.3. Materials and Methods
4.3.1 Animals and Diets

Male C57BL/6J mice (6 weeks old) were obtained from Jackson Laboratory (Bar Harbor, ME)
and allowed to acclimate for 2 weeks before being fed 1 of 4 lard-based diets for 10 weeks: low
fat diet control (LFD; 10% kcal from fat; n = 10); high fat, high cholesterol diet control (HFD;
60% kcal from fat, 0.15% cholesterol added by weight; n = 14); HFD modified to contain 0.1% of
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milk SM added by weight (HFMSM; n = 14); or HFD with 0.1% of egg SM added by weight
(HFESM; 60% kcal from fat; n = 14). Diet composition details are provided in Table 4.1.
Experimental diets were made using ingredients obtained from Dyets, Inc. (Bethlehem, PA). Milk
SM (bovine; >99% purity) and egg SM (chicken egg; >99% purity) powders were obtained from
Avanti Polar Lipids, Inc. (Alabaster, AL) and were substituted for an equal weight of lard in their
respective experimental groups. Fatty acid composition varied between the milk SM (34% C23:0,
21% C24:0, 20%, C22:0, 16% C16:0, 3% C24:1 and 6% unknown) and egg SM (86% C16:0, 6%
C18:0, 3%, C22:0, 3% C24:1 and 2% unknown) powders. Egg SM and milk SM also vary in the
distribution of sphingoid bases; egg SM contains almost entirely sphingosine (d18:1) bases, while
milk SM contains a more varied distribution (d16:0 to d19:0) [30]. Based on body surface
normalization and accounting for weight gain throughout the study, the experimental diets
provided the equivalent of consuming approximately 405-670 mg/day in a 70 kg human [31].
Fresh food was provided biweekly and mice were allowed to eat ad libitum. Body weights
were recorded on a weekly basis, while food intake was estimated biweekly. After 10 weeks on
their respective diets, mice were fasted for 6-8 hours prior to blood collection by cardiac puncture
following euthanasia. Blood was allowed to clot at room temperature for 30 minutes before serum
was isolated by centrifugation (10,000 x g for 10 minutes at 4°C) and then stored at -80°C. Tissues
were perfused with sterile saline before being harvested, snap-frozen in liquid nitrogen and stored
at -80˚C. The liver, skeletal muscle (quadriceps femoris), and epididymal adipose tissues were
collected from animals. Pieces of liver were harvested from the left lateral lobe for histology and
lipid analysis. Liver and epididymal adipose tissues were fixed in 10% neutral-buffered formalin
for at least 48 hours prior to histological processing. Mice were housed in the University of
Connecticut-Storrs vivarium in a temperature-controlled room and maintained in a 12-hour
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light/12-hour dark cycle. The Animal Care and Use Committee of the University of ConnecticutStorrs approved all procedures used in the current study.
Table 4.1. Diet composition
(g/kg)
Diet Component

LFD

HFD

210

265

HFMSM /
HFESM
265

3

4

4

Corn Starch

467

0

0

Maltodextrin

100

0

0

Sucrose

90

253.5

253.5

Lard

20

310

309

Soybean Oil

20

30

30

37.15

64

64

Mineral Mix, AIN-93G-MX (94046)

35

48

48

Vitamin Mix, AIN-93-VX (94047)

15

21

21

2.75

3

3

Cholesterol

0

1.5

1.5

Milk or Egg Sphingomyelin

0

0

1

Casein
L-Cystine

Cellulose

Choline Bitartrate

4.3.2. Serum Biochemical Analysis

Total serum cholesterol, TG, NEFA, liver enzymes, and glucose concentrations were measured
using commercial assays according to manufacturer instructions. Serum cholesterol, NEFA, and
TG were measured using enzymatic kits obtained from Wako Diagnostics (Richmond, VA).
Fasting glucose, serum alanine transaminase (ALT), and aspartate transaminase (AST) were
measured using kits obtained from Pointe Scientific, Inc. (Canton, MI). Serum insulin and C-C
motif chemokine ligand 2 (CCL2) were measured by ultra-sensitive ELISA (Crystal Chem, Inc.,
Downers Grove, IL) and magnetic bead-based assay (EMD Millipore, Billerica, MA),
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respectively. The homeostasis model assessment (HOMA-IR) equation was used to estimate
insulin resistance based on fasting serum insulin and glucose concentrations [32].

4.3.3. Tissue Lipid Extraction and Analysis

Hepatic and skeletal muscle lipids were extracted using a modified Folch method as previously
reported [33], with solubilization and enzymatic analysis of lipid extracts by the methods of Carr
et al. [34]. Briefly, tissue lipids were extracted with chloroform:methanol (2:1), dried under
nitrogen, and solubilized in Triton X-100. The solubilized lipid extracts were analyzed for total
cholesterol (TC), free cholesterol (FC), choline-containing phospholipids (PL), and TG by
enzymatic methods. Cholesteryl ester (CE) mass was calculated as (TC – FC) X 1.67 to account
for the fatty acid moiety contribution to CE [35].

4.3.4. Tissue Histology

Formalin-fixed liver and epididymal adipose tissues were embedded in paraffin and cut into 5-μm
sections prior to staining with hematoxylin and eosin (H&E). All histological procedures were
conducted at the Connecticut Veterinary Medical Diagnostic Laboratory (Storrs, CT). The stained
tissue sections were viewed under bright field microscopy at ×200 magnification and images were
taken with an AxioCam ICc3 camera (Zeiss, Thornwood, NY, USA). The infiltration of
macrophages into adipose tissue was assessed by the counting of crown-like structures (3 slides
per animal) by a technician blinded to group assignment.

4.3.5. RNA Isolation, cDNA Synthesis, and Real Time qRT-PCR

Total RNA from liver, epididymal adipose, and skeletal muscle was isolated using TRIzol reagent
(Life Technologies, Carlsbad, CA). Total RNA was treated with DNase I, and reverse transcribed
using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real-time qRT-PCR was performed
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using iTaq Universal SYBR Green Supermix (Bio-Rad) on a CFX96 real-time PCR detection
system (Bio-Rad). For liver, gene expression was normalized to the geometric mean of the
reference genes, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and beta actin, using the 2ΔΔCt

method. The geometric mean of Gapdh and ribosomal protein, large, P0 (36B4) was used as

a reference gene control for both adipose tissue and skeletal muscle. Primer sequences used for
qRT-PCR analysis are listed in Appendix A.

4.3.6. SDS-PAGE and Immunoblotting

Hepatic protein was isolated and analyzed by SDS-PAGE and immunoblotting as previously
described [36]. Briefly, livers were homogenized in a tissue lysate RIPA buffer (Cell Signaling
Technologies, Beverly, MA) containing 2 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma
Aldrich, St. Louis, MO). Total protein concentrations of the lysates were determined by
bicinchoninic acid (BCA) assay (Cell Signaling Technologies). Sixty µg of total protein was mixed
with loading buffer containing dithiothreitol (DTT) (BioRad) and loaded onto 4-20% SDS StainFree gels (BioRad). Gels were activated using the Stain-Free protocol on a ChemiDoc XRS+
imager (BioRad). Protein was then transferred to a PVDF membrane (Thermo Fisher Scientific,
Waltham, MA) through a semi-dry protocol using a Trans-Blot Turbo System (BioRad). StainFree blot images were captured and membranes were blocked for 1 hour at room temperature with
blocking buffer (20 mM Tris base, 150 mM NaCl, 0.05% Tween-20, 5% w/v non-fat dry milk).
Primary rabbit anti-mouse PPARγ antibody was obtained from Santa Cruz Biotechnology (Dallas,
TX), diluted according to manufacturer’s recommendation, and incubated overnight at 4°C. After
washing the membrane with TBS buffer (20 mM Tris base, 150 mM NaCl, 0.05% Tween-20), a
1:10,000 dilution of secondary HRP-anti-rabbit antibody (Thermo Fisher Scientific) was incubated
with the membrane at room temperature for 1 hour. Pierce ECL Western Blotting Substrate
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(Thermo Fisher Scientific) was used for the final imaging of the blot. PPARγ relative abundance
was quantified after standardizing to total protein images obtained from the Stain-Free blot using
ImageLab Software V5.1 (BioRad).
4.3.7. Statistical Analysis

Differences between groups were evaluated by one-way ANOVA with post hoc comparisons
(Holm-Sidak). Bivariate Pearson correlations were used to assess relationships between variables.
All statistical analyses were conducted using GraphPad Prism version 6 software. Data are
reported as mean ± SEM.

4.4. Results
4.4.1. Egg SM Reduced HFD-induced Weight Gain and Increases in Adiposity

Ten weeks of a high fat, high cholesterol diet induced significant gains in body weight, epididymal
fat, and liver weight in the HFD control group compared to LFD (Figure 4.1). Egg SM
supplementation attenuated these effects, significantly decreasing body weight (Figure 4.1B) and
epididymal fat pad mass (Figure 4.1D) compared to HFD by 14% and 19%, respectively. Liver
weight tended to be lower in HFESM compared to HFD, however, the weight change did not reach
statistical significance (Figure 4.1D). No differences were observed in food intake (Figure 4.1C)
between HFD groups.

4.4.2. Egg SM Reduced Serum Total Cholesterol and Fasting Glucose

Serum lipids and glycemic markers are presented in Table 4.2. Serum cholesterol (+135%), fasting
glucose (+108%), fasting insulin (+340%), and HOMA-IR (+848%) were significantly increased
with HFD relative to LFD. Supplementation of egg SM significantly reduced serum cholesterol (22%) and fasting glucose (-28%) compared to HFD. Serum NEFA were significantly reduced in
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Figure 4.1. Egg SM reduces body weight and epididymal fat with no change in food intake. Body weight was assessed weekly (A,
B). Food intake (C) was measured biweekly and daily food intake calculated. Wet tissue weights were taken at the time of sacrifice (D).
Each value represents the mean + SEM for n = 10 mice for low fat diet control (LFD) and n = 13-14 mice each for high fat diet control
(HFD), HFD + milk SM (HFMSM), and HFD + egg SM (HFESM). Mean values with unlike letters indicate differences at P < 0.05
using post hoc comparisons.
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both dietary SM groups compared to HFD. No significant differences were detected in serum
TG, fasting insulin, or HOMA-IR between HFD groups.
Table 4.2. Serum markers of C57BL/6J mice after 10 weeks of diets.
Parameter

LFD

HFD

1.94 ± 0.09a

4.56 ± 0.27

0.29 ± 0.03

0.29 ± 0.03

0.36 ± 0.05

0.38 ± 0.04

NEFA (mmol/L)

0.44 ± 0.06a

0.46 ± 0.07a

0.28 ± 0.02b

0.31 ± 0.02b

Fasting Glucose
(mmol/L)

8.86 ± 0.61a

18.48 ± 1.68b

16.03 ± 0.66bc

13.24 ± 0.73c

Insulin (ng/mL)

0.15 ± 0.01a

0.66 ± 0.09b

0.53 ± 0.06b

0.55 ± 0.10b

HOMA-IR

1.61 ± 0.22a

15.26 ± 3.40b

10.86 ± 1.88b

9.34 ± 1.79b

Total Cholesterol
(mmol/L)
Triglycerides
(mmol/L)

HFMSM
b

4.33 ± 0.33

HFESM
b

3.54 ± 0.26

c

Each value represents the mean ± SEM of the values for n = 10-14 mice. NEFA, non-esterified
fatty acids; HOMA-IR, homeostasis model assessment-insulin resistance. Superscripts with
different letters indicate differences at p < 0.05 using post-hoc comparisons.
4.4.3. Dietary SM Attenuated HFD-induced Hepatic Steatosis and Reduced PPARγ-related mRNA
Expression

H&E stained livers showed extensive lipid droplet accumulation in the HFD group (Figure 4.2A).
Milk SM attenuated the accumulation of hepatic lipid droplets compared to HFD, while egg SM
further reduced the hepatic steatosis observed with HFD. These observations were confirmed by
liver lipid analysis; HFD significantly increased hepatic TG, TC, and CE compared to LFD
(Figure 4.2B). Egg SM strongly reduced hepatic TG (-60%) compared to HFD, while milk SM
lowered hepatic TG to a lesser extent (-33%). Both dietary SM groups lowered hepatic TC and CE
by ~25-30%. HFD increased serum ALT (+43%) compared to LFD, but this effect was not
significantly altered by dietary SM (Figure 4.2C).
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Figure 4.2. Dietary SM attenuates hepatic steatosis and reduces hepatic PPARγ-related gene expression. Liver sections were
formalin-fixed, sectioned and H&E stained (A) for visualizing hepatic steatosis. Liver lipids were extracted using a modified Folch
extraction and measured by enzymatic methods (B), (triglycerides, TG; total cholesterol, TC; cholesteryl ester, CE; free cholesterol, FC;
choline-containing phospholipids, PL) (n = 10-14 per group, mean + SEM). Serum activities of hepatic enzymes (alanine transaminase,
ALT; aspartate transaminase, AST) were determined using a kinetic assay (C) (n = 10-14 per group, mean + SEM). Hepatic mRNA
expression was determined using real-time qRT-PCR and standardized to the geometric mean of Gapdh and β-actin reference genes
(-ΔΔCt)
using the 2
method (D) (n = 13-14 per group, mean + SEM). Mean values with unlike letters indicate differences at P < 0.05 using
post hoc comparisons.
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Compared to HFD, both egg SM (-54%) and milk SM (-33%) significantly reduced Pparg2
mRNA (Figure 4.2D). This corresponded with reductions in the expression of PPARγ target genes
related to TG accumulation; Scd1 was reduced in both SM groups, while Cd36 and Fabp4 (p =
0.05) were reduced in egg SM. Egg SM also reduced Ccl2 mRNA expression compared to HFD
(p = 0.05). No other significant differences were detected in the hepatic expression of other
lipogenic or gluconeogenic genes. Hepatic Pparg2, Scd1, and Cd36 mRNA expression were
significantly associated with hepatic TG among all mice fed HFD (Figure 4.3). Thus, changes in
the expression of these genes were associated with hepatic steatosis. However, there were no
significant differences in PPARγ protein abundance between HFD-fed groups; milk SM tended to
be higher, while egg SM tended to be lower than HFD control (Figure 4.4A,B,C). Total PPARγ
protein abundance had no correlation with hepatic TG (Figure 4.4D). Thus, inconsistent findings
with hepatic PPARγ protein across SM-fed groups suggests that differences in the expression of
PPARγ target genes may be related to altered PPARγ activity, or possibly due to other
transcriptional regulators.

Figure 4.3. Hepatic PPARγ-related lipogenic gene expression positively correlates with
hepatic TGs. Pearson correlations between hepatic Pparg2 (A), Scd1 (B) and Cd36 (C) mRNA
with hepatic TGs for all mice fed high-fat diets (n = 41).
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Figure 4.4. Dietary SM does not alter total PPARγ protein in liver. Hepatic PPARγ protein expression was visualized by
immunoblotting. (A), and total protein was imaged from Stain-Free protein blot (B). Quantitative relative abundance was measured
through densitometry analysis (C) after normalizing to Stain-Free total protein images. Each value represents the mean ± S.E.M. for n
= 12 mice per group. Pearson correlation of total hepatic PPARγ protein with hepatic TGs for HFD, HFMSM and HFESM (D)
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4.4.4. Dietary Egg SM, and to a Lesser Extent Milk SM, Reduces Epididymal Adipose Tissue
Inflammation

Compared to LFD, the HFD control group showed a noticeable enlargement in adipocyte
size and increased macrophage infiltration into epididymal adipose tissue, indicated by the number
of crown-like structures (CLS) (Figure 4.5A,B). The number of CLS was markedly attenuated
with egg SM feeding (-68%) but was unchanged with milk SM feeding (Figure 4.5B). However,
both dietary SM fed groups significantly reduced serum CCL2 compared to HFD control (Figure4.
5C). Compared to HFD control, markers of macrophage infiltration were reduced with egg SM
feeding (F4/80, Cd68, Cd11c) and to a lesser extent milk SM (F4/80) (Figure 4.5D). For
inflammatory gene expression, egg SM reduced both Ccl2 and Tnfa mRNA, whereas milk SM
only reduced Tnfa. Egg SM also increased the expression of GLUT4 and adiponectin (Adipoq)
mRNA, genes that are regulated by PPARγ and CCAAT/enhancer-binding protein alpha
(C/EBPα). Correspondingly, egg SM significantly increased C/EBPα (Cebpa) mRNA and tended
to increase PPARγ (Pparg) mRNA (p = 0.07). Overall, markers of adipose tissue inflammation
were reduced with egg SM feeding and to a lesser extent with milk SM.

4.4.5. Dietary Egg SM Reduces Skeletal Muscle Lipid Accumulation Induced by HFD

Total lipids were extracted from skeletal muscle (quadriceps femoris) and examined for TG
content. HFD significantly increased TG concentration of muscle, whereas only egg SM attenuated
this effect (Figure 4.6A). Both dietary SM groups had significantly lower expression of βoxidative genes in muscle compared to HFD (Figure 4.6B), whereas only egg SM reduced Cd36
and Acad expression. No differences were observed for GLUT4 and Lpl mRNA expression
between HFD group.
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Figure 4.5. Dietary SM attenuates inflammation in adipose tissue. Epididymal adipose tissue sections were formalin-fixed, sectioned
and H&E stained (A). Crown-like structures (CLS) were manually counted from adipose H&E stains and averaged across 3 random
200X high-powered fields (HPF) (B) (n = 4 per group, mean + SEM). Serum CCL2 was determined by magnetic bead-based assay (C)
(n = 13-14 per group, mean + SEM). Epididymal adipose tissue mRNA expression was determined using real-time qRT-PCR and
(-ΔΔCt)
standardized to the geometric mean of Gapdh, 36B4, and β-actin reference genes using the 2
method (D) (n = 13-14 per group,
mean + SEM). Mean values with unlike letters indicate differences at P < 0.05 using post hoc comparisons.

114

4.5. Discussion
High fat and cholesterol-enriched diets have been linked with the development of obesity, hepatic
steatosis, and dyslipidemia in animal models [12-15]. Sphingolipids are dietary bioactives shown
to reduce lipid absorption and alter lipid metabolism both in vitro and in rodent models [18-25].
In the current study, we examined the development of diet-induced obesity and hepatic steatosis
in mice while supplementing with dietary SM. Both dietary egg SM and milk SM supplementation
were able to attenuate the development of hepatic steatosis. Hepatic TG reductions were confirmed
with histological changes in steatosis and reductions in PPARγ-related gene expression. Adipose
tissue inflammation and markers of macrophage infiltration were also decreased with dietary SM.
Contrary to our hypothesis, egg SM reduced serum cholesterol, adipose tissue inflammation,
hepatic TG, and skeletal muscle TG more effectively than milk SM. Overall, the current findings
show dietary SM can attenuate hepatic steatosis and adipose tissue inflammation observed with
diet-induced obesity, with a substantial difference in potency between egg SM and milk SM.
In the current study, egg SM attenuated hypercholesterolemia and hyperglycemia induced
by HFD. Dietary SM is well-documented to acutely reduce cholesterol absorption [18-21], and in
some cases, the absorption of other lipids and fat-soluble compounds [20, 21]. This inhibitory
effect provides the rationale for studies examining chronic intake of dietary SM and lipid
homeostasis [22-25]. We predicted that milk SM would be more effective than egg SM in
preventing diet-induced obesity complications, based on previous studies in rats showing milk SM
had greater inhibition of lipid absorption than
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Figure 4.6 Egg SM attenuates skeletal muscle triglyceride accumulation with HFD. Skeletal
muscle (quadriceps femoris) lipids were extracted using a modified Folch extraction and TG was
measured by enzymatic methods (n = 6 per group, mean + SEM) (A). Muscle mRNA was
measured by real-time qRT-PCR (B). Data was normalized to endogenous reference gene
expression (n = 13-14 per group, mean + SEM). Mean values with unlike letters indicate
differences at P < 0.05 using post hoc comparisons
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egg SM [21]. However, this was not observed, and may be related to differences in study design,
such as duration or animal model. The ratio of cholesterol and SM in lipid emulsions is known to
impact the magnitude of cholesterol absorption in vitro and in vivo [18]. Cholesterol and SM
mutually inhibit each other’s absorption [19]. As little as 0.1% (w/w) dietary milk SM was shown
to reduce cholesterol absorption by 20% in mice on a chow diet [18]. Egg SM (0.2% w/w)
supplemented over 6 weeks to a high fat, high cholesterol diet lowered serum lipids in APOE*3Leiden mice [25]. We have previously shown that milk SM (0.25% w/w) supplementation of a
HFD for 4 weeks, without added cholesterol, was able to reduce serum and hepatic lipids in mice,
while egg SM supplementation (0.25% w/w) surprisingly increased serum and hepatic lipids [23].
Serum lipids in rodents fed various animal-sourced sphingolipids have been shown to decrease
[23-25], not change [22], and even increase in some studies [23, 37]. In general, sphingolipid
supplementation in rodents consuming large amounts of dietary cholesterol typically reduces
serum cholesterol and hepatic lipids, whereas in the absence of large doses of cholesterol,
supplementation with sphingolipids resulted in increased serum and hepatic lipids in some studies
[23, 37]. While in the current study milk SM did not lower serum cholesterol, it successfully
reduced hepatic lipids. Dietary SM has been previously reported to reduce hepatic lipids
independent of changes in serum lipids [22]. More research is required to determine the optimal
conditions for dietary sources of SM to reduce serum and hepatic lipids.
The most striking observation between dietary SM-supplemented groups and HFD control
were the histological and biochemical differences in hepatic steatosis. Both SM groups had lower
hepatic TG and cholesterol concentrations compared to HFD; however, hepatic TG were reduced
most prominently with egg SM. It has been estimated that up to 60% of hepatic TG are derived
from serum NEFA [38]. In the current study, both SM groups lowered serum NEFA concentrations
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compared to HFD. Reduced NEFA uptake by the liver is further supported by the reduction in
hepatic Cd36 and Fabp4 mRNA observed in the egg SM group. CD36 mediates long-chain fatty
acid uptake into cells to be used for TG synthesis [39]. FABP4 is responsible for binding fatty
acids and transporting them inside cells [40]. Differences in oxidation, synthesis, or secretion could
also contribute to the observed reductions in hepatic TG and cholesterol. In the current study, no
differences in hepatic expression of various genes related to β-oxidation, de novo fatty acid
synthesis, or cholesterol biosynthesis were detected, suggesting that fatty acid oxidation and fatty
acid/cholesterol biosynthesis were unchanged. However, Scd1 mRNA was significantly reduced
in both SM groups. SCD1 is an important enzyme in TG synthesis, enzymatically desaturating
stearic and palmitic acid to oleic and palmitoleic acid, respectively [41]. Dietary fatty acids can
also be a source of NEFA for hepatic TG synthesis [38]. Dietary sphingolipids have been
previously shown to reduce the absorption of dietary fat in rodents [20, 21, 25]. While we observed
differences between HFD groups in hepatic steatosis, an early marker of NAFLD, we did not
examine long-term sequelae, such as inflammation and fibrosis. Longer studies are necessary to
determine any effects of dietary SM on more severe stages of NAFLD, such as NASH and fibrosis.
Endogenous ceramide content has been linked with altered hepatic function. Hepatic insulin
sensitivity is reduced in mice lacking ceramide synthase 2 (CerS2), an enzyme required for verylong chain ceramide (C22-C24) synthesis in hepatocytes [42-44]. C16:0-ceramide and the
expression of its major synthetic enzymes, ceramide synthase 5 and 6, markedly increase in the
livers of obese mice [44, 45]. Other studies have reported reductions in very-long chain ceramides
(C22-C24) in the livers of HFD-fed mice [45, 46]. Thus, it will be important in future studies to
determine if there are alterations in hepatic ceramide species with dietary SM intake.
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The hepatic expression of Scd1 [47], Fabp4 [48], Cd36 [49], and Pparg2 [50] mRNA are
known to be induced by PPARγ agonists. Hepatic PPARγ activity is associated with the
accumulation of lipid droplets [51]. PPARγ overexpression in mice accelerates the development
of hepatic steatosis [52]. PPARγ is a ligand-activated transcription factor, shown to be activated
by long-chain fatty acids [53]. In obesity, more long-chain fatty acids would be available to the
liver, offering more potential ligands for PPARγ and substrates for TG synthesis. We failed to
detect significant differences in total PPARγ protein in livers of SM-supplemented mice compared
to HFD control. However, PPARγ protein expression is not a complete picture of PPARγ activity.
PPARγ activity is heavily regulated by post-translational modifications and ligand availability [54,
55]. Both dietary SM-supplemented groups reduced lipid accumulation relative to HFD control.
We speculate that an overabundance of fatty acids, known ligands for PPARγ, are responsible for
driving the higher hepatic expression of Pparg2, Cd36, Fabp4, and Scd1 mRNA detected in HFD
control vs egg SM. Further research should investigate if dietary SM has any direct effects on
altering hepatic PPARγ activity or indirect effects by reducing fatty acid ligand availability.
Obesity-related metabolic complications are associated with adipocyte dysfunction and the
recruitment of inflammatory macrophages into adipose tissue, contributing to adipose tissue
inflammation and insulin resistance [56]. We observed a significant attenuation of adipose tissue
macrophage infiltration and inflammation by egg SM, with a smaller effect by milk SM. The
recruitment of macrophages into adipose tissue is driven by increases in CCL2, a chemokine factor
otherwise known as monocyte chemoattractant protein-1 (MCP-1) [57]. Both dietary SM groups
reduced serum CCL2, while only egg SM had a significant effect on all markers of macrophage
infiltration measured (Cd68, F4/80, Cd11c, crown-like structures). This may be related to the
stronger effect of egg SM on reducing CCL2 mRNA expression in the adipose tissue. However,
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both SM groups had significant reductions in adipose tissue F4/80 and TNFα mRNA expression,
suggesting a general reduction in adipose tissue inflammation with dietary SM. Umemoto et al.
[13] had previously shown a marginal effect of the cholesterol absorption inhibitor, ezetimibe, on
preventing adipose tissue macrophage infiltration and inflammation in diet-induced obese mice.
However, we observed strong effects with egg SM, thus, suggesting dietary SM works through
other mechanisms besides inhibiting dietary cholesterol absorption. Additionally, the stronger
effects observed with egg SM, which is reportedly less effective at inhibiting cholesterol
absorption than milk SM [21], supports this assumption. Along with reduced inflammation, egg
SM increased the expression of GLUT4 and adiponectin (Adipoq) mRNA in adipose tissue,
suggesting an improvement in metabolic function. While skeletal muscle is considered the major
organ involved in whole-body glucose disposal [58], adipose GLUT4 has been shown to promote
glucose tolerance in mice [59] and, thus, may have contributed to the reduced fasting glucose in
egg SM-fed mice compared to HFD.
Skeletal muscle TG content of mice fed egg SM was reduced compared to HFD, and this
may have also contributed to an improvement in fasting glucose [60]. However, we did not observe
differences in skeletal muscle Glut4 mRNA expression between HFD groups and also failed to
observe differences in serum insulin and HOMA-IR. Although lower skeletal muscle TG was
observed with egg SM relative to HFD, the expression of several genes involved in β-oxidation
was reduced (Acox1, Acadl, Cpt1b). It seems plausible that β-oxidative genes were induced in
HFD skeletal muscle to compensate for an increased fatty acid load, an effect which was reversed
with egg SM.
We observed a substantial difference in potency between egg SM and milk SM in the
current study. Compositional variation between egg SM and milk SM would be expected to result
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in differences in bioactivity. Egg SM species are mostly uniform, with amide-linked palmitic acid
(16:0) and sphingosine bases (d18:1) as primary components [28, 29]. In contrast, bovine milk SM
has a more variable fatty acid (16:0, 22:0-24:0) and sphingoid base (d16:0-d19:0 and d16:1-19:1)
composition [28, 30]. The longer amide-linked fatty acyl chains in milk SM are thought to form
tighter hydrophobic interactions with other dietary lipids, inhibiting their absorption to a greater
extent than the 16:0 chains found in egg SM [21]. Saturated sphingoid bases are also more
pervasive

in

milk

SM.

SM

with

saturated

sphingoid

backbones

are

known

as

dihydrosphingomyelin (DHSM). DHSM has been shown to display stronger interactions with
cholesterol than SM [61]. Dihydroceramide, the hydrolytic product of DHSM, demonstrates a
lower bioactivity to induce apoptosis of cells than ceramide [62]. Therefore, variations in
bioactivity and affinity for cholesterol, driven by length of the amide-linked fatty acyl chains and
the saturation of the sphingoid backbone, could have resulted in the differences in bioactivity of
egg SM and milk SM observed in the current study. Another possible explanation for variations in
bioactivity of dietary SM could be related to their hydrolysis in the gut. Alkaline
sphingomyelinase’s in vitro activity is inhibited by excess lipid, especially longer chain fatty acids
and higher cholesterol-to-fatty acid ratios [63]. Ceramide derived from milk SM is a potent
inhibitor of in vitro cholesterol absorption [64]. Sphingosine can also inhibit cholesterol absorption
but is not as effective as ceramide [64] and is readily absorbed [65]. Structural variations between
egg SM and milk SM may result in differential hydrolysis in the gut. Milk SM may not be
hydrolyzed as efficiently as egg SM by alkaline sphingomyelinase, due to its longer fatty acid
chains. Further supporting this notion, increases in very long-chain fatty acids (22:0–24:0) have
not been observed in rat mesenteric lymph after feeding milk SM, whereas palmitic acid (16:0)
increased in rat mesenteric lymph after feeding egg SM [21].
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In conclusion, the current study demonstrates a decrease in the development of hepatic
steatosis and adipose tissue inflammation in diet-induced obese mice when supplemented with egg
SM, and to a lesser extent with milk SM. The visible decreases in hepatic steatosis were confirmed
by reductions in both liver TG and CE in the SM-supplemented groups. These reductions in hepatic
lipids were associated with the reduced expression of PPARγ-related genes involved in TG
synthesis, especially with egg SM. Egg SM was more effective than milk SM in preventing hepatic
steatosis, while also reducing adiposity, fasting glucose, and serum cholesterol. The reason for
such differences observed is unclear, although there are likely additional bioactive effects of
dietary SM beyond impairing lipid absorption. More research is warranted to determine the effects
of dietary SM on other obesity-related outcomes and to delineate mechanisms underlying the
differences in bioactivity between egg and milk SM.
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Chapter 5. Dietary Milk Sphingomyelin
Reduces Systemic Inflammation in DietInduced Obese Mice and Inhibits LPS
Activity in Macrophages
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5.1. Abstract
High fat diets increase lipopolysaccharide (LPS) activity in the blood and may contribute to
systemic inflammation with obesity. We hypothesized that dietary milk sphingomyelin (SM),
which reduces lipid absorption and colitis in mice, would reduce inflammation and be mediated
through effects on gut health and LPS activity. C57BL/6J mice were fed high fat, high cholesterol
diets (HFD, n = 14) or the same diets with milk SM (HFD-MSM, 0.1% by weight, n = 14) for 10
weeks. HFD-MSM significantly reduced serum inflammatory markers and tended to lower serum
LPS (p = 0.08) compared to HFD. Gene expression related to gut barrier function and macrophage
inflammation were largely unchanged in colon and mesenteric adipose tissues. Cecal gut
microbiota composition showed greater abundance of Acetatifactor genus in mice fed milk SM,
but minimal changes in other taxa. Milk SM significantly attenuated the effect of LPS on proinflammatory gene expression in RAW264.7 macrophages. Milk SM lost its effects when
hydrolysis was blocked, while long-chain ceramides and sphingosine, but not dihydroceramides,
were anti-inflammatory. Our data suggest that dietary milk SM may be effective in reducing
systemic inflammation through inhibition of LPS activity and that hydrolytic products of milk SM
are important for these effects.

5.2. Introduction
Chronic low-grade inflammation is involved in the pathogenesis of cardiovascular disease, type 2
diabetes and non-alcoholic fatty liver disease [1]. Metabolically-related chronic low-grade
inflammation may be exacerbated by circulating lipopolysaccharide (LPS), also called
“endotoxin”, a pro-inflammatory molecule found in the outer membrane of Gram-negative
bacteria [2]. Recognition of bacterial LPS by host cells can trigger a pro-inflammatory signaling
cascade mediated by Toll-like receptor-4 (TLR4), a pattern recognition receptor [3]. The human
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gastrointestinal tract has a “gut barrier” to limit the passage of microbes between host intestinal
cells (e.g., tight junctions between enterocytes) and into the bloodstream [4]. These features of the
gut barrier function to reduce permeability to LPS, which may otherwise trigger host inflammation
and disease [5]. However, LPS translocation from the gut to circulation is enhanced by the
absorption of dietary lipids [6]. High fat diets (HFD) have been shown to promote inflammation
of the distal intestine, causing an impairment of the protective gut barrier and translocation of LPS
into host circulation [7]. Diets high in fat can also alter the gut microbiota [8], resulting in
diminished amounts of beneficial bacteria, such as some bifidobacteria, which would promote gut
barrier permeability [7]. Additionally, diets rich in triglyceride and cholesterol increase
chylomicron production during digestion and absorption. It has been shown that LPS can be
incorporated into chylomicrons and transported into the bloodstream of mice [6]. Overall, these
effects of HFD result in the paracellular and transcellular translocation of LPS from the gut into
the circulation. The presence of LPS in the circulation activates the inflammatory response of the
immune system, mainly through the activation of TLR4 [3]. Lipopolysaccharide engages the
TLR4/MD-2 receptor complex via LPS-binding protein (LBP) and CD14. Toll-like receptor 4
signaling then activates the nuclear factor-kappa B (NF-κb) transcription factor resulting in the
production of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) [3].
Macrophages in the colon have been shown to be the first pro-inflammatory immune responders
to an HFD [9]; thus, inhibiting LPS translocation and the subsequent inflammatory responses of
macrophages shows great potential in reducing the detrimental effects of a diet rich in fat and
cholesterol.
Dietary phospholipids, including sphingolipids, show potential in mitigating chronic
disease through effects on lipid absorption and inflammation [10, 11]. Dietary sphingolipids,
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which include sphingomyelin (SM), ceramides, and sphingosine, are mainly found in milk, eggs,
and soybeans [12]. It is estimated that the average American consumes 0.3 to 0.4 grams of
sphingolipids per day [12]. Sphingomyelin is considered a zoochemical, being present in animal
cell membranes but absent from plants [13]. Sphingomyelin found in milk is an important
component of milk fat globule membranes [14]. Dietary SM and other sphingolipids have been
studied for their effects on dyslipidemia because they interfere with the absorption of dietary fat
and cholesterol [15-21]. In addition to effects on lipid absorption, dietary SM may have additional
bioactive effects by reducing inflammation and LPS activity, potentially influencing chronic
disease. Dietary milk SM has been shown to reduce DSS-induced colitis in mice, suggesting antiinflammatory effects in the gut [22]. Although, the effect of dietary SM on colon inflammation is
controversial, as exacerbation of colitis in mice has been observed with feeding egg-derived SM
[23, 24]. Phospholipids and sphingolipids appear to impact LPS activity, as they have been shown
to dampen LPS-induced inflammation [23, 24]. The presence of LPS in circulation also results in
the liver upregulating sphingolipid biosynthesis via the sphingolipid rate-limiting biosynthetic
enzyme, serine palmitoyltransferase (SPT), possibly as a compensatory mechanism [25]. We have
previously shown that feeding 0.25% (w/w) milk SM reduced serum LPS and altered the gut
microbiota in HFD-fed mice after 4 weeks [26]. We also recently reported that feeding dietary SM
(0.1% w/w) attenuated hepatic steatosis and adipose tissue inflammation in diet-induced obese
mice [27]. The current study aimed to assess the effects of dietary milk SM on systemic and gut
inflammation using a high fat diet-induced obese mouse model. We also sought to elucidate
whether milk SM and its hydrolytic products (ceramides, dihydroceramides, and sphingosine)
directly affect the inflammatory response of macrophages stimulated by LPS.

131

5.3. Materials and Methods
5.3.1. Animals and Diets

Male C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME) at 6 weeks
of age. Mice were housed in a temperature-controlled room and maintained in a 12-h light/12-h
dark cycle within the University of Connecticut-Storrs vivarium. The Animal Care and Use
Committee of the University of Connecticut-Storrs approved all procedures used in the current
study. Mice were acclimated to the facility for two weeks before being placed on either a lardbased high fat, high cholesterol diet (HFD; 60% kcal from fat, 0.15% cholesterol added by weight;
n = 14) or HFD supplemented with 0.1% of milk SM added by weight (HFD-MSM; n = 14).
Detailed diet compositions are presented in Table 4.1. Experimental diets were prepared using
purified ingredients commercially available from Dyets, Inc. (Bethlehem, PA). Milk SM (bovine;
>99% purity) was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL) and then substituted for
an equal weight of lard in the treatment group. Accounting for weight gained throughout the study,
HFD-MSM provided the equivalent of consuming approximately 405-670 mg milk SM/day in a
70-kg human based on body surface normalization [28].

Mice consumed the diets ad libitum and fresh food was provided twice per week. Body
weight was assessed weekly, while food intake was calculated at each feeding. After 10 weeks,
mice were fasted for 6–8 h followed by euthanasia and subsequent blood collection via cardiac
puncture. Blood clotted at room temperature for 30 min before serum isolation by centrifugation
(10,000×g for 10 min at 4°C) and then stored at -80°C. Special precautions were taken to minimize
endotoxin contamination of the serum samples. Mesenteric adipose and colon tissues were isolated
and snap frozen in liquid nitrogen before storage in -80°C.
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5.3.2. Serum Biochemical Analysis

Serum IL-6, TNF-α, IFNγ, and MIP-1β were measured by Luminex/xMAP magnetic bead-based
multiplexing assay using MAGPIX instrumentation from EMD Millipore (Billerica, MA). Serum
LPS was measured using a chromogenic limulus amebocyte lysate (LAL) assay (QCL-1000)
obtained from Lonza (Basel, Switzerland).
5.3.3. Gut Microbiota Analysis

Cecal fecal samples were collected from mice and submitted to the University of ConnecticutStorrs Microbial Analysis, Resources and Services (MARS) facility for microbiota
characterization utilizing 16S V4 analysis. DNA was extracted from 0.25 g of fecal sample using
the MoBio PowerMag Soil 96 well kit (MoBio Laboratories, Inc, Carlsbad, CA) according to the
manufacturer’s protocol for the Eppendorf epMotion liquid handling robot. DNA extracts were
quantified using the Quant-iT PicoGreen kit (ThermoFisher Scientific). Partial bacterial 16S rRNA
(V4) and fungal ITS2 genes were amplified using 30 ng extracted DNA as template. The V4 region
was amplified using 515F and 806R with Illumina adapters and dual indices (8 basepair golay on
3’[29], and 8 basepair on the 5’ [30]). Samples were amplified in triplicate using Accuprime PFX
PCR master mix (ThermoFisher) with the addition of 10 µg BSA (New England BioLabs, Ipswich,
MA). The PCR reaction was incubated at 95˚C for 2 min., the 30 cycles of 15 s at 95.0°C, 1 min.
at 55°C and 1 min. at 68°C, followed by final extension as 68°C for 5 min. PCR products were
pooled for quantification and visualization using the QIAxcel DNA Fast Analysis (Qiagen, Hilden,
Germany). PCR products were normalized based on the concentration of DNA from 250-400 bp
then pooled using the QIAgility liquid handling robot. The pooled PCR products were cleaned
using Mag-Bind RXNPure Plus (Omega Bio-Tek, Norcross, GA) according to the manufacturer’s
protocol. The cleaned pool was sequenced on the MiSeq using v2 2x250 base pair kit (Illumina,
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Inc, San Diego, CA). Sequences were demultiplexed using onboard bcl2fastq. Demultiplexed
sequences were processed in Mothur v. 1.39.4 following the MiSeq SOP [30]. Exact commands
can be found here https://github.com/krmaas/bioinformatics/blob/master/mothur.batch. Merged
sequences that had any ambiguities or did not meet length expectations were removed. Sequences
were aligned to the Silva nr_v119 alignment [31]. Taxonomic identification of OTUs was done
using the RDP Bayesian classifier [32] against the Silva nr_v119 taxonomy database.
5.3.4. Cell Culture

Murine RAW264.7 macrophages were obtained from ATCC (Manassas, VA) and cultured in a
humidified incubator at 37°C and 5% CO2. Cells were maintained in DMEM (4 g/L glucose)
containing sodium pyruvate, 10% fetal bovine serum (Hyclone, Logan, UT), 2 mM L-glutamine,
100 U/mL penicillin, 100 µg/mL streptomycin antibiotic (ThermoFisher Scientific, Waltham, MA)
and 100 µg/mL Normocin (Invitrogen, Carlsbad, CA). Cell counts and viability were routinely
measured using Trypan blue and TC-20 automated cell counter (Bio-Rad, Hercules, CA).
5.3.5. Effects of Sphingolipids on LPS Stimulation of RAW264.7 Macrophages

Milk sphingomyelin (bovine), sphingosine (d18:1), C16-ceramide (d18:1/16:0), C24-ceramide
(d18:1/24:0), C16-dihydroceramide (d18:0/16:0), and C24-dihydroceramide (d18:0/24:0) were
obtained from Avanti Polar Lipids at >99% purity. Milk SM and sphingosine were dissolved in
100% ethanol (EtOH), while ceramides were dissolved in EtOH/dodecane (98.8/0.2, v/v).
RAW264.7 cells were seeded in 24-well plates and allowed to adhere overnight prior to
experimentation. To examine possible anti-inflammatory effects of milk SM, RAW264.7
macrophages were pre-incubated with milk SM (0.8-8 µg/mL) or EtOH vehicle control for 1 h,
followed by a 4 h co-incubation in the presence or absence of 1 ng/mL LPS (E. coli 0111:B4)
(Sigma-Aldrich, St. Louis, MO). Since milk SM comprised of a natural mixture of SM species,
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concentrations are reported in 0.8-8 µg/mL, which is comparable to 1-10 µM of a pure SM species.
To determine if effects were dependent on SM hydrolysis, cells incubated for 2 h with 100 μM
imipramine (Sigma-Aldrich) prior to 1 h incubation with milk SM or control ± 4 h co-incubation
with LPS. Imipramine has been shown to reduce acid sphingomyelinase (SMase) activity to ~20%
of basal levels after 2 h of incubation [33]. To test the effects of various ceramides and sphingosine,
RAW264.7 macrophages were incubated for 4 h with ceramides (10 µM), dihydroceramides (10
µM), sphingosine (1-10 µM), or vehicle control ± LPS (1 ng/mL). Ethanol was used as a vehicle
control for milk SM and sphingosine treatments, while EtOH/dodecane (98.8/0.2, v/v) was used
as a control for ceramide treatments. To test for cytotoxicity, Cell Counting Kit-8 (CCK-8) (SigmaAldrich) was used after cells were treated with the different sphingolipids. Sodium dodecyl sulfate
(SDS, 50 μM) was used as a cytotoxic positive control. Caspase 3 activity was also determined as
an indicator of apoptosis using a colorimetric protease assay kit (ThermoFisher Scientific)
according to manufacturer instructions. Cisplatin (ThermoFisher Scientific) at 50 µM
concentration was used on cells as a positive control to induce apoptosis.
5.3.6. RNA isolation, cDNA Synthesis, and qRT-PCR

Total RNA from small intestine, colon, mesenteric adipose tissue and RAW264.7 macrophages
was isolated using TRIzol reagent (Life Technologies, Carlsbad, CA). RNA was treated with
DNase I before reverse transcription using iScript cDNA synthesis kit (Bio-Rad). Real-time qRTPCR using the iTaq Universal SYBR Green Supermix was performed on a CFX96 real-time-PCR
detection system (Bio-Rad). For small intestine, colon, and mesenteric adipose tissues, the
geometric mean of the reference genes, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and
beta actin was used to standardize mRNA expression using the 2−ΔΔCt method. The macrophage
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mRNA was standardized to Gapdh expression. All primer sequences used are listed in Appendix
A.
5.2.7. Statistical Analysis

Data were analyzed using GraphPad Prism 6. Means were compared using Student’s t test or oneway analysis of variance with Holm-Sidak post hoc analysis where indicated. For gut microbiota
analysis, alpha and beta diversity statistics were calculated by taking the average of 1000 random
subsampling to 10,000 reads per sample in Mothur. NMS and Permanova were run in R 3.3.2. A
subsampled species matrix was used for indicator species analysis [34]. Figures were drawn in R
3.3.2 using ggplot2 2.2.1 and RColorBrewer 1.1-2. Data are reported as mean ± SEM. Significance
is reported as p < 0.05.

5.4. Results
5.4.1. Dietary milk SM reduces systemic inflammation and tends to lower circulating LPS

All mice fed the lard-based HFD were obese and insulin-resistant after 10 weeks, while
supplementation of 0.1% (w/w) milk SM did not affect food intake, body or tissue weight gain
compared to HFD control [27]. However, feeding milk SM strongly decreased serum
inflammatory cytokines/chemokines compared to HFD control (Figure 5.1A). Milk SM tended to
reduce LPS compared to HFD control (-36%), but it was not significantly different (p = 0.08)
(Figure 5.1B). Milk SM tended to increase Niemann-Pick C1-Like 1 (NPC1L1) mRNA
expression (p = 0.07) in the small intestine (Figure 5.2A), which is induced by cellular cholesterol
depletion [35]. No other significant changes were observed in the small intestine for gene
expression related to lipid absorption. Interestingly, C-C motif chemokine ligand 2 (CCL2) mRNA
expression was significantly increased in the colon by milk SM (Figure 5.2B). However, this did
not appear to alter gut health, as mRNA expression of genes related to macrophage
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Figure 5.1. Dietary milk SM reduces serum inflammation markers in diet-induced obese mice. Male C57BL/6J mice were fed
high fat diet (60% kcal fat, 31% lard, 0.15% added cholesterol) (HFD) or HFD supplemented with 0.1% (w/w) milk SM (HFMSM)
for 10 weeks. Serum cytokines/chemokines (A) and endotoxin concentrations (B) were by magnetic bead-based assay and
chromogenic LAL assay, respectively. Mean ± SEM, n = 13-14 per group. *p < 0.05, **p < 0.01 compared to HFD.
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Figure 5.2. Intestinal and mesenteric adipose tissue mRNA expression of diet-induced obese mice. Small intestine mRNA (A),
colon mRNA (B), and mesenteric adipose tissue mRNA (C) was determined using real-time qRT-PCR and standardized to the
(-ΔΔCt)
geometric mean of Gapdh, 36B4, and β-actin reference genes using the 2
method. Mean ± SEM, n = 13-14 per group. **p <
0.01 compared to HFD.
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infiltration/inflammation (F4/80, Cd68, Cd11c, Tnf) and gut barrier function (Tjp1, Alpi, Ocln)
was mostly unaffected by milk SM (Figure 5.2B). Furthermore, mesenteric adipose tissue mRNA
expression related to inflammation was also unchanged, while there was a trend in GLUT4 mRNA
expression to be increased by milk SM (p = 0.09) (Figure 5.2C).

5.4.2. Gut microbiota composition is mostly unaffected by 0.1% (w/w) dietary milk SM

To determine if alterations in gut microbiota could explain differences in systemic inflammation
in the present study, cecal feces microbiota composition was examined by 16S rRNA sequence
analysis and results are presented in Figure 5.3. Verrucomicrobia was the major phylum in cecal
feces, but there were no significant differences between groups in its relative abundance or that of
its major genus, Akkermansia (Figure 5.3B). Additionally, no significant differences were
observed in the relative abundance of Firmicutes or Bacteroidetes phyla between groups (Figure
5.3B) or when phyla were grouped as Gram-negative bacteria (HFD: 76.9% ± 1.5% vs. HFDMSM: 73.5% ± 2.8%, p = 0.31). However, relative abundance of Acetatifactor, a genus of the
Firmicutes phylum, was significantly higher in the group fed milk SM compared to HFD control
(Figure 5.3B). Alpha-diversity analysis (diversity within a sample) determined by inverse
Simpson index was not significantly different between groups (HFD: 2.19 ± 0.16 vs. HFD-MSM:
2.46 ± 0.32, p = 0.45). Furthermore, beta-diversity analysis (between sample diversity) by BrayCurtis revealed no significant clustering of samples according to diet (Figure 5.3C). Therefore, in
the context of diet-induced obesity, gut microbiota composition was generally unaffected by
supplementation of 0.1% (w/w) milk SM in the diet.
5.4.3. Milk SM inhibits LPS stimulation of macrophages

Since dietary milk SM may directly influence inflammatory processes beyond inhibiting lipid
absorption, we examined its effects on pro-inflammatory gene expression in RAW264.7
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Figure 5.3. Gut microbiota composition of diet-induced obese mice. Cecal fecal samples were collected and microbiota
composition was assessed by 16S rRNA sequencing as described in Materials and Methods. Mean phylogenetic abundance (% of
total sequences) of mice (A) and taxa comparisons (B). Beta diversity shown by Bray-Curtis based non-metric multidimensional
scaling plot to visualize between sample diversity (C). Mean ± SEM, n = 10 per group. *p < 0.05 compared to HFD. Abbreviations:
Lachnospiraceae_u, Lachnospiraceae_unclassified; Ruminococcaceae_u, Ruminococcaceae_unclassified
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macrophages. Increases in TNF-α and CCL2 mRNA with 4 h LPS stimulation were both
significantly reduced with milk SM (0.8 and 8 μg/mL) (Figure 5.4A,B). Milk SM in the absence
of LPS did not influence pro-inflammatory gene expression. Furthermore, cell viability was not
affected by milk SM at concentrations shown to affect pro-inflammatory gene expression (Figure
5.4C). With the addition of imipramine, LPS-stimulated inflammation was not reduced in the
presence of milk SM (Figure 5.4D). Imipramine causes proteolytic degradation of acid
sphingomyelinase, which hydrolyzes SM to ceramide and phosphorylcholine. This suggests that a
hydrolytic product of SM (e.g. ceramide, sphingosine) is important for milk SM’s effect on
inflammation.
5.4.4. Ceramides and sphingosine, but not dihydroceramides, inhibit LPS stimulation of
macrophages

Since milk SM contains a mixture of SM species with different fatty acid chain lengths and
sphingoid backbones, we tested the effects of C16-ceramide, C24-ceramide, C16dihydroceramide, and C24-dihydroceramide on macrophage pro-inflammatory gene expression
(Figure 5.5A,B). Interestingly, both C16-ceramide and C24-ceramide at 10 µM concentrations
significantly reduced TNF-α mRNA (Figure 5.5A) and CCL2 mRNA (Figure 5.5B) in LPSstimulated macrophages, but their corresponding dihydroceramides did not. None of the ceramides
tested altered inflammatory gene expression in the absence of LPS. The anti-inflammatory effects
of ceramides (sphingosine base), but not dihydroceramides (sphinganine base), suggest
sphingosine is important for bioactivity Supporting this notion, sphingosine significantly reduced
LPS-stimulation of TNF-α mRNA (Figure 5.6A) and CCL2 mRNA (Figure 5.6B) in
macrophages. Neither ceramides nor sphingosine significantly affected cell viability (Figure
5.7A,B) or caspase 3 activity (Figure 5.7C) at the concentrations tested, suggesting cell death was
not the cause of anti-inflammatory effects.
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Figure 5.4. Milk SM inhibits LPS-activation of macrophages. RAW264.7 macrophages were pre-incubated with milk SM
(MSM) or EtOH vehicle control for 1 h, followed by a 4 h co-incubation ± LPS (1 ng/mL). TNF-α mRNA (A) and CCL2 mRNA
(B) were measured by real-time qRT-PCR. Cell viability determined using Cell Counting Kit-8 (C). Sodium dodecyl sulfate (SDS)
(0.5 mM) was used on cells as a positive control to induce cell death, **p < 0.001 compared to control. TNF-α mRNA was measured
in cells incubated for 2 h with 100 μM imipramine prior to a 1 h incubation with milk SM or control ± a 4 h co-incubation with LPS
(D). Mean ± SEM, n = 3-7 independent experiments. Unlike letters p < 0.05 by Holm-Sidak post hoc test.
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Figure 5.5. Long-chain ceramides inhibit LPS-activation of macrophages. RAW264.7 macrophages were incubated for 4 h
with ceramides (10 µM), dihydroceramides (10 µM), or vehicle control ± LPS (1 ng/mL). C16-ceramide (d18:1/16:0), C24ceramide (d18:1/24:0), C16-dihydroceramide (d18:0/16:0), and C24-dihydroceramide (d18:0/24:0) were tested. TNF-α mRNA (A)
and CCL2 mRNA (B) measured by real-time qRT-PCR. Mean ± SEM, n = 3-7 independent experiments. Unlike letters p < 0.05 by
Holm-Sidak post hoc test.
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Figure 5.6. Sphingosine inhibits LPS-activation of macrophages. RAW264.7 macrophages were incubated for 4 h with
sphingosine (1-10 µM) or vehicle control ± LPS (1 ng/mL). TNF-α mRNA (A) and CCL2 mRNA (B) measured by real-time qRTPCR. Mean ± SEM, n = 3-7 independent experiments. Unlike letters p < 0.05 by Holm-Sidak post hoc test.
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Figure 5.7. Ceramides and sphingosine do not affect cell viability or apoptosis. Cell viability determined using Cell Counting
Kit-8 for ceramides (A) and sphingosine (B). Sodium dodecyl sulfate (SDS) (0.5 mM) was used on cells as a positive control to
induce cell death. Caspase 3 activity measured as an indicator of apoptosis (C). Cisplatin (50 µM) was used on cells as a positive
control to induce apoptosis. Mean ± SEM, n = 3-5 independent experiments. **p < 0.01 compared to control.
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5.5. Discussion
Chronic low-grade inflammation is a common underlying factor in many diseases afflicting
Western societies, including diabetes, non-alcoholic fatty liver disease, and atherosclerosis [36].
Low-grade inflammation in these states may be exacerbated by circulating LPS, also known as
endotoxin [2]. LPS translocation from the gut to circulation is enhanced by lipid absorption [6].
Dietary SM has been studied for its effects on dyslipidemia because it reduces the absorption of
other lipids (e.g., fat and cholesterol), and therefore, could potentially influence systemic
inflammation. In this study, the addition of 0.1% (w/w) dietary milk SM to a lard-based HFD
significantly reduced systemic inflammation markers and tended to lower circulating LPS but had
no effect on gene expression of inflammation or gut barrier function markers in the mesenteric
adipose tissue or colon. Furthermore, microbiota composition of cecal feces was mostly unaffected
by the addition of milk SM to the HFD diet, suggesting gut microbiota compositional differences
did not play a major role in altering systemic inflammation markers. Milk SM directly attenuated
LPS stimulation of pro-inflammatory gene expression in RAW 264.7 macrophages. Interestingly,
hydrolytic products of milk SM (C16-ceramide, C24-ceramide, and sphingosine) showed similar
anti-inflammatory effects, whereas the inhibition of SM hydrolysis with imipramine prevented
such effects. These results suggest that dietary SM may have additional bioactive effects beyond
inhibiting lipid absorption through the lowering of macrophage inflammatory responses,
potentially influencing metabolic disease.
In rodent studies, dietary patterns rich in saturated fat and cholesterol, so called “Western”
diets, have been linked to chronic disease through increasing inflammation [37, 38]. Detrimental
effects of Western diets in mice appear to be influenced by the presence of microbes in the GI
tract, since depletion of gut microbiota with oral antibiotics reduces the inflammatory response
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[39]. This is partly related to the effect that Western diets have on increasing LPS in circulation,
termed “metabolic endotoxemia”, which has been shown to precede increases in systemic
inflammation in animal models [2, 39]. There is also evidence that diets high in fat and cholesterol
increase endotoxin concentration in the bloodstream of humans [40, 41]. With the current study,
we fed milk SM (0.1%) for 10 weeks to HFD-fed mice (60% kcal as fat; 0.15% cholesterol added)
to determine if dietary SM could affect chronic low-grade inflammation. Milk SM strongly
reduced serum inflammatory cytokines/chemokines and tended to reduce serum LPS (p = 0.08).
Lower serum CCL2 and mRNA expression of inflammation markers in epididymal adipose tissue
were also previously shown in mice fed milk SM [27]. We have previously reported that the 4week dietary supplementation of a higher dose of milk SM (0.25% w/w) reduced circulating LPS
by 35% in mice fed a milkfat-based high fat diet [26]. Although we did not observe any differences
in mRNA expression of gut barrier markers in the small intestine, reductions in circulating LPS
are expected to be partly due to the inhibitory effect of milk SM on lipid absorption. Supporting
this notion, we have previously observed reductions in serum and hepatic lipids with the feeding
of milk SM [26, 27].
Recently, chronic feeding of HFD to mice was shown to increase colonic pro-inflammatory
macrophages and gut inflammation, which promoted LPS translocation, insulin resistance, and
adipose tissue inflammation [9]. These effects were mediated by early induction of CCL2 in
intestinal epithelial cells, which attracted pro-inflammatory macrophages to colon tissue [9]. In
this study, although we observed significantly greater colon CCL2 mRNA expression with milk
SM intake, we did not observe any significant changes between groups in gene expression of gut
barrier markers or macrophage infiltration/inflammation in colon and mesenteric adipose tissues.
This suggests that CCL2 mRNA expression was possibly induced with milk SM because of greater
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dietary fat/cholesterol reaching the colon, but this did not induce macrophage infiltration and TNFα expression in the colon and surrounding adipose tissue. Although dietary SM is known to inhibit
cholesterol absorption, luminal cholesterol can reciprocally inhibit SM digestion [16]. Feeding
mice a high fat diet has also been shown to reduce the expression of the key enzyme in SM
digestion, alkaline sphingomyelinase [45, 46]. Therefore, it is possible that the use of a high fat
lard diet with added cholesterol in this study influenced ileal and colonic exposure to SM and
bioactive metabolic products (ceramide, sphingosine, and sphingosine-1-phosphate), which in turn
could affect colon inflammation [47, 48].
The intake of HFD has been shown to negatively alter the gut microbiota [42]. Gut
dysbiosis has been linked with endotoxin-mediated chronic disease in mouse models [43, 44].
Sphingosine, a hydrolytic product of dietary SM, is known to have bactericidal effects [45]. We
have previously reported that supplementation of 0.25% (w/w) milk SM to high fat diet-fed mice
altered the fecal microbiota composition by reducing Gram-negative bacterial phyla and increasing
Bifidobacterium [26]. In the current study, however, we did not observe such large changes in gut
microbiota composition, possibly related to the lower dose used or the more severe high fat diet
challenge. We observed a significant difference in the relative abundance of Acetatifactor genus,
with higher levels in mice fed milk SM. This genus was shown to be isolated from the intestine of
obese mice and produces the short-chain fatty acids, acetate and butyrate [46]. The abundance of
Acetatifactor in the gut was also related to lard intake in mice and correlated with the
concentrations of secondary bile acids in mouse cecum [47]. We also have observed increases in
Acetatifactor genus with 0.25% (w/w) milk SM feeding on a low-fat diet background (Norris and
Blesso, unpublished observations 2016). At this point, it is unclear if these bacteria contribute to
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the inflammatory changes observed or in response to the effects of milk SM on lipid absorption.
Further research is needed to clarify these associations.
Milk SM significantly reduced TNF-α and CCL2 mRNA expression in LPS-stimulated
RAW264.7 macrophages. There are several potential mechanisms that could explain this observed
effect. First, there could be a direct interaction between milk SM and LPS within the media, where
intact SM itself is neutralizing LPS, possibly due to the formation of a complex. In our current
study, this would mean that the LPS would be neutralized by SM before it could enter the cell, as
part of a lipid vesicle that masked the reactive lipid-A moiety of LPS. Incubation with 100 µM
bovine brain SM was reported to neutralize LPS stimulation of polymorphonuclear leukocytes
(PMN) in the presence of soluble CD14 and LBP [23]. Furthermore, SM hydrolysis can yield
bioactive products, including ceramide and sphingosine. Imipramine is a tricyclic anti-depressant
(TCA) that causes proteolytic degradation of the enzyme acid-SMase [33]. Imipramine may also
have other effects besides acid-SMase degradation, as it was shown that acid ceramidase was
down-regulated by another TCA, desipramine [48]. Interestingly, the addition of imipramine
completely abolished the anti-inflammatory effects of milk SM. This indicates that one of the
hydrolytic products of SM (e.g. ceramide, sphingosine, phosphorylcholine) may be responsible for
the reduction in inflammation. If milk SM were hydrolyzed by SMase and ceramidase to ceramide
and sphingosine, respectively, each of those products could potentially exert anti-inflammatory
effects. Longer-chain ceramides may compete with LPS and block TLR4 signaling, as they have
been shown to bind to CD14 in monocytes and form a multi-molecular complex that contains
CD36, but lacks TLR4 [49]. To confirm this, ceramides containing different amide-linked fatty
acid chain lengths (16:0 and 24:0) and sphingoid bases (dihydroceramides) were tested. We used
ceramides with 16-carbon and 24-carbon fatty acid chain lengths because these ceramides would
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be produced from the hydrolysis of the natural mixture of SM species that comprise milk SM.
Additionally, these fatty acid chain lengths within the ceramide have the ability to alter its
bioactivity [50]. Specifically, it has been shown that intracellular C16-ceramide is particularly proapoptotic, whereas C24-ceramide and dihydroceramides antagonize apoptosis induced by shorter
ceramides [51-53]. Interestingly, both C16-ceramide and C24-ceramide treatment of macrophages
resulted in significant reductions in TNF-α and CCL2 mRNA expression, while dihydroceramides
had no effect. None of the ceramides or dihydroceramides affected cell viability or the early
apoptosis marker, caspase 3 activity, suggesting the effects were not due to an induction of cell
death. Although intracellular ceramides have been shown to be pro-apoptotic [50], exogenously
added long-chain ceramides do not affect viability of macrophages [54]. These data indicate that
ceramides are responsible for the anti-inflammatory effect of milk SM and strengthens the findings
of the imipramine data. However, since only the sphingosine base containing-ceramides showed
anti-inflammatory effects and not sphinganine-containing dihydroceramides, we further tested the
effects of sphingosine on LPS stimulation of macrophages. We observed similar effects of
sphingosine (d18:1) on inhibiting TNF-α and CCL2 mRNA without affecting cell viability or
apoptosis, as C16- and C24-ceramides. Sphingosine could display anti-inflammatory effects
through the activation of the nuclear receptor, peroxisome proliferator-activate receptor-gamma
(PPARγ) [22]. In support of our findings, exogenous C8-ceramide and sphingosine have been
previously reported to reduce TNF-α secretion from LPS-stimulated macrophages [55].
Furthermore, both C16-ceramide and membrane-permeable C2-ceramide have been shown to
reduce TNF-α secretion from LPS-stimulated macrophages by post-translational mechanisms [56].
In summary, dietary milk SM reduces systemic inflammation in diet-induced obese mice,
without altering gene expression of macrophage or barrier function markers in the mesenteric
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adipose tissue or colon. Milk SM directly attenuates LPS stimulation of pro-inflammatory gene
expression in RAW 264.7 macrophages. The inhibition of SM hydrolysis prevents milk SM antiinflammatory effects, while the hydrolytic products C16-ceramide, C24-ceramide, and
sphingosine showed anti-inflammatory effects. In addition to effects on lipid absorption, dietary
SM may have additional bioactive effects by lowering inflammation and LPS activity, potentially
influencing metabolic disease. Further research is warranted to confirm the mechanism and effect
of dietary milk SM on inflammation.

151

5.6. References
1.
Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006, 444:860-867.
2.
Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F,
Tuohy KM, Chabo C, et al: Metabolic endotoxemia initiates obesity and insulin resistance.
Diabetes 2007, 56:1761-1772.
3.
Lu YC, Yeh WC, Ohashi PS: LPS/TLR4 signal transduction pathway. Cytokine 2008,
42:145-151.
4.
Suzuki T: Regulation of intestinal epithelial permeability by tight junctions. Cell Mol
Life Sci 2013, 70:631-659.
5.
Neurath MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014, 14:329342.
6.
Ghoshal S, Witta J, Zhong J, de Villiers W, Eckhardt E: Chylomicrons promote intestinal
absorption of lipopolysaccharides. J Lipid Res 2009, 50:90-97.
7.
Serino M, Luche E, Gres S, Baylac A, Berge M, Cenac C, Waget A, Klopp P, Iacovoni J,
Klopp C, et al: Metabolic adaptation to a high-fat diet is associated with a change in the gut
microbiota. Gut 2012, 61:543-553.
8.
Tilg H, Moschen AR, Kaser A: Obesity and the microbiota. Gastroenterology 2009,
136:1476-1483.
9.
Kawano Y, Nakae J, Watanabe N, Kikuchi T, Tateya S, Tamori Y, Kaneko M, Abe T,
Onodera M, Itoh H: Colonic Pro-inflammatory Macrophages Cause Insulin Resistance in an
Intestinal Ccl2/Ccr2-Dependent Manner. Cell Metab 2016, 24:295-310.
10.
Blesso CN: Egg phospholipids and cardiovascular health. Nutrients 2015, 7:2731-2747.
11.
Norris GH, Blesso CN: Dietary sphingolipids: potential for management of
dyslipidemia and nonalcoholic fatty liver disease. Nutr Rev 2017.
12.
Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH,
Jr.: Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr
1999, 129:1239-1250.
13.
Hannich JT, Umebayashi K, Riezman H: Distribution and functions of sterols and
sphingolipids. Cold Spring Harb Perspect Biol 2011, 3.
14.
Rombaut R, Dewettinck K: Properties, analysis and purification of milk polar lipids.
International Dairy Journal 2006, 16:1362-1373.
15.
Noh SK, Koo SI: Egg sphingomyelin lowers the lymphatic absorption of cholesterol
and alpha-tocopherol in rats. J Nutr 2003, 133:3571-3576.
16.
Nyberg L, Duan RD, Nilsson A: A mutual inhibitory effect on absorption of
sphingomyelin and cholesterol. J Nutr Biochem 2000, 11:244-249.
17.
Duivenvoorden I, Voshol PJ, Rensen PC, van Duyvenvoorde W, Romijn JA, Emeis JJ,
Havekes LM, Nieuwenhuizen WF: Dietary sphingolipids lower plasma cholesterol and
triacylglycerol and prevent liver steatosis in APOE*3Leiden mice. Am J Clin Nutr 2006,
84:312-321.
18.
Noh SK, Koo SI: Milk sphingomyelin is more effective than egg sphingomyelin in
inhibiting intestinal absorption of cholesterol and fat in rats. J Nutr 2004, 134:2611-2616.
19.
Garmy N, Taieb N, Yahi N, Fantini J: Interaction of cholesterol with sphingosine:
physicochemical characterization and impact on intestinal absorption. J Lipid Res 2005,
46:36-45.

152

20.
Eckhardt ER, Wang DQ, Donovan JM, Carey MC: Dietary sphingomyelin suppresses
intestinal cholesterol absorption by decreasing thermodynamic activity of cholesterol
monomers. Gastroenterology 2002, 122:948-956.
21.
Chung RW, Kamili A, Tandy S, Weir JM, Gaire R, Wong G, Meikle PJ, Cohn JS, Rye
KA: Dietary sphingomyelin lowers hepatic lipid levels and inhibits intestinal cholesterol
absorption in high-fat-fed mice. PLoS One 2013, 8:e55949.
22.
Mazzei JC, Zhou H, Brayfield BP, Hontecillas R, Bassaganya-Riera J, Schmelz EM:
Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by
dietary sphingomyelin: importance of peroxisome proliferator-activated receptor gamma
expression. J Nutr Biochem 2011, 22:1160-1171.
23.
Wurfel MM, Wright SD: Lipopolysaccharide-binding protein and soluble CD14
transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular
classes of lipid. J Immunol 1997, 158:3925-3934.
24.
Parker TS, Levine DM, Chang JC, Laxer J, Coffin CC, Rubin AL: Reconstituted highdensity lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole
blood. Infect Immun 1995, 63:253-258.
25.
Memon RA, Holleran WM, Moser AH, Seki T, Uchida Y, Fuller J, Shigenaga JK, Grunfeld
C, Feingold KR: Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and
produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscler Thromb Vasc
Biol 1998, 18:1257-1265.
26.
Norris GH, Jiang C, Ryan J, Porter CM, Blesso CN: Milk sphingomyelin improves lipid
metabolism and alters gut microbiota in high fat diet-fed mice. J Nutr Biochem 2016, 30:93101.
27.
Norris GH, Porter CM, Jiang C, Millar CL, Blesso CN: Dietary sphingomyelin attenuates
hepatic steatosis and adipose tissue inflammation in high-fat-diet-induced obese mice. J Nutr
Biochem 2017, 40:36-43.
28.
Nair AB, Jacob S: A simple practice guide for dose conversion between animals and
human. J Basic Clin Pharm 2016, 7:27-31.
29.
Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM,
Betley J, Fraser L, Bauer M, et al: Ultra-high-throughput microbial community analysis on the
Illumina HiSeq and MiSeq platforms. ISME J 2012, 6:1621-1624.
30.
Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD: Development of a dualindex sequencing strategy and curation pipeline for analyzing amplicon sequence data on the
MiSeq Illumina sequencing platform. Appl Environ Microbiol 2013, 79:5112-5120.
31.
Quast C, Pruesse E, Yilmaz P, Gerken J, Schweer T, Yarza P, Peplies J, Glockner FO: The
SILVA ribosomal RNA gene database project: improved data processing and web-based
tools. Nucleic Acids Res 2013, 41:D590-596.
32.
Wang Q, Garrity GM, Tiedje JM, Cole JR: Naive Bayesian classifier for rapid
assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol
2007, 73:5261-5267.
33.
Hurwitz R, Ferlinz K, Sandhoff K: The tricyclic antidepressant desipramine causes
proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem
Hoppe Seyler 1994, 375:447-450.
34.
De Caceres M, Legendre P: Associations between species and groups of sites: indices
and statistical inference. Ecology 2009, 90:3566-3574.

153

35.
Alrefai WA, Annaba F, Sarwar Z, Dwivedi A, Saksena S, Singla A, Dudeja PK, Gill RK:
Modulation of human Niemann-Pick C1-like 1 gene expression by sterol: Role of sterol
regulatory element binding protein 2. Am J Physiol Gastrointest Liver Physiol 2007, 292:G369376.
36.
Baker RG, Hayden MS, Ghosh S: NF-kappaB, inflammation, and metabolic disease.
Cell Metab 2011, 13:11-22.
37.
Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lutjohann D, Kerksiek A, van
Kruchten R, Maeda N, Staels B, et al: Dietary cholesterol, rather than liver steatosis, leads to
hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis.
Hepatology 2008, 48:474-486.
38.
Wang Y, Qian Y, Fang Q, Zhong P, Li W, Wang L, Fu W, Zhang Y, Xu Z, Li X, Liang G:
Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to
TLR4 accessory protein MD2. Nat Commun 2017, 8:13997.
39.
Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R:
Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat
diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
40.
Pendyala S, Walker JM, Holt PR: A high-fat diet is associated with endotoxemia that
originates from the gut. Gastroenterology 2012, 142:1100-1101 e1102.
41.
Erridge C, Attina T, Spickett CM, Webb DJ: A high-fat meal induces low-grade
endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr
2007, 86:1286-1292.
42.
Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, Fouhy F, Clarke SF, O'Toole
PW, Quigley EM, Stanton C, et al: Composition and energy harvesting capacity of the gut
microbiota: relationship to diet, obesity and time in mouse models. Gut 2010, 59:1635-1642.
43.
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL,
Eisenbarth SC, Jurczak MJ, et al: Inflammasome-mediated dysbiosis regulates progression of
NAFLD and obesity. Nature 2012, 482:179-185.
44.
De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L,
Mingarelli E, Facinelli B, Magi G, Palmieri C, et al: Dysbiosis contributes to fibrogenesis in the
course of chronic liver injury in mice. Hepatology 2014, 59:1738-1749.
45.
Sprong RC, Hulstein MF, Van der Meer R: Bactericidal activities of milk lipids.
Antimicrob Agents Chemother 2001, 45:1298-1301.
46.
Pfeiffer N, Desmarchelier C, Blaut M, Daniel H, Haller D, Clavel T: Acetatifactor muris
gen. nov., sp. nov., a novel bacterium isolated from the intestine of an obese mouse. Arch
Microbiol 2012, 194:901-907.
47.
Kubeck R, Bonet-Ripoll C, Hoffmann C, Walker A, Muller VM, Schuppel VL,
Lagkouvardos I, Scholz B, Engel KH, Daniel H, et al: Dietary fat and gut microbiota
interactions determine diet-induced obesity in mice. Mol Metab 2016, 5:1162-1174.
48.
Zeidan YH, Pettus BJ, Elojeimy S, Taha T, Obeid LM, Kawamori T, Norris JS, Hannun
YA: Acid ceramidase but not acid sphingomyelinase is required for tumor necrosis factor{alpha}-induced PGE2 production. J Biol Chem 2006, 281:24695-24703.
49.
Pfeiffer A, Bottcher A, Orso E, Kapinsky M, Nagy P, Bodnar A, Spreitzer I, Liebisch G,
Drobnik W, Gempel K, et al: Lipopolysaccharide and ceramide docking to CD14 provokes
ligand-specific receptor clustering in rafts. Eur J Immunol 2001, 31:3153-3164.
50.
Grosch S, Schiffmann S, Geisslinger G: Chain length-specific properties of ceramides.
Prog Lipid Res 2012, 51:50-62.
154

51.
Bielawska A, Crane HM, Liotta D, Obeid LM, Hannun YA: Selectivity of ceramidemediated biology. Lack of activity of erythro-dihydroceramide. J Biol Chem 1993, 268:2622626232.
52.
Stiban J, Fistere D, Colombini M: Dihydroceramide hinders ceramide channel
formation: Implications on apoptosis. Apoptosis 2006, 11:773-780.
53.
Stiban J, Perera M: Very long chain ceramides interfere with C16-ceramide-induced
channel formation: A plausible mechanism for regulating the initiation of intrinsic apoptosis.
Biochim Biophys Acta 2015, 1848:561-567.
54.
Shabbits JA, Mayer LD: Intracellular delivery of ceramide lipids via liposomes
enhances apoptosis in vitro. Biochim Biophys Acta 2003, 1612:98-106.
55.
Jozefowski S, Czerkies M, Lukasik A, Bielawska A, Bielawski J, Kwiatkowska K, Sobota
A: Ceramide and ceramide 1-phosphate are negative regulators of TNF-alpha production
induced by lipopolysaccharide. J Immunol 2010, 185:6960-6973.
56.
Rozenova KA, Deevska GM, Karakashian AA, Nikolova-Karakashian MN: Studies on
the role of acid sphingomyelinase and ceramide in the regulation of tumor necrosis factor
alpha (TNFalpha)-converting enzyme activity and TNFalpha secretion in macrophages. J
Biol Chem 2010, 285:21103-21113.

155

Chapter 6. Dietary Milk Phospholipids
Improve Dyslipidemia and Hepatic
Steatosis in LDLr-/- Mice Fed a Westerntype Diet
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6.1. Abstract
We have previously shown that chronic feeding of purified milk sphingomyelin (SM), a
phospholipid (PL) component of milk fat globule membranes (MFGM), is protective against
hepatic steatosis and dyslipidemia in high fat diet-fed mice. However, it is unclear whether
ingestion of the total milk PL fraction can have effects similar to purified SM. Therefore, male
LDLr-/- mice were fed ad libitum a high-fat, high-cholesterol diet (CTL; 45% kcal from fat, 0.22%
cholesterol added by weight; n = 15), or the same diet supplemented with 1% milk PL (1%; n =
15) or 2% milk PL (2%; n = 15) added by weight from beta serum for 14 weeks. No differences
were detected in food intake, body weight, or tissue weights between the groups. Total serum
cholesterol, non-HDL cholesterol, and non-esterified fatty acids (NEFAs) were significantly lower
in the 2% group compared to CTL (-51%, -56%, and -26% respectively, p < 0.01). Hepatic total
cholesterol concentrations were reduced by 53% (p < 0.05) and 55% (p < 0.01) compared to CTL
in the 1% and 2% groups, respectively. These coincided with increased expression of hepatic
Hmgcr mRNA, and decreased expression levels of Scd1 and Mip1b in the 2% group. Epididymal
adipose Ccl2 mRNA was reduced in the 2% group. Milk PL demonstrated hypolipidemic effects
by strongly reducing serum and hepatic cholesterol pools in LDLr-/- mice fed a Western-type diet.
Beta serum could be utilized as a value-added source of milk PL to potentially improve
hyperlipidemia-related disease outcomes.

6.2. Introduction
Current available research and results presented within this dissertation thus far have established
dietary sphingomyelin (SM) as a potential mediator of chronic metabolic diseases. However,
current commercially-available purified forms of dietary SM are likely too expensive to be used
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as a daily supplement in humans (~$300-500 per gram). Therefore, we searched for whole foods
or food byproducts, rich in dietary SM, that could be incorporated into diets or used for SM
purification. Table 6.1. illustrates that beta serum is at least 2 times as concentrated in SM when
compared to other common dietary sources. Beta serum is a polar lipid byproduct of anhydrous
milk fat production [1]. Beta serum is particularly rich in milk polar lipids, including SM [2] and
thus may provide a financially-viable dietary source of SM. It should be noted that milk polar
lipids (MPLs) may influence the efficacy of milk-derived SM, as dietary MPLs have been shown
to enhance SM absorption in animal studies [3]. Additionally, other dietary PLs have been shown
to have beneficial effects in cardiometabolic disease [4]. Therefore, assessing MPLs’ effects in
chronic metabolic disease is necessary. Some studies have demonstrated chronic feeding of MPL
fractions reduces serum and hepatic lipids in rodents [5-7]. Dietary MPLs also reduce the
inflammatory response with acute inflammatory challenges in mice [8, 9].
Table 6.4 Dietary SM content by source
Source

Content
(mg/100g)

Ref

Bovine Milk, Whole
Beef
Egg
Cottage Cheese
Chicken Liver
Beta Serum
Beta Serum

9
44-69
82
139
291
420
1015

[10]
[11]
[12]
[13]
[14]
[2]
Manufacturer’s Report

Multiple rodent feeding studies have examined the effects of dietary MPLs on lipid
homeostasis. Feeding a MPL extract at 1.7% to KK-Ay mice improved both serum and hepatic
lipids [7]. Supplementing a high-fat diet (HFD) with MPL (2.5% wt:wt of the diet) lowered serum
cholesterol, hepatic total lipids, hepatic cholesterol, and hepatic triglycerides, while increasing
fecal lipids in mice, suggesting a decrease in lipid absorption [5]. However, not all animal studies
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with MPLs have shown beneficial effects. For instance, a diet supplemented with 10% milk fat
globular membranes (wt:wt, MFGM) increased serum triglycerides in rats compared to an
isocaloric low-fat control diet [15]. Overall, in most animal studies dietary MPLs improved serum
and hepatic lipids, most likely through preventing the absorption of dietary fat and/or luminal
cholesterol.
In this chapter, we will examine MPLs for their efficacy in reducing diet-induced metabolic
dysfunction and inflammation in low-density lipoprotein receptor-deficient (LDLr-/-) mice. When
fed cholesterol-enriched HFD for 12 weeks, total cholesterol of mice reaches over 1000 mg/dL
compared to 200-300 mg/dL on a control chow diet [16]. High-fat, high-cholesterol diets given to
LDLr-/- mice also exacerbate inflammation in adipose tissue [17] and livers [18, 19]. For these
reasons, LDLr-/- mice are particularly useful as a model of NAFLD [16], the hepatic manifestation
of metabolic dysfunction. This mouse model is particularly sensitive to the benefits of inhibiting
cholesterol absorption. Treatment of Western-type diet-fed LDLr-/- mice with ezetimibe reduced
some of the metabolic dysfunction-related consequences of the diet [18]. Therefore, we
hypothesized that feeding LDLr-/- mice a high-fat, high-cholesterol, high-sucrose diet
supplemented with MPLs from beta serum would attenuate the detrimental effects of the Westerntype diet.

6.3. Materials and Methods
6.3.1 Animals and Diets

Male LDLr-/- mice on a C57BL/6J background (4 weeks old) were purchased from Jackson
Laboratory (Bar Harbor, ME, USA) and allowed to acclimate for 2 weeks before being fed one of
three milk fat-based diets over 14 weeks: high-fat control (CTL; 45% kcal from fat, 0.15%
cholesterol added by weight; n=15); CTL adjusted to contain 1% (wt:wt) of PLs (1%; n=15) or
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CTL with 2% PLs added by weight (2%; n=15). Beta serum powder was used as a rich source of
PLs and was obtained from Tatua Dairy Cooperative (Morrinsville, New Zealand). The 1% and
2% PL diets supplied 0.2% and 0.4% milk-derived SM (wt:wt of the diet), respectively. Diets were
adjusted to have similar mineral content, lactose, milk fat, and cholesterol. Skim milk was added
to the CTL and 1% groups to account for milk bioactives outside of the MFGMs. Diet composition
details are provided in Table 6.2. and 6.3. Experimental diets were made using ingredients
obtained from Dyets, Inc. (Bethlehem, PA, USA). Body weight was assessed weekly, while food
intake was estimated biweekly. Mice were provided with fresh food weekly. At 20 weeks old, the
mice were fasted for 6–8 h prior to blood collection by cardiac puncture following euthanasia.
Blood samples were allowed to clot at room temperature for 30 min before serum was isolated by
centrifugation (10,000g for 10 min at 4°C) and then stored at −80°C. Mice were perfused with
sterile saline before tissues were harvested. The liver and epididymal adipose were collected from
animals, snap-frozen in liquid nitrogen, and stored at −80°C. Sections of these tissues were fixed
in 10% phosphate-buffered formalin. All mice were housed in a temperature-controlled room and
maintained in a 12-h light/12-h dark cycle at the University of Connecticut-Storrs vivarium. The
Animal Care and Use Committee of the University of Connecticut-Storrs approved all procedures
used in the current study.

6.3.2. Serum Biochemical Analysis

Total serum cholesterol, triglycerides, glucose, non-esterified fatty acids (NEFAs), and serum
hepatic enzymes (ALT and AST) were measured using enzymatic or spectrophotometric assays
according to manufacturer instructions. High-density lipoprotein cholesterol (HDL-C) was
measured by quantifying serum cholesterol after precipitating apolipoprotein B (ApoB)-containing
lipoproteins with Mg2+/dextran sulfate [20]. Cholesterol, triglycerides, and NEFA kits were
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obtained from Wako Diagnostics (Richmond, VA). The glucose hexokinase kit and hepatic
enzyme kits were obtained from Pointe Scientific, Inc. (Canton, MI). Non-HDL-C was calculated
as the difference between total cholesterol and HDL-C. Insulin and Adiponectin was measured
using commercially available ELISA (Crystal Chem, Elk Grove Village, IL). HOMA-IR was
calculated as in Aim 2.
Table 6.2. Diet composition by component
Diet Component

CTL

1%

2%

(g/kg)
Casein

80

80

80

L-Cystine

3

3

3

Sucrose

200

200

200

Corn Starch

20

17.5

15

21.35

10.68

0

Anhydrous Milkfat

207

181

155

Soybean Oil

20

20

20

Cellulose

50

50

50

Mineral Mix, AIN-93G-MX (94046)

43

43

43

Vitamin Mix, AIN-93-VX (94047)

19

19

19

Choline Bitartrate

3

3

3

TBHQ, antioxidant

0.04

0.04

0.04

Cholesterol

1.5

1.31

1.13

Skim milk powder (403150)

332

166

0

Butter serum

0

205.5

411

Calcium Carbonate

0

0.68

1.36

Potassium Chloride

0

0.19

0.38

Sodium Chloride

0

0.25

0.51

Lactose

6.3.3. Hepatic Lipid Extraction and Analysis

Hepatic lipids were extracted from liver samples and analyzed as in Chapters 3 and 4.
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Table 6.3. Diet composition by macronutrient
Diet Component

CTL

1%

2%

Total Protein (g/kg)

200.2

200.3

200.4

Total Carbohydrate (g/kg)

414.0

411.5

409.0

Total Fat (g/kg)

229.7

231.3

233.0

Total Lactose (g/kg)

194.0

194.0

194.0

Total Cholesterol (g/kg)

2.06

2.06

2.06

Total Phospholipid (g/kg)

0.5

10.3

20.0

% kcal from Protein

17.7

17.7

17.7

% kcal from Carbohydrate

36.6

36.3

36.1

% kcal from Fat

45.7

46.0

46.2

Calorie Density (kcal/g)

4.52

4.52

4.52

6.3.4. Tissue Histology

Paraffin-embedded formalin-fixed liver and epididymal adipose tissues were cut into 5 μm sections
before staining with hematoxylin and eosin (H&E) by the Connecticut Veterinary Medical
Diagnostic Laboratory (Storrs, CT). Each stained section was viewed under bright field
microscopy at ×200 magnification and images were taken with an AxioCam ICc3 camera (Zeiss,
Thornwood, NY, USA).
3.3.5. RNA Isolation, cDNA Synthesis and qRT-PCR

Total RNA was isolated from liver and epididymal adipose tissue and used for cDNA synthesis as
in previous chapters. Gene expression was normalized to the geometric mean of the reference
genes, glyceraldehyde 3-phosphate dehydrogenase, β-actin and ribosomal protein, large, P0 using
the 2−ΔΔCt method [21]. Primer sequences used for qRT-PCR analysis are listed in Appendix A.
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3.3.6. Statistical Analysis

Differences between groups were evaluated by one-way ANOVA with post hoc comparisons
(Holm-Sidak) or the Kruskal-Wallis nonparametric test for non-normally distributed data (P <
0.05 deemed significant). D’Agostino-Pearson omnibus normality test was used to assess
normality for each data set. All statistical analyses were conducted using GraphPad Prism version
6 software. Data are reported as mean ± SEM.

6.4. Results
6.4.1. Dietary Phospholipids Do Not Alter Body Weight and Food Intake

There were no differences between the groups in body weight, tissue weight, or tissue weight as a
percentage of body weight (Table 6.4.). Expectedly, there were no significant differences in
estimated daily food intake.
Table 6.4. Body and tissue weights after 14 weeks of diets
CTL
1%
Body Weight (g)
34.25 ± 1.49
35.27 ± 1.34
Food Intake (g/day)
3.40 ± 0.12
3.69 ± 0.13
Liver (g)
1.44 ± 0.11
1.48 ± 0.10
% Liver Weight
4.17 ± 0.16
4.16 ± 0.14
Epididymal Adipose (g)
1.29 ± 0.18
1.61 ± 0.22
% Epididymal Adipose

3.79 ± 0.53

4.34 ± 0.48

2%
33.19 ± 0.91
3.73 ± 0.23
1.29 ± 0.04
3.88 ± 0.06
1.23 ± 0.19
3.55 ± 0.50

Values are presented as mean ± SEM (n = 15)

6.4.2. MPL Treatment Attenuated Hypercholesterolemia and Reduced Circulating NEFAs

The 2% had a 50% reduction in total serum cholesterol compared to the CTL group (Table 6.5).
Additionally, HDL-C remained unchanged between the groups. After calculating non-HDL-C, it
was found that estimated non-HDL-C was reduced by 53% in the 2% treatment. Circulating
NEFAs were 25% lower in the 2% group compared to the control. Fasting triglycerides and glucose
were unchanged by either treatment. Additionally, serum hepatic enzymes ALT and AST were not
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significantly different between the groups. Lastly, insulin, HOMA-IR, resistin, and adiponectin
were similar between all three groups (Table 6.5).
Table 6.5. Serum values of LDLr-/- after 14 weeks of diets
CTL

Total Cholesterol (mg/dL)
non-HDL-C (mg/dL)
HDL-C (mg/dL)
Triglycerides (mg/dL)
ALT (U/L)
AST (U/L)
NEFA (mmol/L)
Glucose (mg/dL)
Insulin (ng/mL)
HOMA-IR
Adiponectin (μg/mL)
Resistin (ng/mL)

1%
a

1001 ± 149
928 ± 158a
81 ± 5
404 ± 83
64 ± 6
137 ± 18
0.83 ± 0.06a
177 ± 15
0.11 ± 0.01
1.31 ± 0.20
6.18 ± 0.22
45.1 ± 2.0

2%
ab

877 ± 123
840 ± 134ab
83 ± 5
433 ± 78
92 ± 20
140 ± 15
0.83 ± 0.05a
178 ± 10
0.13 ± 0.01
1.50 ± 0.24
6.72 ± 0.26
42.6 ± 2.2

491 ± 69b
433 ± 74b
84 ± 5
268 ± 41
59 ± 8
104 ± 7
0.62 ± 0.04b
195 ± 12
0.10 ± 0.01
1.24 ± 0.13
6.38 ± 1.28
48.4 ± 2.8

Values are presented as mean ± SEM (n = 15), different superscripts indicate statistical significance (p = 0.05)

6.4.3. Hepatic Cholesterol Accumulation and Inflammation were reduced by MPLs

Compared to the CTL, the 2% group demonstrated reduced hepatic total cholesterol and
cholesteryl esters by 56% and 74%, respectively. The 1% treatment reduced total cholesterol (50%) and free cholesterol (-23%) compared to the CTL group. Hepatic triglycerides were
unchanged between the groups (Figure 6.1B). Histologically, the CTL H&E-stained liver sections
appeared to have more lipid droplets compared to the 2%, although the steatosis appeared to be
mild (Figure 6.1A).
Notably, the observed changes in hepatic cholesterol were corroborated in the 2% group by an
increase in Hmgcr mRNA (+46%) compared to the control (Figure 6.1C). Although the hepatic
triglycerides were not reduced in the treatment groups, Scd1 mRNA was significantly lower in the
2% group compared to CTL (-51%). Macrophage inflammatory protein 1β (Mip1b) was
significantly lower (-77%) in the 2% treatment compared to the control. Chemokine (C-C) motif
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A

Figure 6.1. Dietary milk phospholipids reduced hepatic cholesterol accumulation and inflammation. Liver sections were formalinfixed before sectioned and H&E stained (A) (CTL, Control; 1%, 1% (wt:wt) MPL; 2%, 2% (wt:wt) MPL) for visualizing hepatic steatosis. Liver
lipids were extracted using a modified Folch extraction and measured by enzymatic methods (B), (triglycerides, TG; total cholesterol, TC;
cholesteryl ester, CE; free cholesterol, FC; choline-containing phospholipids, PL) (n = 15 per group, mean + SEM). Hepatic mRNA
expression was determined using real-time qRT-PCR and standardized to the geometric mean of Gapdh and β-actin reference genes using
(-ΔΔCt)

the 2
method (D) (n = 13-14 per group, mean + SEM). Mean values with unlike letters indicate differences at P < 0.05 using post hoc
comparisons.
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ligand 2 (Ccl2) mRNA data was analyzed using the Kruskal-Wallis nonparametric test because the
data was not normally distributed. While the mean expression of Ccl2 was lower in the 2%
treatment group by 82%, the data failed to reach significance (p = 0.1). The macrophage marker
Adgre1 (encoding F4/80 protein) remained unchanged between the groups. Genes related to
lipogenesis (Cd36, Dgat2, Nr1h3, Srebf2, Srebf1, and Pparg), lipolysis (Acad1 and Acox), and
Pepck remained unchanged by the dietary intervention.
6.4.4. Consuming MPLs Reduces Ccl2 mRNA Expression in the Epididymal Adipose

The epididymal adipose mRNA expression was assessed for potential changes in metabolism and
inflammation. The expression of Ccl2 was attenuated in the 2% treatment by 56% compared to
the CTL group (Figure 6.2B). In addition to this, Il6 mRNA expression appeared to be lower in
both treatment groups; however, this failed to reach significance (p > 0.1). The mRNA of Slc2a4
was non-significantly greater in the 2% (p > 0.1) compared to CTL. Target genes of PPARγ
(aP2, AdipoQ, Lpl) were trending to be reduced in the 1% group compared to the CTL group.
The histology between the groups revealed no major differences in H&E staining of adipose
tissue (Figure 6.2A).

6.5. Discussion
High-fat, high-cholesterol diets fed to LDLr-/- will induce hypercholesterolemia and hepatic lipid
accumulation [16, 22]. Non-alcoholic steatohepatitis (NASH) will develop if LDLr-/- mice are
exposed to these diets for >16 weeks [16]. Dietary PLs [23] and sphingolipids have been shown
to inhibit lipid absorption and thus may slow the progression of NASH induced by a lipid-rich diet.
Beta serum is a dairy byproduct, rich in both PLs and sphingolipids. In this chapter, we
demonstrated the hypolipidemic effect of dietary MPLs serum in genetically hypercholesterolemic
LDLr-/- mice. The higher dose of MPLs (2%) reduced serum and hepatic cholesterol levels as well
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Figure 6.2. MPLs mildly reduces adipose inflammation. Epididymal adipose tissue sections were formalin-fixed, sectioned and H&E
stained (A). Epididymal adipose tissue mRNA expression was determined using real-time qRT-PCR and standardized to the geometric
(-ΔΔCt)
mean of Gapdh, 36B4, and β-actin reference genes using the 2
method (B) (n = 13-14 per group, mean + SEM). Mean values with
unlike letters indicate differences at P < 0.05 using post hoc comparisons.
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as reduced markers of hepatic and adipose tissue inflammation compared to controls.
Unsurprisingly, the lower dose treatment (i.e. 1% (wt:wt) MPL) was less effective, as it only
reduced hepatic cholesterol concentration. These effects may be suggestive of inhibitory effects
on cholesterol absorption because reducing cholesterol absorption has been shown to improve
dyslipidemia, hepatic steatosis, and adipose inflammation in animal studies similar to a study
examining the effects of ezetimibe on this model [17].
In this study we used increasing doses of beta serum to supply 1% and 2% (wt:wt) MPLs.
This is equivalent to 6 and 12 g of dietary PL/day in a 70-kg adult human. This will contribute
0.21-0.42% milk-derived SM, or 1.2-2.4 g/day in an adult. The typical western diet consists of 610 g/day of PLs and 0.3-0.4 g/day of sphingolipids [24]. The higher dose of MPLs reduced serum
total cholesterol and non-HDL-C. Due to the fact that hepatic cholesterol was also reduced and the
adipose phenotype was largely unchanged between the CTL and 2% group, it seems likely that
some of this effect could be attributed to the inhibition of cholesterol absorption attributed to both
PLs and sphingolipids [4]. It is interesting to compare these dosages of SM to the previous studies
on dietary SM. The 1% PL diet supplied ~0.21% (wt:wt of the diet) SM to the animals, a dose
previously shown to be effective in reducing hyperlipidemia and steatosis [25, 26]. Yet, the 1%
PL diet did not have a strong effect on serum lipids and only reduced hepatic cholesterol levels.
This could be due to differences in diets and/or rodent models, however it is interesting to note
that dietary PLs have been shown to increase the appearance of SM-derived ceramide in the lymph
[27]. Therefore, additional PLs found in the beta serum may increase the absorption of SM and
decrease its efficacy by removing it from the lumen. High doses of dietary PLs have also been
shown to inhibit cholesterol absorption [28-30]. The higher dose of beta serum could be providing
enough PLs to inhibit lipid absorption. Alternatively, the additional SM (~0.42% wt:wt) could be
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compensating for the increase in SM absorption. These results highlight the necessity to account
for the food matrix when interpreting data concerning dietary SM. The effects of a complex PL
mixture like this has yet to be tested directly in models of cholesterol or fatty acid absorption.
Therefore, directly comparing the efficacy of beta serum to its individual components could be an
effective means to understand the mechanism.
There have been several studies reporting beneficial effects on lipid homeostasis similar to
this study. After 5 weeks on a HFD supplemented with MPLs (2.5% wt:wt of the diet), mice in the
treatment group had reduced serum cholesterol, hepatic total lipids, hepatic cholesterol, and
hepatic triglycerides, while increasing fecal lipids in mice compared to HFD control [5]. KK-Ay
mice supplemented with MPL also improved both serum and hepatic lipids [7]. Similarly, 8 weeks
on a HFD, hepatic lipids and serum cholesterol as well as triglycerides were improved by
supplementation of 2.5% milk polar lipids [6]. Mice supplemented with MFGM on a HFD have
an improved lipid profile [31]. In the context of these studies, this aim further demonstrates the
ability of dietary MPL to reduce diet-induced dyslipidemia and hepatic lipid accumulation.
Some clinical trials have examined the effects of MPL supplements on lipid homeostasis.
Overweight adults in a single-blind, randomized, controlled, isocaloric parallel study for 8 weeks,
treated with 40 g of milkfat/day as whipping cream significantly reduced plasma LDL-C and
apoB:apoA-I ratio compared to a milk fat control [32]. Whipping cream is particularly rich in PLs.
Two clinical trials feeding buttermilk found slightly different effects. First, Ohlsson et al. observed
that a 4-week supplementation of a buttermilk drink enriched in MFGM, in a placebo-controlled
parallel study with healthy adults had no effect on the plasma lipids. However, a non-significant
reduction in plasma LDL-C (p = 0.056) in women was observed [33]. This study was likely
underpowered with a small sample size and a parallel design. However, 4-week supplementation
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with 45 g/day of buttermilk significantly reduced both plasma cholesterol and TG in healthy adults
[34]. This study was a double-blind, randomized, crossover study and indirectly measured
cholesterol absorption through serum β-sitosterol concentration. The β-sitosterol concentration
values were correlated with the reductions in plasma LDL-C. suggesting a reduction in cholesterol
absorption may have contributed to the reduction in LDL-C [34]. This study was much more robust
with 38 participants, and the crossover design improved statistical power. In aggregate, there is
some clinical data that suggests the hypolipidemic effects found in animal studies described above
is translatable to humans.
Hepatic mRNA analysis revealed a relative increase in Hmgcr mRNA expression in the
2% treatment group compared to the CTL. This is likely reflective of a compensatory mechanism
in the liver. A high-cholesterol diet has been shown to decrease hepatic mRNA expression of
Hmgcr in mice [35]. If MPLs are reducing cholesterol absorption, the dietary cholesterol is likely
not suppressing Hmgcr mRNA to the same degree as in the control diet. Similarly, Scd1 mRNA
expression was reduced in the 2% group compared to CTL. High-fat diets can induce hepatic Scd1
mRNA in mice [36]. Therefore, reducing lipid absorption will cause the HFD to induce Scd1 less
strongly. These findings are comparable to the results of Aims 1 and 2, where SM treatment
reduced Scd1 and increased Hmgcr mRNA levels in liver. Additionally, Mip1b expression was
significantly reduced by the 2% group compared to the CTL group, while Ccl2 was trending
towards significance, suggesting a decrease in hepatic inflammation. However, both Mip1b and
Ccl2 mRNA expression levels were variable in the CTL, suggesting the duration of the diet may
have been too short to induce hepatitis, or that the diet did not have enough lipids. Most studies of
high-fat, high-cholesterol steatohepatitis are >16 weeks and have used higher fat content diets [3739]. Additionally, some studies of LDLr-/- mice reveal an increase locomotor activity [40].
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LDLr-/- mice fed a HFD had increased thermogenesis, and decreased food intake [41]. This could
hinder their response to a HFD compared to wild-type controls [41, 42]. Therefore, although LDLr/-

mice are a useful model of liver disease they are more resistant to early diet-induced metabolic

dysfunction and inflammation.
Analysis of the epididymal adipose mRNA for metabolic and inflammatory changes
showed a reduction in Ccl2 mRNA. This suggests the adipose in this treatment group is somewhat
less inflamed than in the CTL, which is corroborated by the significantly lower circulating NEFAs.
Recently, it was shown that feeding increasing doses of MFGM reduces adipose weight as well as
the expression of lipogenic genes and proteins in adipose tissue [31] returning the high fat-fed
mice’s phenotype similar to the low-fat control. Whether inhibiting cholesterol absorption could
be solely responsible for a decrease in adipose tissue inflammation in this model remains uncertain.
Ezetimibe has been shown to lower both total cholesterol and hepatic cholesterol [17]. Adding
excessive cholesterol to the diet has been shown to induce adipose tissue inflammation in LDLr-/mice [17]. However, treatment of LDLr-/- mice with ezetimibe has shown only marginal effects on
adipose tissue inflammation [43]. Therefore, an independent effect of dietary MPL may be
responsible for the reduction in adipose inflammation.
The potential anti-inflammatory effects of MPL cannot be ignored. Multiple recent studies
have tested MPL fractions for anti-inflammatory effects. When examining acute inflammation in
mice, 5 weeks of dietary MPL reduced the cytokine response within 24 hours to LPS
intraperitoneal injection, while increasing survival rates at 48 hours [8]. Following 8 weeks of a
HFD, mice fed MPL had decreased expression of adipose inflammatory markers (e.g., cluster of
differentiation 68) compared to HFD control. This was in contrast to a group of mice fed soy PL,
whom had increased responses of inflammatory markers [9]. In humans, adding MFGM to palm
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oil-based drinks ingested by overweight and obese men reduced soluble intracellular adhesion
molecule, while increasing IL-10 in the post-prandial state [44]. This suggests an improvement in
post-prandial inflammation, which is usually observed in obese populations and has been
considered a predictor of metabolic disease [45]. Ultimately, there is some evidence for the antiinflammatory effects of MFGM or MPL-fractions, which would be beneficial to improve
metabolic outcomes.
The higher dose was effective in attenuating the hypercholesterolemia and hepatic
cholesterol accumulation associated with our model. Additionally, there were modest reductions
in hepatic and adipose tissue inflammation, which may have been limited by the length of the
study. Regardless, MPLs have potential to function as a preventative treatment for metabolic
dysfunction. Therefore, more research is warranted to further understand all the potential
mechanisms and the translatability to humans.

6.6. Acknowledgments
This work was supported by a research grant to C. Blesso from the National Dairy Council (Dairy
Management Inc.).

172

6.7. References
1.
Vanderghem C, Bodson P, Danthine S, Paquot M, Deroanne C, Blecker C: Milk fat globule
membrane and buttermilks: from composition to valorization. Biotechnologie 2010, 14:485-500.
2.
Contarini G, Povolo M: Phospholipids in Milk Fat: Composition, Biological and Technological
Significance, and Analytical Strategies. International Journal of Molecular Sciences 2013, 14:28082831.
3.
Lecomte M, Bourlieu C, Meugnier E, Penhoat A, Cheillan D, Pineau G, Loizon E, Trauchessec M,
Claude M, Menard O, et al: Milk Polar Lipids Affect In Vitro Digestive Lipolysis and Postprandial
Lipid Metabolism in Mice. J Nutr 2015, 145:1770-1777.
4.
Blesso CN: Egg phospholipids and cardiovascular health. Nutrients 2015, 7:2731-2747.
5.
Kamili A, Wat E, Chung RW, Tandy S, Weir JM, Meikle PJ, Cohn JS: Hepatic accumulation of
intestinal cholesterol is decreased and fecal cholesterol excretion is increased in mice fed a high-fat
diet supplemented with milk phospholipids. Nutrition & Metabolism 2010, 7:90.
6.
Wat E, Tandy S, Kapera E, Kamili A, Chung RW, Brown A, Rowney M, Cohn JS: Dietary
phospholipid-rich dairy milk extract reduces hepatomegaly, hepatic steatosis and hyperlipidemia in
mice fed a high-fat diet. Atherosclerosis 2009, 205:144-150.
7.
Watanabe S, Takahashi T, Tanaka L, Haruta Y, Shiota M, Hosokawa M, Miyashita K: The effect
of milk polar lipids separated from butter serum on the lipid levels in the liver and the plasma of
obese-model mouse (KK-Ay). Journal of Functional Foods 2011, 3:313-320.
8.
Snow DR, Ward RE, Olsen A, Jimenez-Flores R, Hintze KJ: Membrane-rich milk fat diet
provides protection against gastrointestinal leakiness in mice treated with lipopolysaccharide. J Dairy
Sci 2011, 94:2201-2212.
9.
Lecomte M, Couëdelo L, Meugnier E, Plaisancié P, Létisse M, Benoit B, Gabert L, Penhoat A,
Durand A, Pineau G, et al: Dietary emulsifiers from milk and soybean differently impact adiposity and
inflammation in association with modulation of colonic goblet cells in high-fat fed mice. Molecular
Nutrition & Food Research 2016, 60:609-620.
10.
Morrison WR: The distribution of phospholipids in some mammalian milks. Lipids 1968,
3:101-103.
11.
Nakanishi T, Suyama K: Studies on phospholipids of meat
VIII. Reaction of carbonyl compounds with phospholipids (Part 1) Formation of &alpha;, &beta;unsaturated aldehydes by heat treatment of a mixture of saturated aldehyde and phospholipids.
Nihon Chikusan Gakkaiho 1969, 40:320-326.
12.
Christie WW, Moore JH: The lipid composition and triglyceride structure of eggs from several
avian species. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry 1972,
41:297-306.
13.
Weihrauch JL, Son YS: Phospholipid content of foods. Journal of the American Oil Chemists'
Society 1983, 60:1971-1978.
14.
Marion JE, Miller WO: Phospholipids and Component Fatty Acids of Chicken Tissuesa.
Poultry Science 1968, 47:1453-1459.
15.
Zhou AL, Hintze KJ, Jimenez-Flores R, Ward RE: Dietary Fat Composition Influences Tissue
Lipid Profile and Gene Expression in Fischer-344 Rats. Lipids 2012, 47:1119-1130.
16.
Bieghs V, Van Gorp PJ, Wouters K, Hendrikx T, Gijbels MJ, van Bilsen M, Bakker J, Binder CJ,
Lütjohann D, Staels B, et al: LDL Receptor Knock-Out Mice Are a Physiological Model Particularly
Vulnerable to Study the Onset of Inflammation in Non-Alcoholic Fatty Liver Disease. PLOS ONE
2012, 7:e30668.
17.
Subramanian S, Han CY, Chiba T, McMillen TS, Wang SA, Haw A, Kirk EA, O’Brien KD, Chait
A: Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese
LDL receptor-deficient mice. Arteriosclerosis, thrombosis, and vascular biology 2008, 28:685-691.

173

18.
Umemoto T, Subramanian S, Ding Y, Goodspeed L, Wang S, Han CY, Teresa AS, Kim J, O'Brien
KD, Chait A: Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose
tissue inflammation. Journal of Lipid Research 2012, 53:2380-2389.
19.
Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lutjohann D, Kerksiek A, van Kruchten
R, Maeda N, Staels B, et al: Dietary cholesterol, rather than liver steatosis, leads to hepatic
inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008,
48:474-486.
20.
Warnick GR, Benderson J, Albers JJ: Dextran sulfate-Mg2+ precipitation procedure for
quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982, 28:1379-1388.
21.
Rao X, Huang X, Zhou Z, Lin X: An improvement of the 2ˆ(–delta delta CT) method for
quantitative real-time polymerase chain reaction data analysis. Biostatistics, bioinformatics and
biomathematics 2013, 3:71-85.
22.
Wu L, Vikramadithyan R, Yu S, Pau C, Hu Y, Goldberg IJ, Dansky HM: Addition of dietary fat
to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and
atherosclerosis. Journal of Lipid Research 2006, 47:2215-2222.
23.
Cohn JS, Kamili A, Wat E, Chung RWS, Tandy S: Dietary Phospholipids and Intestinal
Cholesterol Absorption. Nutrients 2010, 2:116-127.
24.
Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH, Jr.:
Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 1999,
129:1239-1250.
25.
Chung RW, Kamili A, Tandy S, Weir JM, Gaire R, Wong G, Meikle PJ, Cohn JS, Rye KA: Dietary
sphingomyelin lowers hepatic lipid levels and inhibits intestinal cholesterol absorption in high-fatfed mice. PLoS One 2013, 8:e55949.
26.
Duivenvoorden I, Voshol PJ, Rensen PC, van Duyvenvoorde W, Romijn JA, Emeis JJ, Havekes
LM, Nieuwenhuizen WF: Dietary sphingolipids lower plasma cholesterol and triacylglycerol and
prevent liver steatosis in APOE*3Leiden mice. Am J Clin Nutr 2006, 84:312-321.
27.
Morifuji M, Higashi S, Oba C, Ichikawa S, Kawahata K, Yamaji T, Itoh H, Manabe Y, Sugawara
T: Milk Phospholipids Enhance Lymphatic Absorption of Dietary Sphingomyelin in LymphCannulated Rats. Lipids 2015, 50:987-996.
28.
Eckhardt ER, Wang DQ, Donovan JM, Carey MC: Dietary sphingomyelin suppresses intestinal
cholesterol absorption by decreasing thermodynamic activity of cholesterol monomers.
Gastroenterology 2002, 122:948-956.
29.
Hollander D, Morgan D: Effect of plant sterols, fatty acids and lecithin on cholesterol
absorption in vivo in the rat. Lipids 1980, 15:395-400.
30.
Jiang Y, Noh SK, Koo SI: Egg phosphatidylcholine decreases the lymphatic absorption of
cholesterol in rats. J Nutr 2001, 131:2358-2363.
31.
Li T, Gao J, Du M, Song J, Mao X: Milk Fat Globule Membrane Attenuates High-Fat DietInduced Obesity by Inhibiting Adipogenesis and Increasing Uncoupling Protein 1 Expression in
White Adipose Tissue of Mice. Nutrients 2018, 10:331.
32.
Rosqvist F, Smedman A, Lindmark-Mansson H, Paulsson M, Petrus P, Straniero S, Rudling M,
Dahlman I, Riserus U: Potential role of milk fat globule membrane in modulating plasma lipoproteins,
gene expression, and cholesterol metabolism in humans: a randomized study. Am J Clin Nutr 2015,
102:20-30.
33.
Ohlsson L, Burling H, Nilsson A: Long term effects on human plasma lipoproteins of a
formulation enriched in butter milk polar lipid. Lipids Health Dis 2009, 8:44.
34.
Conway V, Couture P, Richard C, Gauthier SF, Pouliot Y, Lamarche B: Impact of buttermilk
consumption on plasma lipids and surrogate markers of cholesterol homeostasis in men and women.
Nutr Metab Cardiovasc Dis 2013, 23:1255-1262.
35.
Hwang S, Hartman IZ, Calhoun LN, Garland K, Young GA, Mitsche MA, McDonald J, Xu F,
Engelking L, DeBose-Boyd RA: Contribution of Accelerated Degradation to Feedback Regulation of

174

3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver. The
Journal of Biological Chemistry 2016, 291:13479-13494.
36.
Hu CC, Qing K, Chen Y: Diet-induced changes in stearoyl-CoA desaturase 1 expression in
obesity-prone and -resistant mice. Obes Res 2004, 12:1264-1270.
37.
Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM,
Quinn LS, Ioannou GN: Synergistic interaction of dietary cholesterol and dietary fat in inducing
experimental steatohepatitis. Hepatology 2013, 57:81-92.
38.
Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM: Model of
nonalcoholic steatohepatitis. Am J Clin Nutr 2004, 79:502-509.
39.
Takahashi Y, Soejima Y, Fukusato T: Animal models of nonalcoholic fatty liver
disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology : WJG 2012, 18:2300-2308.
40.
Elder GA, Ragnauth A, Dorr N, Franciosi S, Schmeidler J, Haroutunian V, Buxbaum JD:
Increased locomotor activity in mice lacking the low-density lipoprotein receptor. Behavioural brain
research 2008, 191:256-265.
41.
Ngai YF, Quong WL, Glier MB, Glavas MM, Babich SL, Innis SM, Kieffer TJ, Gibson WT: Ldlr/- mice display decreased susceptibility to Western-type diet-induced obesity due to increased
thermogenesis. Endocrinology 2010, 151:5226-5236.
42.
Karagiannides I, Abdou R, Tzortzopoulou A, Voshol PJ, Kypreos KE: Apolipoprotein E
predisposes to obesity and related metabolic dysfunctions in mice. Febs j 2008, 275:4796-4809.
43.
Umemoto T, Subramanian S, Ding Y, Goodspeed L, Wang S, Han CY, Teresa AS, Kim J, O'Brien
KD, Chait A: Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose
tissue inflammation. J Lipid Res 2012, 53:2380-2389.
44.
Demmer E, Van Loan MD, Rivera N, Rogers TS, Gertz ER, German JB, Smilowitz JT, Zivkovic
AM: Addition of a dairy fraction rich in milk fat globule membrane to a high-saturated fat meal
reduces the postprandial insulinaemic and inflammatory response in overweight and obese adults. J
Nutr Sci 2016, 5:e14.
45.
Klop B, Proctor SD, Mamo JC, Botham KM, Castro Cabezas M: Understanding postprandial
inflammation and its relationship to lifestyle behaviour and metabolic diseases. Int J Vasc Med 2012,
2012:947417.

175

Chapter 7. Summary, Conclusions, and
Future Directions
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7.1. Summary and Conclusions
The focus of this dissertation was to further define the effects of dietary SM on diet-induced
metabolic dysfunction and inflammation. Our central hypothesis was that dietary SM would reduce
dyslipidemia, metabolic dysfunction, and inflammation in mice fed Western-type diets. In Aim 1,
we sought to determine the potential differences in the effects of dietary milk-derived and eggderived SM on serum and hepatic lipid concentrations. As expected, milk-derived SM improved
both hepatic lipid accumulation and serum cholesterol. Surprisingly, egg-derived SM increased
both hepatic lipid accumulation and serum lipids. These findings led to Aim 2, where we
investigated both egg- and milk-derived SM effects on preventing metabolic dysfunction in an
obesogenic diet. In contrast to Aim 1, egg-derived SM reduced hypercholesterolemia and
hyperglycemia. In this aim, both SM treatments reduced hepatic steatosis and adipose
inflammation, although egg-derived SM was more effective than milk-derived SM. While the first
two aims highlight differences in egg-derived and milk-derived SM in the context of SM and its
hypolipidemic effects, for Aim 3 we targeted the anti-inflammatory effects of SM. In Aim 3, we
found that feeding milk-derived SM reduced systemic cytokines and LPS in mice fed an
obesogenic diet. Most in vitro studies have demonstrated anti-inflammatory effects of exogenous
sphingolipids; however, the mechanism is poorly understood. Therefore, we used LPS-stimulation
in RAW264.7 macrophages to examine the anti-inflammatory effects of SM, ceramide, and
sphingosine. We observed all three compounds to be effective, and that SM hydrolysis was
required for SM effectiveness. Purified SM was used in Aims 1-3, however, consumption of
dietary SM found in foods will be accompanied by other dietary phospholipids. Therefore, we also
tested MPL supplied by beta-serum, a dairy byproduct that is rich in phospholipids, including SM,
on diet-induced metabolic dysfunction and inflammation in genetically hypercholesterolemic
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mice. We found that the highest dose of MPL (2% of diet by weight) reduced
hypercholesterolemia, adipose tissue inflammation, hepatic cholesterol and inflammation. A
detailed review of the findings from each of the 4 specific aims follows and is described in Figure
7.1..
Aim 1: To evaluate differential effects of dietary egg-derived SM and milk-derived SM on
dyslipidemia and metabolic dysfunction in mice fed a short-term high-fat diet.
Hypothesis 1: We hypothesized that both SM supplements would improve Western-type dietinduced metabolic dysfunction and endotoxemia, but milk-derived SM would be more potent
compared to egg-derived SM. This difference would be due to milk-derived SM’s more potent
inhibitory effect on lipid absorption compared to egg-derived SM.
Findings of Aim 1: There were clear and distinct effects of milk and egg SM. Milk-derived SM
reduced weight gain and serum cholesterol compared to CTL. Conversely, egg-derived SM
treatment increased serum concentrations of cholesterol, triglycerides, phospholipids, and SM
compared to CTL. Milk-derived SM significantly decreased, while egg-derived SM increased,
hepatic triglycerides. Milk-derived SM-fed mice displayed gene expression changes consistent
with cholesterol depletion in the intestine and liver. In terms of inflammation, serum LPS was
reduced in the milk-derived SM compared to CTL. Differences in serum LPS may have been
related to changes in gut microbiota. The fecal Gram-negative bacteria were significantly lower,
and fecal Bifidobacterium were higher, in the milk-derived SM group. There was no effect of
dietary SM on fasting gut permeability. Thus, milk-derived SM has potential to reduce the early
stages of diet-induced metabolic dysfunction.
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Aim 2: To determine the effects of dietary egg-derived SM and milk-derived SM on the
development of high-fat diet-induced NAFLD, inflammation, and metabolic dysfunction.
Hypothesis 2: Both SM treatment groups would reduce the metabolic dysfunction phenotype due
to SM’s effects on both lipid absorption and inflammation compared to high-fat control. However,
milk-derived SM would be more effective than egg-derived SM because of the stronger inhibitory
effect on lipid absorption.
Findings of Aim 2: After 10 weeks, egg-derived SM ameliorated weight gain,
hypercholesterolemia, and hyperglycemia induced by HFD. Both egg- and milk-derived SM
attenuated hepatic steatosis development, with significantly lower hepatic TG and cholesterol
relative to the HFD control. This reduction in hepatic steatosis was stronger with egg-derived SM
supplementation relative to milk-derived SM. Reductions in hepatic TG observed with dietary SM
were corroborated by lower hepatic mRNA expression of PPARγ-related genes; Scd1 and Pparg2
in both SM groups, and Cd36 and Fabp4 with egg SM. Egg-derived SM, and to a lesser extent
milk-derived SM, reduced inflammation and markers of macrophage infiltration in adipose tissue.
Egg-derived SM also reduced skeletal muscle TG content compared to HFD control. Aim 2
highlights dietary SM’s ability to inhibit diet-induced metabolic dysfunction associated with
obesity.
Aim 3: To evaluate the effects of dietary SM on HFD-induced inflammation and determine if SM
and its metabolites directly affect macrophage inflammation.
Hypothesis 3: We hypothesized that dietary SM would inhibit diet-induced inflammation and
exogenous SM treatment would inhibit LPS-stimulation of RAW264.7 macrophages. Due to the
fact that SM metabolites inhibitory properties, we anticipated that blocking hydrolysis of SM
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would reduce SM’s effectiveness for inhibiting LPS-stimulation. Consequently, the addition of the
hydrolytic products of SM would also inhibit LPS-stimulation. Furthermore, dihydroceramide and
ceramide would have differential effects on macrophage inflammatory response, as they have
previously shown different bioactivities in other contexts.
Findings of Aim 3: Dietary milk-derived SM significantly reduced inflammatory serum cytokines
and tended to lower serum LPS (p = 0.08) compared to HFD. Cecal gut microbiota analysis
revealed that milk-derived SM increased the abundance of Acetatifactor genus, with minimal
changes in other taxa. Milk SM significantly attenuated the in vitro effect of LPS on proinflammatory gene expression in RAW264.7 macrophages. This effect was dependent on SM
hydrolysis, as blocking sphingomyelinase activity caused SM to be ineffective. Additionally, the
metabolites ceramide and sphingosine inhibited the pro-inflammatory changes. Overall, this aim
revealed there are possibly direct anti-inflammatory effects of dietary SM. Additionally, these antiinflammatory effects may be independent of the effects of lipid absorption and are likely dependent
on SM hydrolysis.
Aim 4: To evaluate the effects of dietary milk phospholipids, rich in SM, on the development of
metabolic dysfunction in LDLr-/- mice fed a high-fat, high-cholesterol diet.
Hypothesis 4: Phospholipid supplementation would reduce dyslipidemia and insulin resistance in
Western-type diet-fed LDLr-/- mice. This would result in an improved hepatic phenotype and
decreased adipose inflammation.
Findings of Aim 4: Supplementation of milk phospholipids (2% PL) reduced total serum
cholesterol, non-HDL cholesterol, and NEFAs compared to CTL (-51%, -56%, and -26%
respectively). Hepatic total cholesterol concentrations were reduced compared to CTL by 53% and
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55% in the 1% and 2% groups, respectively. These changes came with an increased hepatic Hmgcr
mRNA, decreased Scd1 and Mip1b in the 2% group. Histology analysis corroborated these
findings although the steatosis was mild. Ccl2 mRNA in the epididymal adipose tissue was reduced
in the 2% group. This aim provides further evidence for MPL to prevent diet-induced dyslipidemia
and hepatic steatosis. Therefore, MPL extracts could be a useful source of dietary bioactives to
potentially combat metabolic complications of obesity.

Figure 7.1. Schematic of dietary sphingomyelin’s effects on metabolic dysfunction. Bolded effects represent
findings from this work. Lined effects are well-established within the literature. Italicized effects are future directions
based off of findings in this work. Solid lines represent known connections between effects, while dashed lined are
potential connections.

7.2. Future Directions
7.2.1. Understanding the Impact of Food Matrix on Dietary SM

Although this dissertation has contributed to the literature that supports a role for dietary SM to
limit lipid absorption and influence lipid metabolism, we still do not completely understand the
mechanism. Sphingomyelin’s effect on inhibiting lipid absorption has been attributed partly to an
inhibition of pancreatic lipase activity [1, 2]. Despite pancreatic lipase having a sphingolipid181

sensing domain, SM seemingly does not bind to a synthetic mimic of pancreatic lipase [3], and
therefore, it is not likely to be a direct inhibition. Alternatively, SM inhibition of pancreatic lipase
may be due in part to the displacement of colipase from pancreatic lipase [2]. The mechanism of
this is not completely clear, but it could be a result from increased lipid ordering caused by
SM:cholesterol interactions [4]. Order can be tested using a laurdan probe [5]. This could be tested
by making micelles with varying concentrations of SM, cholesterol as well as saturated and
unsaturated phosphatidylcholine to generate micelles of different rigidities measured by the
laurdan probe. These micelles could be incubated with lipase and colipase and the association
between them can be measured as a ratio, as previously reported [2]. Comparing degrees of
ordering and colipase:lipase interactions would allow us to see if there is an effect of lipid ordering
on lipase activity. Additionally, comparing micelles of similar rigidities containing different
amounts of SM would elucidate if it is a specific interaction of SM or the consequence of lipid
ordering. Another potential explanation of SM effects on lipid absorption is its potential for
affecting proteins involved in cholesterol uptake by intestinal cells. Recently, exogenous SM was
shown to reduce NPC1L1 protein expression in Caco-2 cells [6]. Although this runs counter to our
in vivo mRNA findings of Aim 1 thought to be a consequence of cellular cholesterol reduction by
dietary SM, it has been shown that increasing membrane rigidity through lysophosphatidylcholine
acyltransferase 3 knockout, disrupts NPC1L1 protein expression in the intestine [7]. If the
membrane is more rigid and prevents NPC1L1 to incorporation, it may be dislocated and degraded,
a change that may not be captured by mRNA analysis. Therefore, quantifying \ the protein
expression of NPC1L1 and other membrane proteins in the intestines of mice fed a long-term SMrich diet may be of interest to confirm these recent findings [6].
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Overall, our understanding of the interactions of the food matrix and SM’s efficacy is
sparse. This is highlighted by the discrepancy in the findings between Aim 1, where milk-derived
SM was more hypolipidemic, and Aim 2, where egg-derived SM was more effective. There are
several differences in these studies, including diet composition, SM dosage, and diet duration.
Since the hypolipidemic effects are thought to be due to the inhibition of lipid absorption, these
discrepancies are likely due to differences among dietary-derived SM structures. Therefore, the
likely important variables are the dosage or diet composition. This work started under the
assumption that milk-derived SM more strongly inhibits lipid absorption than egg-derived SM [8].
However, this direct comparison may not have been fully explored. A major difference between
the diet that can be explored is the compositions in Aims 1 and 2. Aim 2 added a substantial amount
of cholesterol. First, the ratio of SM to cholesterol can alter cholesterol absorption [9, 10], however,
this is not necessarily in a linear fashion. Therefore, the relationship may be more complex than
more SM leads to a greater inhibition of lipid absorption. If this is true, there may be different
optimal ratios of cholesterol:SM for different structurally-distinct sources of SM. Current
absorption studies, with the exception of one [8], have only used a single source of SM. Therefore,
testing the effects of several ratios of egg- and milk-derived SM to cholesterol on lipid absorption
using both cell culture and rodent models could help explain differential effects in Aim 1 and 2.
Lastly, dietary phospholipids have been shown to increase the appearance of milk SMderived ceramide species [11]. This is possibly due to increased SM hydrolysis because there is
little evidence of SM being absorbed whole. However, this would run counter to previous in vitro
studies where phospholipids inhibited alkaline sphingomyelinase [12]. Therefore, this study could
be repeated with intestine-specific alkaline sphingomyelinase knockout mice [13]. If milk
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phospholipids are unable to increase lymphatic milk SM-derived ceramides in this model, the milk
phospholipids are likely enhancing SM digestion.
Using the dual-isotope method [9], it would be important to understand if administration
of SM as a pure compound or as part of a mixture, such as in beta-serum, has differential effects
on cholesterol and lipid absorption. This was suggested by the finding that 1% MPLs (wt:wt) had
little effect on serum cholesterol in Aim 4, while purified SM at similar concentrations to lowered
serum cholesterol in Aims 1 and 2, as well as in other studies [14]. However, direct comparison of
these studies is insufficient to conclude that dietary phospholipids can alter SM’s effects on
cholesterol absorption, because these studies use significantly different animal models and
intestinal cholesterol absorption is not the only factor contributing to hypercholesterolemia.
Therefore, directly comparing purified milk-derived SM and beta-serum would provide evidence
of how the phospholipids alter SM’s efficacy.
7.2.2 Further Elucidating the Molecular Mechanism of SM’s Anti-inflammatory Effects

The effects of exogenous and endogenous sphingolipids on inflammation are contradictory. In
general, research has found most exogenous sphingolipids to be anti-inflammatory [15-17], but
the mechanism is poorly understood. In Aim 3, we managed to determine that the hydrolysis of
SM is necessary for the anti-inflammatory effects. Replicating this finding in bone marrow-derived
macrophages would further strengthen these findings.
One aspect that remains unclear is if ceramide digestion is required for the antiinflammatory effects observed. Sphingosine’s capacity to inhibit inflammation certainly suggests
ceramide digestion is necessary. To test this, we will need to repeat the SM experiments while
inhibiting acid ceramidase, which is also secreted from RAW 264.7 macrophages [18]. We could
make use of the newly synthesized ceramidase inhibitor, LCL521, which targets the lysosome, to
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hopefully avoid off target effects [19]. This would inform us if ceramide hydrolysis is required for
the anti-inflammatory effects of SM and further resolve which metabolite are responsible for the
effects found in Aim 3.
Assuming sphingosine is the causal agent, it would be important to use radiolabeled
sphingosine to examine the fate of sphingosine within the cell in both inflammatory and noninflammatory conditions. To do this, we could simply repeat the experiment from Aim 3 with
radiolabeled sphingosine and separate the lipids of cell lysates using thin layer chromatography.
This would provide insight to whether it is sphingosine or a metabolite of exogenous sphingosine
that is formed and provide a target for further research. Finally, to address the dynamic nature of
sphingolipid metabolism within a cell, these lysates should be analyzed for total sphingolipids and
each sphingolipid class using lipidomics [20]. This would help to determine if there are any
increases in more complex sphingolipid species that could be missed with the radiolabeled tracer
method mentioned above.
Additionally, some in vivo experiments demonstrate anti-colitic effects of dietary SM [21,
22]. Due to dietary SM’s incomplete digestion, it is possible some of the anti-inflammatory effects
are at the level of the intestine. One putative mechanism is inhibiting LPS translocation. Aim 1
and 3 demonstrate reductions in serum LPS activity by dietary milk-derived SM. Ghoshal et al.
has reported that formation of chylomicrons is required for LPS translocation into the lymph [23].
Thus, SM inhibition of lipid absorption could potentially lower LPS translocation. In support of
this, dietary gangliosides have been shown to improve gut barrier function in response to LPS
challenge [24]. Dietary SM helps promote the maturation of the gut in infant rats [25]. Bovine milk
phospholipids have been shown to improved Caco-2 cell barrier function in response to LPS [26].
Therefore, our lab is currently aiming to explore SM’s potential to reduce LPS translocation using
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a Caco-2 cell transwell model. In this model, we will measure transepithelial electrical resistance,
LPS activity of the basal lateral compartment, and triglyceride accumulation. These experiments
will allow us to determine if emulsions containing milk-derived SM can improve barrier function
and/or reduce LPS translocation, and if they are associated with inhibition of lipid absorption.

7.2.3. Interactions between Dietary SM and Gut Microbiota

Sphingosine has been shown to be bactericidal against a variety of enteropathogens [27].
Conversely, some microbes have been identified to possess sphingolipid metabolic capacity [28].
Our results show an increase in Firmicutes, Actinobacterium, and Bifidobacterium with higher
dosages of dietary milk SM (0.25% w/w of diet) in mice. In addition to our results, there are only
a few studies that examine dietary SM and gut microbiota [29, 30]. However, at this point these
studies are difficult to compare, as wild-type mice can have vastly different gut microbiotas
between litters [31]. Additionally, contamination from non-sterile bedding or supplies can be a
factor [31]. Therefore, using gnotobiotics [32], conditions of well-controlled sterility, or mice
inoculated with a known culture [33] could help control for these factors. These types of studies
would offer more clarity in the effects of both background diet and dietary SM on the gut
microbiota.
Another aspect of sphingolipids that has gone unexplored is their impact on the gut
microbiome, or the collective genome of gut microbiota. As mentioned above, there are species of
bacteria that can metabolize sphingolipids. Combined with the broad-spectrum bactericidal effects
of sphingosine, it is fair to hypothesize these bacteria may have a survival advantage in the context
of a sphingolipid-enriched diet. Therefore, bulk genomic sequencing of the microbiome in addition
to 16S ribosomal RNA sequencing of gut microbiota may help further elucidate the effects of
dietary sphingolipids on gut bacteria. I would expect the genes associated with sphingolipid
186

metabolism to be increased in the mice fed sphingolipids. This idea has been illustrated by
measuring the gut bacteria-dependent trimethylamine production from choline and carnitine.
Particularly, in response to carnitine challenge, omnivorous humans produced more
trimethylamine N-oxide compared to strict vegans [34]. This suggests that the chronic
consumption of meat increased the host gut microbiota capacity to produce trimethylamine Noxide’s precursor.
Lastly, while Sprong et al. [27] provided proof-of-concept for the bactericidal effects of
sphingosine, much more work could be done with this concept. Dietary SM and ceramide reach
the distal intestines [35]. Therefore, studying their interactions with common gut bacteria in simple
in vitro models, similar to the Sprong et al. publication, could provide useful information.
Additionally, more species of bacteria should be tested for sphingolipid toxicity. Some members
of the phyla Bacteroidetes can synthesize sphingolipids [36, 37], which are essential for their
survival in the intestines. Additionally, Bifidobacterium, part of the Actinobacteria phyla, can
metabolize sphingolipids [28]. Therefore, it would be interesting to see if exogenous sphingolipids
are less toxic to Bacteroidetes or Bifidobacterium. The results of Aim 1 would suggest
Bifidobacterium are less affected by dietary sphingolipids. Aim 1 revealed a decrease in
Bacteroidetes with milk-derived SM treatment. This may be a result of increased dietary fat
reaching the colon because chronic HFD decreases Bacteroidetes in mice [38].

7.2.4. Dietary SM and Prevention of Chronic Disease

Currently, there is little work on dietary SM and the development of late-stage chronic metabolic
diseases. The work in this dissertation lays the foundation for the investigation into the progression
of non-alcoholic steatohepatitis, cardiovascular disease, and type 2 diabetes mellitus. Currently,
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our laboratory has two studies investigating the impact of dietary SM on atherosclerosis
development in hyperlipidemic mouse models.
A natural progression of Aim 4 would be to induce non-alcoholic steatohepatitis (NASH)
in LDLr-/- mice while feeding beta serum. It is likely the signs of improvement with the higher
dose observed in Aim 4 would result in reductions in disease severity. In this study, comparing the
efficacy of an equal dose of milk-derived SM would help understand if the excess phospholipids
are improving or reducing the beneficial effects of SM.
Another important distinction that needs to be made is if the effects of dietary SM are
exclusively due to effects on lipid absorption. The anti-inflammatory data, effects on gut
microbiota, and the fact that some milk-derived ceramides appear in the lymph suggest otherwise.
Inhibiting diet-induced inflammation may be a secondary effect of SM. A simple comparison study
with ezetimibe could help deduce if there are additional anti-inflammatory effects. First, a dualisotope study could be conducted in mice to determine equivalent hypolipidemic dosages for milkderived SM and ezetimibe on a Western-type diet. These doses could then be used in a diet-induced
obesity mouse model to see if there are significant differences on inflammation outcomes.
The gut microbiota is another important factor in metabolic dysfunction. As demonstrated
in Aims 1 and 3, SM can significantly alter the gut microbiota. Whether this impacts SM’s effects
on metabolic dysfunction remains to be seen. It has been recently shown that egg-derived SM had
anti-atherosclerotic effects in apoE-/- mice, and these effects were attenuated when co-administered
with broad-spectrum antibiotics to deplete gut microbiota [29]. The gut microbiota has
implications in metabolic dysfunction as reviewed in Chapter 2. Therefore, testing the effects of
dietary SM on an obesogenic diet with and without broad spectrum antibiotics would demonstrate
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if there are implications of the SM and gut microbiota interactions on metabolic dysfunction.
Another interesting discovery made recently is the deposition of serine dipeptide lipids in human
atherosclerotic plaques derived from bacteria of the Bacteroidetes phylum, namely lipid 654 and
lipid 430 (L654 and L430) [39]. This association has highlighted another potential bacterial
byproduct that may accumulate in tissue. Due to the hydrophobic nature and sphingolipids’ effects
on microbiota it would be interesting to see if L654 and L430 levels in the liver are modulated by
dietary sphingolipids. More research is needed into the characteristics of these bacterial lipids, as
their transport and metabolism in tissues is not well understood.

7.2.5. Clinical Trials to Measure the Efficacy of SM to Inhibit Cholesterol Absorption in Humans

Although one study did measure phytosterols as a measure of sterol absorption when feeding a
phospholipid mixture, it would be advantageous to directly measure cholesterol absorption in
humans, using stable isotope tracers [40]. The additional alkaline sphingomyelinase in human bile
[41] and the minute gastric lipase activity in rodents [42] could result in differences in dietary SM
effects between rodents and humans. Gastric lipase reduces SM’s inhibitory effect on pancreatic
lipase activity [43]. These tracer studies need to be done with both purified SM and a phospholipid
fraction, such as beta-serum. This type of work should precede any further dietary interventions to
ensure efficacy in humans.

7.2.6. Does Dietary SM Correlate with Disease Outcomes?

An epidemiological study could be conducted to determine if there is an association between
dietary SM intake and serum cholesterol, metabolic syndrome, cardiovascular events, or liver
disease. The intakes could be estimated using the National Health and Nutrition Examination
Survey (NHANES) data in combination with multiple sources citing the abundance of SM in
foods. This study would need to control for the intake of plant-based foods, fats, sugars, and
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cholesterol, as these are some of the possible confounders that could influence the findings.
Hypothetically, if there was an association it would strengthen the hypolipidemic effects observed
in preclinical and clinical trials.
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Gene

Protein*

5'-Forward Primer-3'

5'-Reverse Primer-3'

Acaca
Abcg5
Acad
Acox1
Actb
Adgre1
Adipoq
Apoa4
Ccl2
Cd36
Cd68
Cebpa
Cpt1a
Cpt1b
Dgat2
Fabp2
Fabp4
Gapdh
Hmgcr
Il1b
Il6
Itgax
Ldlr
Lpl
Mip1b
Mttp
Mylip
Npc1l1
Nr1h3

ACC
ABCG5
ACAD1
ACOX1
β-actin
F4/80
Adiponectin
ApoA-IV
MCP-1
CD36
CD68
C/EBPα
CPT1α
CPT1β
DGAT2
FABP2
FABP4
GAPDH
HMGCR
IL-1β
IL-6
Cd11c
LDLr
LPL
MIP-1β
MTTP
IDOL
NPC1L1
LXRα

GTCCCGGCCACATAACTGAT
GCGTAGGTCTCCTTTACCAGTTTG
AGAGCAAGTCCCCACCAATG
CCCAAGACCCAAGAGTTCATTC
TCCTTCTTGGGTATGGAATCCT
GAGTGGAATGTCAAGATGTTA
CAACCAACAGAATCATTATG
TTCCTGAAGGCTGCGGTGCTG
TTCCTCCACCACCATGCAG
CTTACACATACAGAGTTCGTTATC
TGTCTGATCTTGCTAGGACCG
CAAGAGCCGAGATAAAGC
GAACCCCAACATCCCCAAAC
GCTCTGAGACACATCTACC
GGAATAAGTGGGAACCAGATCA
GTCTAGCAGACGACGGAACGGA
CACCATCCGGTCAGAGAGTACTT
TGTGTCCGTCGTGGATCTGA
GATGATTATGTCTTTAGGCTTG
GTCACAAGAAACCATGGCACAT
GACTGATGCTGGTGACAA
CTGGATAGCCTTTCTTCTGCTG
TTCCTGTCCATCTTCTTCC
AAGGTCATCTTCTGTGCTAGG
TCTGTGCAAACCTAACCCCG
CTACCAGGCCCAACAAGAC
AGGAGATCAACTCCACCTTCTG
CGTCTGTCCCCGCCTATACA
TTTAGGGATAGGGTTGGAGTCA

CGCTCAGGTCACCAAAAAGAAT
GGAAACAGATTCACAGCGTTCA
GGCTTGCTTGGCATCAACA
CAGGCCACCACTTGATGGA
CAGCACTGTGTTGGCATAGA
CAGTGGAAGAAGAGAAGC
GGTAAGAGAAGTAGTAGAGT
CTGCTGAGTGACATCCGTCTTCTG
CCAGCCGGCAACTGTGA
TCCAACAGACAGTGAAGG
GAGAGTAACGGCCTTTTTGTGA
TCATTGTCACTGGTCAAC
TCCTGGCATTCTCCTGGAAT
CTAAGGATGCCATTCTTGATTC
CCGCAAAGGCTTTGTGAAG
AGAAACCTCTCGGACAGCAA
CGGTGATTTCATCGAATTCCA
CCTGCTTCACCACCTTCTTGAT
CAGAGAGAAACACTTGGT
GCCCATCAGAGGCAAGGA
GCCATTGCACAACTCTTT
GCACACTGTGTCCGAACTC
GACCATCTGTCTTGAGGG
CCAGTGTCAGCCAGACTT
GAGGGTCAGAGCCCATTGGT
CGCTCAATTTTGCATGTATCC
ATCTGCAGACCGGACAGG
CTAATGACACCAGCTGCTTGGT
GTGGACGAAGCTCTGTCG
195

Ocln
Pck1
Pcsk9
Ppara
Pparg
Pparg2
Ppargc1a
Rplp0
Scd1
Slc2a4
Srebf1
Srebf2
Tgfb1
Tjp1
Tnfa

OCLN
PEPCK
PCSK9
PPARα
PPARγ
PPARγ2
PGC-1α
RPLP0 (36B4)
SCD1
GLUT4
SREBP-1c
SREBP-2
TGFβ
TJP1
TNFα

CACCTATCACTTCAGATCAACAA
AACTGACAGACTCGCCCTATGTG
AGGTGGAGGTGTATCTCTTAGA
CGGCAGTGCCCTGAACA
CACAATGCCATCAGGTTTGG
TTCGCTGATGCACTGCCTAT
AAGCTGAAGCCCTCTTGCAA
CCTGAAGTGCTCGACATCAC
CAGTGCCGCGCATCTCT
CATGGCTGTCGCTGGTTTC
GGAGCCATGGATTGCACATT
GTGTGCGGAGGAGAAAATCC
CGCAACAACGCCATCTAT
AGAGGAAGAGCGAATGTC
GGCTGCCCCGACTACGT

CAGCAGCCATGTACTCTTC
TGCCCATCCGAGTCATGAT
CACTTGCTCGCCTGTCTG
TGGTACCCTGAGGCCTTGTC
GCTGGTCGATATCACTGGAGATC
GCATCTCTGTGTCAACCATGGT
ACTGTACCGGGCCCTCTTG
CCACAGACAATGCCAGGAC
CCCGGGATTGAATCTTCTTG
AAACCCATGCCGACAATGA
GGCCCGGGAAGTCACTGT
CCCATGGCCGCTGTCA
TGCTTCCCGAATGTCTGA
TTCGGTTCTGGAAGAGTG
ACTTTCTCCTGGTATGAGATAGCAAAT
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